thiazoles has been researched along with edoxaban in 810 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (0.25) | 29.6817 |
| 2010's | 613 (75.68) | 24.3611 |
| 2020's | 195 (24.07) | 2.80 |
| Authors | Studies |
|---|---|
| Furugohri, T; Honda, Y; Isobe, K; Kamisato-Matsumoto, C; Morishima, Y; Nagahara, T; Shibano, T; Sugiyama, N | 1 |
| Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M | 1 |
| Kojima, M; Kunitada, S; Masumoto, H; Mendell-Harary, J; Ogata, K; Oguma, T; Tachibana, M | 1 |
| Lopes, RD; Mahaffey, KW; Piccini, JP | 1 |
| Kunitada, S; Mendell, J; Shi, M; Tachibana, M | 1 |
| Bocanegra, T; Cohen, AT; Eriksson, BI; Puskas, D; Raskob, G; Shi, M; Weitz, JI | 1 |
| Connolly, SJ; Jin, J; Kastrissios, H; Kunitada, S; Mendell, J; Patel, I; Rohatagi, S; Salazar, D; Weitz, JI | 1 |
| Morishima, Y; Shibano, T | 1 |
| Hiroe, K; Kawamura, M; Konishi, N | 1 |
| Fuji, T; Fujita, S; Kawai, Y; Tachibana, S | 1 |
| Depasse, F; Heptinstall, S; Kunitada, S; Oursin, A; Samama, MM | 1 |
| Antman, EM; Bocanegra, T; Braunwald, E; Crugnale, SE; Giugliano, RP; Hanyok, J; McCabe, CH; Mercuri, M; Patel, I; Ruff, CT; Salazar, D; Shi, M | 1 |
| Chen, SA; Chung, N; Chung, WS; Jeon, HK; Lai, WT; Lee, TH; Lien, LM; Tse, HF | 1 |
| Weitz, JI | 2 |
| Basavapathruni, R; Draves, A; Mendell, J; Morganroth, J; Swearingen, D; Zhang, G | 1 |
| Eikelboom, JW; Eriksson, BI; Quinlan, DJ | 1 |
| Kapiotis, S; Kunitada, S; Mendell, J; Ogata, K; Samama, MM; Wolzt, M | 1 |
| Keltai, K; Keltai, M | 1 |
| Giugliano, RP; Partida, RA | 1 |
| Guinet, C; Kunitada, S; Le Flem, L; Mendell, J; Samama, MM | 1 |
| Bounameaux, H; Camm, AJ | 2 |
| Di Pasquale, G; Riva, L | 2 |
| Fukuda, T; Honda, Y; Kamisato, C; Morishima, Y; Shibano, T; Tsuji, N | 1 |
| Furugohri, T; Morishima, Y; Shibano, T; Sugiyama, N | 1 |
| Breen, KA; Hunt, BJ | 1 |
| Gras, J | 1 |
| Fukuda, T; Honda, Y; Kamisato, C; Morishima, Y; Shibano, T | 1 |
| Nagao, T | 1 |
| Antman, EM; Bocanegra, TS; Carrothers, TJ; Dornseif, B; Giugliano, RP; Green, M; Kastrissios, H; Kunitada, S; Mendell, J; Patel, I; Rohatagi, S; Salazar, DE; Shi, M; Song, S; Tachibana, M; Zhou, S | 1 |
| Cohen, AT | 1 |
| Fukuda, T; Furugohri, T; Kita, A; Morishima, Y; Shibano, T; Tsuji, N | 1 |
| Bommer, WJ | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Halim, AB; He, L; Lee, F; Matsushima, N; Mendell, J; Worland, V; Zahir, H; Zhang, G | 1 |
| Edo, N; Honda, Y; Kamisato, C; Kita, A; Morishima, Y; Shibano, T; Tsuji, N | 1 |
| Inoue, H; Kawai, Y; Koretsune, Y; Matsumoto, M; Ogawa, S; Uchiyama, S; Yamaguchi, T; Yamashita, T; Yasaka, M | 1 |
| Lip, GY; Marín, F; Roldán, V | 1 |
| Ahrens, I; Bode, C | 1 |
| Mendell, J; Noveck, RJ; Shi, M | 2 |
| Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC | 1 |
| Bathala, MS; He, L; Lowrie, C; Masumoto, H; Mendell, J; Oguma, T | 1 |
| Brenner, B; Hoffman, R | 1 |
| Furugohri, T; Honda, Y; Kamisato, C; Morishima, Y; Shibano, T | 1 |
| Green, M; Kastrissios, H; Mendell, J; Patel, I; Rohatagi, S; Salazar, DE; Shi, M | 1 |
| Fredenburgh, JC; Weitz, JI; Yeh, CH | 1 |
| Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K | 1 |
| Valle Bernad, R | 1 |
| Kaatz, S; Mahan, CE | 1 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Graff, J; Harder, S | 1 |
| Nieto Rodríguez, JA | 1 |
| Dalla Valle, F; Pesavento, R; Piovella, C; Prandoni, P; Tormene, D | 1 |
| Büller, H; Mercuri, M; Prins, M; Raskob, G; Schwocho, L; Segers, A; Shi, M; van Kranen, R | 1 |
| Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
| Chen, S; Lee, F; Mendell, J; Samama, MM; Shi, M; Worland, V | 1 |
| Arachchillage, DJ; Cohen, H | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Fukuda, T; Furugohri, T; Honda, Y; Kamisato, C; Kojima, T; Matsushita, T; Morishima, Y; Shibano, T | 1 |
| Honda, Y; Kamisato, C; Morishima, Y; Shibano, T | 1 |
| Chen, S; Lee, F; Matsushima, N; Mendell, J; Noveck, R; Shi, M; Zahir, H; Zhang, G | 1 |
| Baruch, L | 1 |
| Lopes, RD; Newby, LK; Truffa, AA | 1 |
| Morishima, Y; Shibano, T; Shirasaki, Y | 1 |
| Agnelli, G; Becattini, C; Franco, L | 1 |
| Majeed, A; Schulman, S | 1 |
| Ishida, K; Kuroda, R; Kurosaka, M; Matsumoto, T; Sasaki, H; Shibanuma, N; Tateishi, H; Tei, K; Toda, A; Yamashiro, Y | 1 |
| Schulman, S | 2 |
| Hirayama, C; Hotoda, H; Kuroda, Y; Nishikawa, Y; Nishiwaki, A | 1 |
| Antman, EM; Betcher, J; Braunwald, E; Ezekowitz, MD; Giugliano, RP; Grip, LT; Halperin, JL; Hanyok, JJ; Koretsune, Y; Mercuri, M; Murphy, SA; Patel, I; Patel, SP; Ruda, M; Ruff, CT; Ruzyllo, W; Shi, M; Špinar, J; Waldo, AL; Weitz, JI; Wiviott, SD | 1 |
| Einecke, D | 1 |
| Sprynger, M | 1 |
| Antman, EM; Braunwald, E; Deenadayalu, N; Giugliano, RP; Grip, LT; Gupta, DK; Hoffman, E; Mercuri, M; Mitrovic, V; Patel, I; Ruff, CT; Shah, AM; Shi, M; Solomon, SD | 1 |
| Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T | 1 |
| Mitka, M | 1 |
| Fischer, T; Imaoka, T; Izumi, T; Masumoto, H; Mikkaichi, T; Okudaira, N; Rozehnal, V; Yoshigae, Y | 1 |
| Rondina, MT; Vazquez, S; Vo, T | 1 |
| Arellano-Rodrigo, E; Diaz-Ricart, M; Escolar, G; Galán, AM | 1 |
| Giugliano, RP; Gonzalez-Quesada, CJ | 1 |
| Bounameaux, H; Fontana, P; Goldhaber, SZ | 1 |
| Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS | 1 |
| Dempfle, CE | 2 |
| Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Giugliano, RP; Plitt, A | 3 |
| Meddahi, S; Samama, MM | 1 |
| Abe, K; Fuji, T; Fujita, S; Kawai, Y; Kimura, T; Kiuchi, Y; Nakamura, M; Tachibana, S | 1 |
| Arya, R; Couchman, L; Flanagan, RJ; Gous, T; Paradzai, C; Patel, JP | 1 |
| Halim, AB; Kang, D; Miller, R; Song, S | 1 |
| Yorozu, T | 1 |
| Li, S; Liu, B; Xu, D; Xu, Y | 1 |
| Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
| Agnelli, G; Lip, GY | 1 |
| Cohen, AT; Imfeld, S; Rider, T | 1 |
| Andersen, JF; Lauritsen, ML; Wilhelmsen, M | 1 |
| Prandoni, P; Taher, A; Temraz, S | 1 |
| Beer, JH; Holy, EW | 1 |
| Hürlimann, D; Noll, G; Noll, S | 1 |
| Corelli, K; Ezekowitz, MD; Ghosh, P; Spahr, J | 1 |
| Ishihara, H; Morishima, Y; Murata, M; Noguchi, K; Shibano, T; Takahashi, S | 1 |
| Prabhakaran, S; Veltkamp, R | 1 |
| Gross, PL; Weitz, JI; Yeh, CH | 1 |
| Antman, EM; Betcher, JM; Braunwald, E; Dave, J; Deenadayalu, N; Duggal, A; Giugliano, RP; Grip, LT; Lowe, C; Mercuri, M; Murphy, SA; Rost, NS; Ruff, CT; Shi, M; Silverman, S; Wiviott, SD | 1 |
| Kakkos, SK; Kirkilesis, GI; Tsolakis, IA | 1 |
| Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
| Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N | 1 |
| Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C | 1 |
| Ansell, J; Mantha, S | 1 |
| Cowell, RP | 1 |
| Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Fuji, T; Fujita, S; Kawai, Y; Kimura, T; Tachibana, S; Wang, CJ | 1 |
| Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Mitchell, AR; Page, PL; Thomas, R | 1 |
| Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P | 1 |
| Antman, EM; Betcher, J; Braunwald, E; Cange, AL; Crompton, AE; Curt, V; Deenadayalu, N; Giugliano, RP; Grip, L; Mercuri, M; Murphy, SA; Ruff, CT | 1 |
| Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH | 1 |
| Hunt, BJ; Sciascia, S | 1 |
| Miller, R; Tetsuya, K; Yin, OQ | 1 |
| Meddahi, S; Samama, CM; Samama, MM | 1 |
| Halim, AB; Mendell, J; Samama, MM | 1 |
| Honda, Y; Kamisato, C; Morishima, Y | 6 |
| Giugliano, RP | 1 |
| Miller, R; Yin, OQ | 1 |
| Lane, DA; Lip, GY; Senoo, K | 1 |
| Aota, T; Asanuma, K; Hasegawa, M; Katayama, N; Matsumoto, T; Miyamoto, N; Naitoh, K; Nishikawa, M; Ohishi, K; Shimokariya, Y; Sudo, A; Uchida, A; Wada, H; Wakabayashi, H; Yamada, N; Yamashita, Y; Yoshida, K | 1 |
| Madhusudhana, S; Qasem, A; Strasser, KM | 1 |
| Abe, K; Fuji, T; Fujita, S; Ibusuki, K; Kawai, Y; Kimura, T; Nakamura, M; Tachibana, S; Ushida, H; Wang, CJ | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Dobesh, PP; Fanikos, J | 1 |
| Ageno, W; Beyer-Westendorf, J | 1 |
| Ezekowitz, MD; Kent, AP | 1 |
| Baber, U; Mastoris, I; Mehran, R | 1 |
| Ansell, JE; Bakhru, SH; Brown, K; Costin, JC; Dishy, V; Grosso, M; Laulicht, BE; Noveck, RJ; Steiner, SS | 1 |
| Antman, EM; Brown, KS; Desai, M; Dishy, V; Feng, W; Feussner, A; Grosso, MA; He, L; Lanz, HJ; Lomeli, B; Maa, JF; Vandell, AG; Zahir, H | 1 |
| Dickneite, G; Doerr, B; Herzog, E; Kaspereit, F; Krege, W; Morishima, Y; Mueller-Cohrs, J; Pragst, I | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Lavie, CJ; Lip, GY; Mukherjee, D; Sardar, P | 1 |
| Davis, EM; Schardt, GL; Schmidt, DP; Uhlmeyer, EM | 1 |
| Peerlinck, K; Vanassche, T; Vandenbriele, C; Verhamme, P | 1 |
| Amin, A; Deitelzweig, S | 1 |
| Blann, AD | 1 |
| Brown, KS; Chen, S; Dishy, V; He, L; Marbury, T; Matsushima, N; Parasrampuria, DA; Wickremasingha, PK | 1 |
| Amin, A; Bruno, A; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Kamisato, C; Morishima, Y | 1 |
| Traynor, K | 1 |
| Cuker, A; Husseinzadeh, H | 1 |
| Ansell, JE; Cabral, KP | 1 |
| Antman, EM; Braunwald, E; Cermak, O; Giugliano, RP; Grip, LT; Kania, G; Mercuri, MF; Murphy, SA; O'Donoghue, ML; Ruff, CT; Rutman, H; Shi, M | 1 |
| Bacchus, F; Schulman, S | 1 |
| Loffredo, L; Perri, L; Violi, F | 2 |
| Oberhofer, E | 1 |
| Bonfanti, C; Franchini, M; Lippi, G | 1 |
| Powell, JR | 1 |
| Antman, EM; Braunwald, E; Deenadayalu, N; Giugliano, RP; Lee, J; Mega, JL; Mercuri, MF; Murphy, SA; Nordio, F; Ruff, CT; Sabatine, MS; Vandell, AG; Walker, JR | 1 |
| Antman, EM; Betcher, J; Braunwald, E; Brown, K; Deenadayalu, N; Giugliano, RP; Jarolim, P; Kuder, JF; Mercuri, M; Morrow, DA; Murphy, SA; Patel, I; Ruff, CT; Shi, M | 1 |
| Honda, Y; Morishima, Y | 3 |
| Hogg, K; Weitz, JI; Yeh, CH | 1 |
| Adams, G; Ansel, G; Baumgartner, I; Duggal, A; Grosso, M; Jaff, M; Mercuri, M; Minar, E; Moll, FL; Nwachuku, CE; Shi, M; Tangelder, MJ | 1 |
| Greinacher, A; Selleng, K; Thiele, T | 1 |
| Agnelli, G; Prandoni, P; Verso, M | 1 |
| Harenberg, J; Krejczy, M; Lip, GY; Obermann, K; Wehling, M | 1 |
| Bass, AR | 1 |
| Armbruster, AL; Minor, C; Tellor, KB | 1 |
| Ito, M; Nakamura, M; Yamada, N | 2 |
| Lane, DA; Wood, K | 1 |
| Abe, K; Fukuzawa, M; Kimura, T; Koretsune, Y; Yamashita, T; Yasaka, M | 1 |
| Al-Saadi, N; Ellenbogen, K; Ezekowitz, M; Goette, A; Jin, J; Lanz, H; Lip, GY; Mercuri, M; Merino, J; Zamoryakhin, D | 1 |
| Jönsson, S; Karlsson, MO; Miller, R; Simonsson, US | 1 |
| Connor, A; Kanamaru, T; Kunitada, S; Ogata, K; Parasrampuria, DA; Shimoto, Y; Wilding, I | 1 |
| Antman, EM; Atar, D; Braunwald, E; Camm, AJ; Giugliano, RP; Heidbuchel, H; Murphy, SA; Ruff, CT; Steffel, J | 1 |
| Chen, S; Johnson, L; Mendell, J | 1 |
| Ikeda, T | 1 |
| Blann, AD; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Conen, D | 1 |
| Alie, N; Besa, C; Fayad, ZA; Goldhaber, SZ; Grosso, M; Mani, V; Mercuri, M; Piazza, G; Ramachandran, S; Robson, PM; Taouli, B | 1 |
| Barrios, V; Escobar, C | 2 |
| Chen, S; Desai, M; He, L; Mendell, J; Parasramupria, DA | 1 |
| Lip, GY; Proietti, M | 2 |
| Ge, D; Morrill, AM; Willett, KC | 1 |
| Kesteven, P; McCaslin, JE; Robertson, L | 2 |
| Krähenbühl, S; Liakoni, E; Rätz Bravo, AE | 1 |
| Crawford, B; Morimoto, T; Ueda, S; Wada, K | 1 |
| Abe, K; Büller, H; Kimura, T; Lee, LH; Mercuri, M; Miyazaki, K; Nakamura, M; Oh, D; Segers, A; Wang, C; Wang, YQ; Yin, WH | 1 |
| Furugohri, T; Morishima, Y | 1 |
| Jönsson, S; Karlsson, MO; Krekels, EH; Miller, R; Niebecker, R; Nyberg, J; Simonsson, US | 1 |
| Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA | 1 |
| Beyer-Westendorf, J; Bleker, SM; Boda, Z; Büller, HR; Carrier, M; Chlumsky, J; Décousus, H; Di Nisio, M; Garcia, D; Gibbs, H; Grosso, MA; Kakkar, A; Kamphuisen, PW; Mercuri, MF; Monreal, M; Ockelford, P; Pabinger, I; Raskob, GE; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Weitz, JI | 1 |
| Lau, YC; Lip, GY; Xiong, Q | 1 |
| Rondina, MT; Vazquez, S | 1 |
| Brown, KS; Dishy, V; He, L; Kochan, J; Parasrampuria, DA; Shi, M; Weiss, D; Wickremasingha, P | 1 |
| Chen, J; Long, M; Su, C; Wang, L; Zhuang, X | 1 |
| Hong, K; Lane, DA; Lau, YC; Lip, GY; Senoo, K; Xiong, Q | 1 |
| Kawaguchi, M; Konuma, S; Nehashi, Y; Okuda, Y; Uchimura, N | 1 |
| Hijazi, Z; Oldgren, J | 1 |
| McCormack, PL | 1 |
| Banerjee, A; Blann, AD; Lane, DA; Lip, GY; Torp-Pedersen, C | 1 |
| Antman, EM; Braunwald, E; Geller, BJ; Giugliano, RP; Hanyok, JJ; Jin, J; Mercuri, M; Murphy, SA; Ruff, CT | 1 |
| Colonna, P; Rubboli, A | 1 |
| Eikelboom, J; Weitz, JI | 1 |
| Riess, H | 1 |
| Chalkiadaki, C; Dorian, P; Kongnakorn, T; Kuznik, A; Lanitis, T; Lawrence, J; Lip, GY; Liu, X; Phatak, H | 1 |
| Chan, NC; Dale, BJ; Eikelboom, JW | 1 |
| Goldenberg, NA; Kittelson, JM; Massicotte, MP; Takemoto, CM; Yee, DL | 1 |
| Azimi, N; Forest, CP; Holden, A | 1 |
| Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F | 1 |
| Ferguson, K; Klibanov, OM; Phan, D | 1 |
| Dhillon, S; Shirley, M | 1 |
| Ageno, W; Bauersachs, R; Couturaud, F; Décousus, H; Mismetti, P | 1 |
| Goldhaber, SZ; Kwong, WJ; Preblick, R; White, RH | 1 |
| Dzeshka, MS; Lip, GY | 1 |
| Brekelmans, M; Coppens, M; Middeldorp, S | 1 |
| Brown, KS; Dishy, V; Kochan, J; Maa, JF; Parasrampuria, DA; Shi, M; Weilert, D | 1 |
| Daley, MJ; Hobbs, AL; Roberts, KM; Shea, KM | 1 |
| Gonzalez, MG; Levy, PD; Peacock, WF; Than, M | 1 |
| Gehrie, EA; Tormey, CA | 1 |
| Parasrampuria, DA; Truitt, KE | 1 |
| Cuker, A; Siegal, D | 1 |
| Roca, B; Roca, M | 1 |
| Batson, S; Kachroo, S; Lip, GY; Liu, LZ; Liu, X; Mitchell, SA; Phatak, H | 1 |
| McBane, RD; Schaefer, JK; Wysokinski, WE | 1 |
| Antman, EM; Cohen, DJ; Giugliano, RP; Kwong, WJ; Li, H; Magnuson, EA; Ruff, CT; Vilain, K; Wang, K | 1 |
| Eisen, A; Ruff, CT | 1 |
| Gosavi, S; Mukherjee, D; Switzer, MP; Wani, P | 1 |
| Didier, R; Escarcega, RO; Kiramijyan, S; Koifman, E; Lipinski, MJ; Torguson, R; Waksman, R | 1 |
| Batson, S; Bird, A; Cohen, AT; Hamilton, M; Liu, X; Mitchell, SA; Phatak, H; Tushabe, D | 1 |
| Cheung, BM; Kumana, CR; Lauder, IJ; Siu, DC; Tse, HF | 1 |
| Benöhr, P; Hohmann, C; Neumann-Haefelin, T; Radziwill, R | 1 |
| Asahara, T; Izumi, M; Jiuchi, Y; Kidera, K; Kozuru, H; Kumagai, K; Mawatari, M; Migita, K; Motokawa, S; Osaki, M; Sakai, T; Yamaguchi, T | 1 |
| Stiefelhagen, P | 1 |
| Ajioka, M; Asano, H; Inoue, Y; Ishihama, S; Kanbara, T; Kuwayama, T; Masutomi, T; Nakashima, Y; Osanai, H; Sakai, K; Takahashi, M | 1 |
| Antman, EM; Awasty, VR; Braunwald, E; Eisen, A; Giugliano, RP; Gogia, HS; Henderson, DA; Mercuri, MF; Nordio, F; Ruff, CT; Rutman, H | 1 |
| Alamneh, EA; Bereznicki, LR; Chalmers, L | 1 |
| Smolewski, P; Witkowska, M; Witkowski, M | 1 |
| Enomoto, Y; Iida, H; Iwama, T; Kito, Y; Kozawa, O; Kuroyanagi, G; Matsushima-Nishiwaki, R; Ogura, S; Otsuka, T; Tokuda, H; Tsujimoto, M | 1 |
| Abe, K; Chen, SA; Chung, N; Giugliano, RP; Kimura, T; Koretsune, Y; Mercuri, M; Miyazaki, K; Ruff, CT; Shimada, YJ; Yamashita, T; Yang, Y | 1 |
| Antman, EM; Braunwald, E; Giugliano, RP; Mercuri, M; Murphy, SA; Nordio, F; Patel, I; Ruff, CT; Shi, M; Xu, H | 1 |
| Dobesh, PP; Finks, SW; Trujillo, TC | 1 |
| Alcocer, L | 1 |
| Kaufner, L; Rosenthal, C; Sander, M; von Heymann, C | 1 |
| Hussar, DA | 1 |
| Aoyama, K; Ishigaki, N; Kita, S; Nakamura, A; Noguchi, T; Shirai, Y; Tanimoto, H; Yoshida, T | 1 |
| Jönsson, S; Karlsson, KE; Karlsson, MO; Krekels, EH; Miller, R; Niebecker, R; Ruff, CT; Shimizu, T; Simonsson, US | 1 |
| Andreotti, F; Arnesen, H; Bachmann, F; Baigent, C; Collet, JP; De Caterina, R; Halvorsen, S; Huber, K; Husted, S; Jespersen, J; Kristensen, SD; Lip, GY; Morais, J; Rasmussen, LH; Ricci, F; Sibbing, D; Siegbahn, A; Storey, RF; Ten Berg, J; Verheugt, FW; Wallentin, L; Weitz, JI | 1 |
| Boehlen, F; Bounameaux, H; Fontana, P; Righini, M; Robert-Ebadi, H | 1 |
| Boda, Z | 1 |
| Aihara, K; Emmi, M; Hiki, M; Iba, T; Nagayama, M; Ohsaka, A; Tabe, Y; Yuri, M | 1 |
| Emmi, M; Iba, T; Nagakari, K | 1 |
| Antman, EM; Braunwald, E; Giugliano, RP; Kappelhof, JA; Mercuri, MF; Murphy, SA; Nordio, F; Ruff, CT; Shi, M; Wiviott, SD | 1 |
| Akamatsu, Y; Aratake, M; Ishigatsubo, R; Kobayashi, A; Kobayashi, H; Kumagai, K; Kusayama, Y; Mitsuhashi, S; Saito, T | 1 |
| Bauersachs, R; Bleker, SM; Boda, Z; Brekelmans, MP; Büller, HR; Choi, Y; Cohen, AT; Gallus, A; Grosso, MA; Middeldorp, S; Oh, D; Raskob, G; Schwocho, L | 1 |
| Munson, CF; Reid, AJ | 1 |
| Coleman, CI; Egri, F; Mearns, ES; Nguyen, E; White, CM | 1 |
| Pan, EY; Sobieraj, DM | 1 |
| Pollack, CV | 1 |
| De Caterina, R; Ezekowitz, MD; Giugliano, RP; Nordio, F; Peterson, N; Plitt, A | 1 |
| Egawa, T; Izushi, Y; Kiuchi, T; Ookura, Y; Sato, T; Shimada, K; Shiota, N; Takami, Y; Takuma, R; Tetsunaga, T | 1 |
| Daidoji, H; Kubota, M; Nakamura, K; Sonoo, T; Takaya, N; Tokunaga, K | 1 |
| Tripodi, A | 1 |
| Agnelli, G; Becattini, C | 1 |
| Hayes, CJ; Martin, BC; Shah, A; Shewale, A | 1 |
| Huang, HJ; Lou, D; Zhang, DT; Zhang, WL; Zhang, Y | 1 |
| Marra, A; Perrone, A; Servillo, G; Vargas, M | 1 |
| Hunt, BJ; Levy, JH | 1 |
| Ageno, W; Brekelmans, MP; Büller, HR; Cohen, AT; Grosso, MA; Lin, M; Meyer, G; Raskob, G; Segers, A; Verhamme, P; Weitz, JI; Wells, PS; Winters, SM | 1 |
| Aoyagi, H; Asano, M; Hirao, K; Kawaguchi, N; Kurabayashi, M; Nakamura, T; Okishige, K; Sasano, T; Shimura, T; Suzuki, H; Yamashita, M; Yamauchi, Y | 1 |
| Cannon, K; Chinigo, A; Concha, M; Fayad, ZA; Goldhaber, SZ; Grosso, MA; Hsu, C; Lanz, HJ; Mani, V; Mercuri, M; Nadar, V; Piazza, G; Pullman, J; Ritchie, B; Schul, M; Schussler, S | 1 |
| Alves Júnior, JL; Fernandes, CJ; Gavilanes, F; Morinaga, LK; Prada, LF; Souza, R | 1 |
| Brown, D; Grace, Y; Guirguis, E; Henningfield, S; Patel, D | 1 |
| Bereczki, D; Mirolovics, Á; Papp, C; Zsuga, J | 1 |
| Lesko, LJ | 1 |
| Antman, EM; Braunwald, E; Giugliano, RP; Jin, J; Kato, ET; Kimura, T; Kiss, RG; Koretsune, Y; Lanz, H; Mercuri, M; Murphy, SA; Nordio, F; Ruff, CT; Yamashita, T | 1 |
| Cigarroa, J; Henrikson, CA; Steinberg, JS; Tereshchenko, LG | 1 |
| Adcock, DM; Gosselin, R; Grant, RP | 1 |
| Fushima, T; Hayashi, S; Ito, S; Kisu, K; Oe, Y; Sato, E; Sato, H; Takahashi, N | 1 |
| Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI | 1 |
| Jönsson, S; Karlsson, KE; Karlsson, MO; Miller, R; Nyberg, J; Simonsson, U; Yin, O | 1 |
| Abramson, S; Chan, KE; Giugliano, RP; Jardine, M; Maddux, FW; Patel, MR; Perkovic, V; Piccini, JP; Zhao, S | 1 |
| Mizoguchi, T; Yasaka, M | 1 |
| Cutler, NR; Goldenberg, NA; Halperin, JL; Hiatt, WR; Kessler, CM; Kittelson, JM; Schulman, S; Spyropoulos, AC; Steg, PG; Turpie, AG | 1 |
| Antman, EM; Braunwald, E; Giugliano, RP; Magnani, G; Mercuri, M; Metra, M; Mitrovic, V; Moccetti, T; Murphy, SA; Nordio, F; Ruff, CT; Shi, M | 1 |
| Antman, EM; Bohula, EA; Braunwald, E; Giugliano, RP; Kuder, JF; Murphy, SA; Ruff, CT | 1 |
| Muro, M; Yamada, E; Yoshioka, T | 1 |
| Antman, EM; Braunwald, E; Crompton, AE; Giugliano, RP; Mercuri, MF; Murphy, SA; Nicolau, JC; Norden, AD; Rost, NS; Ruff, CT; Silverman, S; Singhal, AB; SomaRaju, B | 1 |
| Antman, EM; Braunwald, E; Corbalán, R; Dalby, A; Dorobantu, M; Eisen, A; Giugliano, RP; Lanz, H; Mercuri, M; Nordio, F; Ruff, CT; Rutman, H; Wiviott, SD | 1 |
| Abe, A; Kajio, M; Kimura, K; Kirita, K; Nagai, K; Nito, C; Nogami, A; Okubo, S; Sakamoto, Y; Takahashi, S | 1 |
| Antman, EM; Giugliano, RP; Ruff, CT | 1 |
| Ageno, W; Brekelmans, MP; Buller, H; Cohen, AT; Grosso, MA; Meyer, G; Raskob, G; Segers, A; Verhamme, P; Weitz, JI; Wells, PS; Zhang, G | 1 |
| Yasumasu, T | 1 |
| Yamashita, T | 1 |
| Noble, SI | 1 |
| Angchaisuksiri, P; Boda, Z; Büller, HR; Gudz, I; Lanz, H; Lyons, RM; Meijer, K; Mercuri, MF; Oh, D; Raskob, GE; Segers, A; van Es, N; Weitz, JI; Zhang, G | 1 |
| Matsushima, N; Mendell, J; Parasrampuria, DA; Shi, M; Truitt, K; Zahir, H | 1 |
| Levi, M | 1 |
| Schwartz, JB | 1 |
| Asahara, T; Izumi, M; Izumi, Y; Jiuchi, Y; Kozuru, H; Kumagai, K; Mawatari, M; Migita, K; Motokawa, S; Osaki, M; Sakai, T; Shirakawa, A | 1 |
| Chen, X; Hu, P; Jiang, J; Liu, D; Liu, Y; Song, H; Wu, Y | 2 |
| Saito, S; Shindo, S; Shirakawa, M; Tsudaka, S; Uchida, K; Yoshimura, S | 1 |
| Handa, A; Hurst, KV; O'Callaghan, JM | 1 |
| Barco, S | 1 |
| Ageno, W; Beenen, LF; Brekelmans, MP; Brenner, B; Buller, HR; Chen, CZ; Cohen, AT; Grosso, MA; Meyer, G; Raskob, G; Segers, A; Vanassche, T; Verhamme, P; Weitz, JI; Wells, PS; Zhang, G | 1 |
| Eikelboom, J; Merli, G | 2 |
| DeFelipe, A; Masjuan, J | 1 |
| Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S | 1 |
| Jaffer, IH; Weitz, JI | 1 |
| Granger, CB; Hawkins, NM; Jhund, PS; McMurray, JJ; O'Meara, E; Petrie, MC; Pfeffer, MA; Pozzi, A; Solomon, SD; Swedberg, K; Virani, S; Yusuf, S | 1 |
| Antman, EM; Aylward, P; Braunwald, E; Choi, Y; Giugliano, RP; Mercuri, M; Murphy, SA; Ruff, CT; Steffel, J; White, H; Zamorano, JL | 1 |
| Dellegrottaglie, S; Filippatos, G; Giugliano, RP; Lund, LH; Magnani, G; McMurray, J; Perrone-Filardi, P; Rosano, GM; Savarese, G; Trimarco, B | 1 |
| Davies, AH; Lim, CS; Ravikumar, R | 1 |
| Beyer-Westendorf, J; Hauswald-Dörschel, S; Marten, S; Michalski, F; Tittl, L | 1 |
| Fanikos, J; Huisman, MV | 1 |
| Koyfman, A; Long, B | 1 |
| Barrios, V; Masjuan, J | 1 |
| Ansell, J; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Pokorney, SD; Shrader, P; Singer, DE; Thomas, L | 1 |
| Hernandez, I; Smith, KJ; Zhang, Y | 1 |
| AlEmad, H; AlHajri, L; AlKitbi, N; AlMahri, K; AlMahri, M; Jabbari, S | 1 |
| Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Nishizaki, K; Okumura, K; Sasaki, K; Sasaki, S; Shoji, Y; Tomita, H; Tsushima, Y | 1 |
| Bramlage, P; Minguet, J; Sims, HM; Smith, KH | 1 |
| Aspromonte, N; Colivicchi, F | 1 |
| Dunn, A | 1 |
| Ansell, JE; Bakhru, SH; Brown, K; Costin, JC; Dishy, V; Grosso, MA; Lanz, HJ; Laulicht, BE; Mercuri, MF; Noveck, RJ; Steiner, SS | 1 |
| Doukky, R; Jaffer, AK; Moseley, A; Volgman, AS; Williams, KA | 1 |
| Blann, AD; Boriani, G; Lip, GY | 1 |
| Douglas, JS; Gauthier-Lewis, ML; Riley, TR; Sanchez, CK | 1 |
| Brown, KS; Lee, J; Rubets, I; Shi, M; Vandell, AG; Walker, JR | 1 |
| Bhatt, DL; Fonarow, GC; Harding, T; Hernandez, AF; Khan, Y; Peterson, ED; Schwamm, LH; Suter, RE; Xian, Y | 1 |
| Guo, L; Hong, Y; Li, S; Wang, P; Zhong, X | 1 |
| Coyle, D | 1 |
| Kimura, T; Kumakura, T; Shimizu, T; Tachibana, M; Yoshihara, K | 1 |
| Antman, EM; Braunwald, E; Fanola, CL; Giugliano, RP; Mercuri, MF; Nordio, F; Ruff, CT; Trevisan, M | 1 |
| Buerke, M; Hoffmeister, HM | 1 |
| Antman, EM; Braunwald, E; Crompton, AE; Giugliano, RP; Huikuri, H; Lanz, H; Link, MS; Mercuri, MF; Murphy, SA; Oto, A; Ruff, CT; Scirica, BM | 1 |
| Baig, U; David, T; Poulakos, M; Walker, JN | 1 |
| Oda, H; Sugiyama, T | 1 |
| Broscaru, L; Gulba, DC | 1 |
| Büller, HR; Cohen, A; Di Nisio, M; Grosso, MA; Raskob, G; Winters, SM; Zhang, G | 1 |
| Burkart, T; Rao, PSS | 1 |
| Ageno, W; Becattini, C; D'Angelo, A; Davì, G; De Cristofaro, R; Dentali, F; Di Minno, G; Falanga, A; Gussoni, G; Masotti, L; Palareti, G; Pignatelli, P; Prisco, D; Santi, RM; Santilli, F; Silingardi, M; Tufano, A; Violi, F | 1 |
| Ageno, W; Agnelli, G; Boriani, G; Colonna, P; De Caterina, R; Ghirarduzzi, A; Patti, G; Rossini, R; Rubboli, A; Schinco, P | 1 |
| Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH | 1 |
| Antman, E; Carnicelli, AP; De Caterina, R; Giugliano, RP; Halperin, JL; Mercuri, MF; Nordio, F; Renda, G; Ruff, CT; Trevisan, M | 1 |
| EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I | 1 |
| Ay, C; Dieplinger, B; Domanovits, H; Fries, D; Gary, T; Rohla, M; Vosko, MR; Weiss, TW | 1 |
| Barco, S; Klok, FA; Konstantinides, SV | 1 |
| Antman, EM; Braunwald, E; Carnicelli, AP; De Caterina, R; Giugliano, RP; Mercuri, MF; Nordio, F; Renda, G; Ruff, CT; Trevisan, M | 1 |
| Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P | 1 |
| Blaich, C; Michels, G; Müller, C; Streichert, T; Wiesen, MHJ | 1 |
| Connolly, SJ; Eikelboom, JW; Hirsh, J; Quinlan, DJ; Weitz, JI | 1 |
| Finks, SW; Gibson, CM | 1 |
| Chida, R; Hayashi, A; Kobayashi, S; Komatsu, T; Nakahara, S; Nakamura, H; Nishiyama, N; Taguchi, I; Toratani, M | 1 |
| Barbera, V; Bellasi, A; Campana, C; Cozzolino, M; De Pascalis, A; Di Iorio, B; Di Lullo, L; Galliani, M; Ronco, C; Russo, D; Russo, L; Santoboni, F; Vitaliano, E | 1 |
| Collins, R; Gil, VM; Hanon, O; Hardt, R; Hoffmeister, M; Monteiro, P; Quinn, TJ; Ropers, D; Sergi, G; Verheugt, FWA; Wehling, M | 1 |
| Burnett, AE; Dobesh, PP; Fanikos, J; Mahan, CE | 1 |
| Langer, F; Voigtlaender, M | 1 |
| Cifu, AS; Jain, A | 1 |
| Atiee, GJ; Duchin, K; Duggal, A; He, L; Kakkar, T; Kidokoro, M; Shipitofsky, NL; Takatani, T; Zhang, G | 1 |
| Abugattas de Torres, JP; Brugada, P; Chierchia, GB; Choudhury, R; Coutino-Moreno, HE; de Asmundis, C; De Regibus, V; Iacopino, S; Longobardi, M; Mugnai, G; Storti, C; Stroker, E; Takarada, K | 1 |
| Brown, K; Depasse, F; He, L; Kochan, J; Lin, M; Vandell, A | 1 |
| Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y | 1 |
| Antman, EM; Giugliano, RP; Hamershock, RA; Lanz, HJ; Mercuri, MF; Murphy, SA; Roy, D; Ruff, CT; Senior, R; Steffel, J | 1 |
| Ashaye, A; Deitelzweig, S; Farmer, C; Hamilton, M; Horblyuk, R; Li, X; Luo, X; Vo, L | 1 |
| Imberti, D; Mastroiacovo, D | 1 |
| Cohen, DJ; Giugliano, RP; Hsu, WH; Hui Tan, EC; Li, H; Magnuson, EA; Vilain, KA; Wang, K; Yang, MC | 1 |
| Dentali, F; Fantoni, C | 1 |
| Hu, SJ; Wu, T; Xu, WW | 1 |
| Casson, RJ; Chan, W; Sanders, P; Selva, D; Sun, MT; Wong, CX; Wood, MK | 1 |
| Brown, KS; Grosso, MA; Lin, M; Mercuri, MF; Vandell, AG; Walker, J; Zhang, G | 1 |
| Jolobe, OM | 1 |
| Byström, B; Norrving, B; Oldgren, J; Renlund, H; Själander, A; Sjögren, V; Svensson, PJ | 1 |
| Jolobe, OMP | 1 |
| Amemiya, T; Gi, H; Ikai, Y; Kameda, K; Nagaoka, S; Uesaka, T; Uno, J | 1 |
| Alonso, A; Norby, FL | 1 |
| Furukawa, F; Makino, T; Mizawa, M; Shimizu, T | 1 |
| Blank, BF; Calvert, M; Camm, AJ; Chlouverakis, G; Diener, HC; Goette, A; Huening, A; Kirchhof, P; Lip, GYH; Simantirakis, E; Vardas, P | 1 |
| Hashimoto, S; Hayashi, S; Ishida, K; Kodato, K; Kuroda, R; Kurosaka, M; Matsumoto, T; Oka, S; Shibanuma, N; Takayama, K; Toda, A | 1 |
| Kamata, F; Kamata, M; Murano, J; Nagaba, H; Nagaba, Y; Nonoguchi, H; Okina, C; Shimada, H; Shimada, Y; Takeuchi, Y | 1 |
| Kabra, R; Oliphant, CS; Owens, RE | 1 |
| Davis, DO; Davis, KA | 1 |
| Douxfils, J; Gosselin, RC | 1 |
| Fogerty, AE; Oertel, LB | 1 |
| Petrasko, M; Petraskova, T; Raizada, A | 1 |
| Goette, A; Hammwöhner, M | 1 |
| Antman, EM; Cohen, DJ; Giugliano, RP; Kwong, WJ; Li, H; Magnuson, EA; Ruff, CT; Wang, K | 1 |
| Fujimoto, N; Hasegawa, M; Ikejiri, M; Katayama, N; Matsumoto, T; Ohishi, K; Sudo, A; Tone, S; Wada, H; Wakabayashi, H; Watanabe, M; Yamaguchi, T; Yamashita, Y | 1 |
| Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Iwashita, S; Kaikita, K; Mitsuse, T; Mizuta, H; Nakamura, E; Ogawa, H; Oimatsu, Y; Okamoto, N; Sueta, D; Tsujita, K; Yamabe, S | 1 |
| Akamatsu, Y; Hirotomi, K; Kobayashi, H; Kumagai, K; Kusayama, Y; Okuyama, H; Saito, T; Shinohara, K | 1 |
| Bansal, VK; Choi, MJ; Herzog, CA; Jaar, BG; Kramer, H; Mehta, R; Rocco, MV; Sarnak, MJ | 1 |
| Aihara, S; Fukumitsu, K; Harada, A; Hiramatsu, Y; Hirashima, Y; Iwata, R; Kamimura, T; Kondo, M; Oka, H; Tsuruya, K | 1 |
| Ci, H; Ge, X; Song, W; Tian, G; Zhang, Y | 1 |
| Griffiths, CL; Hicks, S; Livengood, SJ; Vestal, ML | 1 |
| Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX | 1 |
| Basto, AN; Gibson, CM; Howard, ML | 1 |
| Boulouis, G; Charidimou, A; Goldstein, JN; Gurol, ME; Morotti, A; Pasi, M | 1 |
| Kanai, Y; Matsuda, H; Mitaki, S; Oguro, H; Onoda, K; Tahara, N; Takayoshi, H; Yamaguchi, S | 1 |
| Ali, M; Gunasekaran, K; Kaatz, S; Lavender, R; Mahan, CE; Nakhle, A; Paje, DG | 1 |
| Bridgeman, MB; Dalal, KS | 1 |
| Kroeger, K; Kujath, P | 1 |
| Akaike, M; Amano, R; Fukuda, D; Hara, T; Ise, T; Kadota, M; Kusunose, K; Matsuura, T; Oomichi, Y; Sangawa, T; Sata, M; Soeki, T; Tobiume, T; Torii, Y; Ueno, R; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K; Yamazaki, H | 1 |
| Fukuhara, S; Fukuma, S; Furukawa, TA; Goto, Y; Kimachi, K; Kimachi, M | 1 |
| Beer, TM; Daughety, MM; DeLoughery, TG; Olson, SR; Shatzel, JJ | 1 |
| Al-Saady, N; Banach, M; Ezekowitz, MD; Goette, A; Lip, GYH | 1 |
| Furugohri, T; Honda, Y; Morishima, Y | 1 |
| Grove, EL; Hellfritzsch, M; Pottegård, A | 1 |
| Ageno, W; Brekelmans, MPA; Büller, HR; Chen, CZ; Cohen, AT; Grosso, MA; Lin, M; Medina, A; Mercuri, MF; Raskob, G; Segers, A; Vanassche, T; Verhamme, P; Weitz, JI; Wells, PS; Winters, SM | 1 |
| Abe, K; Akao, M; Akishita, M; Fukuzawa, M; Lip, GYH; Okumura, K; Tanizawa, K; Yamashita, T | 1 |
| Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI | 1 |
| Ageno, W; Brekelmans, MPA; Büller, HR; Chen, CZ; Cohen, AT; Grosso, MA; Medina, AP; Mercuri, MF; Raskob, GE; Segers, A; Vanassche, T; Verhamme, P; Weitz, JI; Wells, PS; Winters, SM; Zhang, G | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Glynn, RJ; Krumme, AA; Kulldorff, M; Ortiz, AS; Pawar, A; Schneeweiss, S | 1 |
| Hu, Y; Tang, L; Zhang, Z | 1 |
| Fujino, T; Hamai, A; Hara, F; Harada, M; Ikeda, T; Kabuki, T; Ohara, H; Wakakura, S | 1 |
| Ammar-Busch, S; Bourier, F; Brkic, A; Brooks, S; Deisenhofer, I; Dillier, R; Grebmer, C; Hessling, G; Kaess, B; Koch-Büttner, K; Kolb, C; Kornmayer, M; Kottmaier, M; Lengauer, S; Lennerz, C; Pausch, H; Reents, T; Rousseva, E; Semmler, V; Telishevska, M | 1 |
| Franco Moreno, AI; García Navarro, MJ; Martín Díaz, RM | 1 |
| Bleker, SM; Brekelmans, MPA; Büller, HR; Cohen, AT; Eerenberg, ES; Kraaijpoel, N; Middeldorp, S; Raskob, GE; van Es, N | 1 |
| Arya, R; Chitongo, PB; Dighe, P; Patel, JP; Patel, RK; Roberts, LN; Vadher, B | 1 |
| Emoto, N; Hirata, KI; Nakayama, K; Okano, M; Okita, Y; Onishi, H; Shinke, T; Shinkura, Y; Tamada, N; Tanaka, H; Yanaka, KI | 1 |
| Gil, M; Webster, E | 1 |
| Antman, EM; Braunwald, E; Cavallari, I; Deenadayalu, N; Giugliano, RP; Lanz, H; Mercuri, MF; Nordio, F; Ruff, CT; Rutman, H; Shi, M | 1 |
| Houkin, K; Iwasaki, M; Kawabori, M; Mabuchi, S; Matsubara, K; Niiya, Y; Ozaki, H | 1 |
| Atar, D; Ghanima, W; König, MSS; Raouf, N; Risnes, K; Rutherford, OW | 1 |
| Eckardt, L; Goette, A; Lanz, HJ; Lewalter, T; Reimitz, PE; Smolnik, R; Tijssen, JG; Valgimigli, M; Vranckx, P; Zierhut, W | 1 |
| Adcock, DM; Bates, SM; Douxfils, J; Favaloro, EJ; Gosselin, RC; Gouin-Thibault, I; Guillermo, C; Kawai, Y; Kitchen, S; Lindhoff-Last, E | 1 |
| Asahina, H; Furuta, M; Goudarzi, H; Ikezawa, Y; Kikuchi, E; Kikuchi, H; Kikuchi, J; Mizugaki, H; Nishimura, M; Sakakibara-Konishi, J; Shinagawa, N; Shoji, T; Takashima, Y; Tsujino, I | 1 |
| Ginsberg, JS; Hirsh, J | 1 |
| Hanada, K; Matsubara, H; Matsumoto, SI; Shibata, S; Takahashi, H; Tsukimura, Y | 1 |
| Fortier, K; Reebye, UN; Shroff, D | 1 |
| Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S | 1 |
| Higashiya, S; Hina, K; Hirohata, S; Kamikawa, S; Kawamura, H; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H | 2 |
| Howard, LS | 1 |
| Csanádi, Z; Szegedi, A | 1 |
| Adams, G; Ansel, G; Baumgartner, I; Grosso, M; Jaff, M; Lin, M; Mercur, MF; Minar, E; Moll, F; Nwachuku, C; Rundback, J; Tangelder, M; Zeller, T | 1 |
| Dyrkorn, R; Hegstad, S; Lindahl, S; Spigset, O | 1 |
| Koscielny, J; Rosenthal, C; von Heymann, C | 1 |
| Conley, PB; Curnutte, JT; DeGuzman, F; Hollenbach, SJ; Leeds, JM; Lin, J; Lu, G; Malinowski, J; Pine, P; Pratikhya, P | 1 |
| Aguinaco, MR; Bustins, A; Campoy, D; Canals, T; Cerdá, M; Constans, M; Ene, G; Gabilondo, M; Jiménez, C; Johansson, E; Las Heras, G; López, M; Marzo, C; Mateo, J; Moya, Á; Oliver, A; Olivera, P; Perea, G; Plensa, E; Pons, V; Reverter, JC; Sánchez, E; Santamaría, A; Santos, N; Sorigue, M; Tàssies, D; Varela, A; Vicente, L | 1 |
| Beyer-Westendorf, I; Beyer-Westendorf, J; Endig, S; Marten, S; Reitter, A; Tittl, L | 1 |
| Badreldin, H | 1 |
| Mukai, Y; Nozawa, S; Suzuki, T | 1 |
| Eguchi, M; Ikeda, S; Kawano, H; Koga, S; Koide, Y; Maemura, K; Muroya, T; Sato, D; Tsuneto, A; Yamagata, Y; Yonekura, T; Yoshimuta, T | 1 |
| Camm, J; Cappato, R; Diener, HC; Heidbuchel, H; Hohnloser, SH; Kautzner, J; Lanz, HJ; Mont, L; Morillo, CA; Smolnik, R; Yin, OQP | 1 |
| Oung, AB | 1 |
| Dülgeroglu, J; Schmidt, D | 1 |
| Boswell, R; Pearson, GJ | 1 |
| Antman, EM; Braunwald, E; Douketis, JD; Giugliano, RP; Grip, LT; Mercuri, MF; Murphy, SA; Ruff, CT; Weitz, JI | 1 |
| Khan, SU; Lash, B; Nasir, F; Raghu Subramanian, C; Wolfe, Z | 1 |
| Egawa, T; Izushi, Y; Kiuchi, T; Sato, T; Shimada, K; Shiota, N; Takami, Y; Takuma, R; Tetsunaga, T | 1 |
| Hernandez, I; Hospodar, AR; Smith, KJ; Zhang, Y | 1 |
| Aisenberg, J; Antman, EM; Braunwald, E; Chatterjee-Murphy, P; Choi, Y; Friedman Flack, K; Giugliano, RP; Mercuri, MF; Nordio, F; Ruff, CT; Weitz, JI | 1 |
| Márk, L | 1 |
| Facchinetti, R; Fantin, F; Ferrari, E; Masciocchi, E; Mazzali, G; Nori, N; Rossi, AP; Sant, S; Zamboni, M; Zoico, E | 1 |
| Ašić, A; Marjanović, D; Mirat, J; Primorac, D | 1 |
| Banach, M; Covic, A; Lopatowska, P; Malyszko, J; Mlodawska, E; Sobkowicz, B; Tomaszuk-Kazberuk, A | 1 |
| Abdel-Razeq, H; Finianos, A; Taher, AT | 1 |
| Jain, N; Reilly, RF | 1 |
| Myers, B | 1 |
| Barden, S; Campbell, T; Condliffe, R; Connolly, V; Davies, CWH; Donaldson, J; Everett, B; Free, C; Horner, D; Howard, LSGE; Hunter, L; Kaler, J; Nelson-Piercy, C; O-Dowd, E; Patel, R; Preston, W; Sheares, K | 1 |
| Mohebbi, N | 1 |
| Ageno, W; Ay, C; Blondon, M; Brekelmans, M; Büller, HR; Delluc, A; Eichinger, S; Hutten, BA; Klok, FA; Middeldorp, S; Scheres, L; Schreiber, K; Stach, K | 1 |
| Banach, M; Ezekowitz, MD; Goette, A; Hjortshoj, SP; Kwong, WJ; Lip, GYH; Zamoryakhin, D | 1 |
| Fiorelli, EM; Rossi, RE | 1 |
| Asada, H; Miyagawa, F; Miyao, M; Nishikawa, M; Ogawa, K; Yamamoto, S | 1 |
| Linkins, LA | 1 |
| Lane, DA; Proietti, M | 1 |
| Antman, EM; Braunwald, E; Giugliano, RP; Mercuri, MF; Miller, R; Morrow, D; Ruff, CT; Truitt, K; Weitz, JI; Yin, OQP | 1 |
| Büller, HR; Raskob, GE; Segers, A | 1 |
| Calabrò, MG; Curigliano, G | 1 |
| Hironaka, S | 1 |
| Dufilho, M; Frere, C | 1 |
| Nasser, NJ | 1 |
| Chang, CJ; Chen, SA; Chen, YC; Chen, YJ; Cheng, CC; Higa, S; Huang, JH | 1 |
| Fujino, H; Fukushima, K; Hamano, H; Horinouchi, Y; Ikeda, Y; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Miyamoto, L; Takechi, K; Tamaki, T; Tsuchiya, K; Zamami, Y | 1 |
| Carrier, M; Khorana, AA; Lee, AYY; Meyer, G; Noble, S; O'Connell, C; Soff, G | 1 |
| Antman, EM; Blanc, JJ; Braunwald, E; Cappato, R; Giugliano, RP; Lanz, H; Mercuri, MF; Nordio, F; Ruff, CT; Wiviott, SD; Zelniker, TA | 1 |
| Hiroshima, R; Ikari, K; Ishibashi, M; Mochizuki, T; Okazaki, K; Yano, K | 1 |
| Arena, G; Baratta, A; Bianchi, S; Catarzi, S; Conti, A; Covelli, A; Dell'Amico, I; Mazzucchelli, M; Molesti, D; Orlandi, G; Pampana, A; Perrotta, ME; Tognarelli, A; Torri, T | 1 |
| Beyer-Westendorf, J; Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, M; Hernandez, CR; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, GE; Santamaria, A; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Zhang, G; Zwicker, JI | 1 |
| Ballardini, G; Cortellini, F; Cortellini, G; Gavioli, B; Lippolis, D; Rossi, F | 1 |
| Colonna, P; Matsushita, Y; Santamaria, A; Unverdorben, M; von Heymann, C | 1 |
| Adam, TJ; Alonso, A; Lutsey, PL; MacLehose, RF; Roetker, NS; Zakai, NA | 1 |
| Birschmann, I; Faust, I; Flieder, T; Gripp, T; Hammerschmidt, A; Hendig, D; Knabbe, C; Kuhn, J | 1 |
| Choi, EK; Han, KD; Jung, JH; Lee, SR; Lip, GYH; Oh, S | 2 |
| Goto, S | 1 |
| Aizawa, Y; Fujita, S; Fuse, K; Ikeda, Y; Kitazawa, H; Okabe, M; Sato, T; Takahashi, M | 1 |
| Akaboshi, S; Fujita, H; Inoue, M; Kada, A; Kaneko, H; Kawasaki, M; Koretsune, Y; Kumode, M; Maruhashi, K; Miyanomae, T; Murata, H; Nakamura, M; Ohmori, H; Okumura, A; Saito, AM; Sanayama, Y; Sano, N; Shinagawa, T; Sone, S; Sumimoto, R; Takechi, T; Takizawa, N; Taniguchi, H; Tanuma, N; Wakisaka, A | 1 |
| Baber, U; Boersma, E; Chen, C; Dangas, GD; Hengstenberg, C; Mehran, R; Saito, S; Shi, M; Unverdorben, M; Valgimigli, M; Van Mieghem, NM; Veltkamp, R; Vranckx, P | 1 |
| Di Vincenzo, A; Mioni, R; Rizzo, A; Russo, L | 1 |
| Alcamo, P; Colonna, P; Dentamaro, I; Fazio, G; Gambacurta, R | 1 |
| Endo, S; Kishi, H; Kogiku, M; Noda, M; Notsu, Y; Ota, M; Shimizu, M; Takekawa, M; Yamazaki, H; Yamazaki-Nishioka, M | 1 |
| Antman, EM; Botero, R; Braunwald, E; Corbalán, R; Garcia-Castillo, A; Giugliano, RP; Grip, LT; Hamershock, RA; Horna, M; López-Sendon, J; Nicolau, JC; Ruff, CT; Sotomora, G | 1 |
| Dubner, SJ; Martinenghi, N | 1 |
| Di Lullo, L; Terranova, A; Uguccioni, M | 1 |
| Di Nisio, M | 1 |
| Maurea, N; Riva, L | 1 |
| Antman, EM; Giugliano, RP; Ruff, CT; Zelniker, TA | 1 |
| Lip, GYH | 1 |
| Eguchi, M; Ikeda, S; Kawano, H; Koga, S; Koide, Y; Maemura, K; Sato, D; Tsuneto, A; Yamagata, Y; Yonekura, T; Yoshimuta, T | 1 |
| Andersen, M; Braunschweig, F; Forslund, T; Hjemdahl, P; Komen, JJ; Mantel-Teeuwisse, AK; von Euler, M; Wettermark, B | 1 |
| Jang, E; Joung, B; Kim, D; Kim, JY; Kim, TH; Lee, MH; Lip, GYH; Pak, HN; Uhm, JS; Yang, PS; Yu, HT | 1 |
| Antman, EM; Babilonia, NA; Braunwald, E; Duggal, A; Fanola, CL; Giugliano, RP; Jin, J; Kamphuisen, PW; Mercuri, MF; Murphy, SA; Ruff, CT; Sritara, P | 1 |
| Aoki, J; Kanamaru, T; Kimura, K; Matsumoto, N; Mishina, M; Nishiyama, Y; Nito, C; Okubo, S; Sakamoto, Y; Sekine, T; Shimoyama, T; Suda, S; Suzuki, K | 1 |
| Chang, SH; Chu, PH; Kuo, CF; Tseng, HJ; Wang, CL; Wen, MS; Wu, VC | 1 |
| Amano, T; Harada, K; Inden, Y; Kato, M; Mamiya, K; Marui, N; Matsunaga, S; Murohara, T; Nagao, T; Nishikawa, Y; Shinoda, N; Suzuki, H | 1 |
| Braunschweig, F; Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wallén, H | 1 |
| Hu, A; Niu, J; Winkelmayer, WC | 1 |
| Carli, G; Chiarini, F; Cortellini, G; Farsi, A; Lippolis, D | 1 |
| Pommer, P; Stöllberger, C | 1 |
| Dei, A; Grifoni, E; Landini, G; Masotti, L; Moroni, F; Panigada, G; Spolveri, S; Vannucchi, V | 1 |
| Hashimoto, S; Hayashi, S; Ishida, K; Kodato, K; Kuroda, R; Kurosaka, M; Matsumoto, T; Matsushita, T; Niikura, T; Sasaki, H; Shibanuma, N; Takayama, K; Toda, A | 1 |
| Antman, EM; Braunwald, E; Giugliano, RP; Hamershock, RA; Lanz, HJ; Mercuri, MF; Murphy, SA; Nieminen, M; Peterson, N; Ruff, CT; Steffel, J | 1 |
| Aguiar, VCR; Casella, IB; Fareed, J; Júnior, VC; Ramacciotti, E; Zerati, AE | 1 |
| Gottsäter, A | 1 |
| Själander, A; Själander, S | 1 |
| Oldgren, J | 1 |
| Strandberg, K | 1 |
| Bakhai, A; de Asmundis, C; De Caterina, R; de Groot, JR; Deharo, JC; Kelly, P; Kirchhof, P; Laeis, P; Levy, P; López-de-Sá, E; Monteiro, P; Reimitz, PE; Steffel, J; Waltenberger, J; Weiss, TW; Zierhut, W | 1 |
| Cowperthwaite, M; Fanale, C; Nadasdy, Z; Ramakrishnan, A; Shpak, M | 1 |
| Cipriano, LE; Hachinski, V; Lee, SAW; Ruiz Vargas, E; Sposato, LA | 1 |
| Jafari, M; MacKay, J; Stecker, EC; Warden, BA; Willman, A | 1 |
| Campodonico, P; Guiddo, G; Lerza, R; Malerba, M; Minuto, P; Motta, G; Riccardi, A; Spinola, MB | 1 |
| Antman, EM; Braunwald, E; Chao, TF; Chen, SA; Giugliano, RP; Hamershock, RA; Mercuri, MF; Ruff, CT | 1 |
| Büller, HR; Chiang, CE; Giugliano, RP; Lopes, RD; Patel, MR; Tan, DS; Wang, KL | 1 |
| Eikelboom, JW; Steffel, J | 1 |
| Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI | 1 |
| Antman, EM; Boriani, G; Braunwald, E; Giugliano, RP; Kuder, JF; Lanz, HJ; Mercuri, MF; Ruff, CT; Rutman, H; Shi, M | 1 |
| Chou, PY; Hsu, PC; Huang, TC; Kao, PH | 1 |
| Cohen, AA; De Caterina, R; Goette, A; Heidbuchel, H; Jin, J; Le Heuzey, JY; Lip, GYH; Melino, M; Merino, JL; Winters, SM | 1 |
| Bosch, F; Cerdá, M; Cerezo-Manchado, JJ; Fernández, M; Johansson, E; Martínez, F; Rodríguez, S; Santamaría, A; Varela, A | 1 |
| Rubboli, A | 1 |
| Amiya, R; Higuchi, Y; Hirata, A; Hirayama, A; Kobayashi, T; Sakata, Y; Sotomi, Y | 1 |
| Abe, H; Doi, T; Inagaki, T; Kishi, F; Kishi, S; Minato, M; Murakami, T; Nagai, K; Nishimura, K; Obata, F; Ono, H; Shibata, E; Tamaki, M; Ueda, S | 1 |
| Ahmad, A; Al-Khatib, SM; Blank, M; Coylewright, M; DiBattiste, P; Gersh, BJ; Granger, CB; Healey, JS; Hedrich, O; Hylek, EM; Kline-Rogers, E; Mendys, P; Mirro, MJ; Naccarelli, G; Patel, P; Peterson, ED; Pokorney, SD; Ruff, CT; Rutman, H; Stockbridge, N; Temple, R | 1 |
| Fujisawa, H; Shimizu, Y; Tsuchiya, K | 1 |
| Ay, C; Beer, R; Haushofer, A; Kwasny, O; Leitgeb, J; Ortler, M; Schaden, E; Schöchl, H; Wiegele, M | 1 |
| Cha, MJ; Choi, EK; Joung, B; Kang, KW; Kim, C; Kim, J; Kim, JB; Kim, TH; Lee, JM; Lee, SR; Lee, YS; Park, HW; Park, J; Park, JK; Park, JS; Shim, J; Uhm, JS | 1 |
| Du, Q; Qian, Y; Xue, W; Yao, X | 1 |
| Ebato, M; Higashino, M; Hozumi, T; Kogo, M; Matsui, M; Nakamura, S; Sasaki, T; Shimizu, T; Sunaga, T; Suzuki, H; Takahashi, N; Watanabe, T | 1 |
| Burhenne, J; Foerster, KI; Haefeli, WE; Lehmann, ML; Mikus, G; Schaumaeker, M | 1 |
| Arakawa, Y; Isobe, K; Koh, K; Mori, M; Watanabe, K; Yanagi, M | 1 |
| Baranchuk, A; Corbalán, R; Enríquez, A | 1 |
| Becattini, C; Giustozzi, M; Vedovati, MC | 1 |
| Hanada, H; Inoue, R; Mitsutake, T; Morinaga, Y; Nii, K; Sakamoto, K | 1 |
| Kataoka, N; Kinoshita, K; Kinugawa, K; Nakatani, Y; Nishida, K; Sakamoto, T; Tsujino, Y; Yamaguchi, Y | 1 |
| Fujitaka, K; Hamada, H; Hattori, N; Horimasu, Y; Iwamoto, H; Masuda, T; Miyamoto, S; Nakao, S; Nakashima, T; Sakamoto, S; Yamaguchi, K | 1 |
| Barrios, V; Cervantes, CE; Merino, JL | 1 |
| Oo, TH; Rojas-Hernandez, CM | 1 |
| Carrier, M; Kimpton, M | 1 |
| Marijon, E; Martin, AC; Narayanan, K | 1 |
| Pickett, JD | 1 |
| Abozguia, K; Camm, J; Cappato, R; Diener, HC; Grimaldi, M; Heidbüchel, H; Hohnloser, SH; Kautzner, J; Mönninghoff, C; Mont, L; Morillo, CA; Rauer, H; Reimitz, PE; Smolnik, R | 1 |
| Doré, E; Grèze, V; Lebreton, A; Pereira, B; Sinegre, T; Zlobecki, M | 1 |
| Abe, T; Hasegawa, I; Itoh, Y; Mino, T; Okamoto, K; Takeda, A | 1 |
| Anguita, M; Barja de Soroa, P; Lekuona, I; Pérez-Alcántara, F; Rodríguez, JM; Zamorano, JL | 1 |
| Anker, SD; Doehner, W; von Haehling, S | 1 |
| De Candia, E; De Cristofaro, R; Di Gennaro, L; Lancellotti, S | 1 |
| Fujimoto, E; Kagawa, K; Sata, M; Yagi, S | 1 |
| Asamura, T; Nakamura, M; Shiosakai, K; Uchino, K; Yamada, N | 1 |
| Chan, YH; Chang, SH; Chao, TF; Kuo, CT; Lee, HF; Lip, GYH; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Arita, T; Morishima, Y; Otsuka, T; Suzuki, S; Takita, A; Yagi, N; Yamashita, T | 2 |
| Akiyoshi, K; Goya, M; Hirao, K; Kawabata, M; Koyama, T; Maeda, S; Sekigawa, M; Takahashi, Y; Yagishita, A; Yamamoto, T | 1 |
| Attena, E; D'Onofrio, A; Galasso, G; Mazzone, C; Melillo, E; Nigro, G; Parisi, V; Rago, A; Riegler, L; Rotunno, R; Russo, V | 1 |
| Granger, CB; Pokorney, SD | 1 |
| Eto, H; Fukuda, H; Imai, T; Ito, H; Kasai, T; Kawabe, K; Miyahara, Y; Muramatsu, S; Nakahara, M | 1 |
| Andreotti, F; Crea, F; D'Amario, D; De Cristofaro, R; Galli, M; Lancellotti, S; Meleo, E; Porto, I; Sabatelli, M; Vergallo, R | 1 |
| Garcia, DA; Li, A; Lyman, GH; Manohar, PM; Steuten, LM | 1 |
| Connell, NT; Connors, JM | 1 |
| Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J | 1 |
| Hirai, A; Ichiki, Y; Imanishi, N; Ishida, T; Kusanagi, K; Shinohara, S; Takeda, Y; Tanaka, F; Tashima, Y; Yoshimatsu, K | 1 |
| Cho, EJ; Cho, YS; Jang, BM; Koo Lee, M; Lee, OS; Rhie, SJ; Shin, EJ; Suh, SY | 1 |
| Choi, EK; Lee, SR | 1 |
| Bakhai, A; de Asmundis, C; De Caterina, R; de Groot, JR; Deharo, JC; Kelly, P; Kerschnitzki, M; Kirchhof, P; Laeis, P; Levy, P; López-de-Sá, E; Monteiro, P; Reimitz, PE; Steffel, J; Waltenberger, J; Weiss, TW; Zierhut, W | 1 |
| Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L | 1 |
| Bergfeldt, L; Blomström-Lundqvist, C; Boriani, G; Botto, GL; Camm, AJ; Capucci, A; Goette, A; Hohnloser, SH; Israel, CW; Lozano, IF; Merino, JL | 1 |
| Daida, H; Fujimoto, S; Hagiwara, N; Iguchi, Y; Iwasaki, YK; Kaburagi, J; Kanamaru, T; Kimura, K; Kimura, T; Kitagawa, K; Kusano, K; Matsumoto, T; Miyamoto, S; Nishiyama, Y; Okumura, K; Otsuka, T; Sakamoto, Y; Shimizu, W; Toyoda, K; Yamamoto, T | 1 |
| Antman, EM; Bergmark, BA; Braunwald, E; Chung, N; Giugliano, RP; Lanz, HJ; Park, S; Ruff, CT; Shi, M | 1 |
| Hasegawa, K; Miyazaki, Y; Morimoto, T; Sase, K | 1 |
| Cohen, AA; De Caterina, R; de Groot, JR; Ezekowitz, MD; Goette, A; Heidbuchel, H; Jin, J; Le Heuzey, JY; Lip, GYH; Melino, M; Merino, JL; Merkely, B; Themistoclakis, S; Winters, SM | 1 |
| Ando, M; Chihara, H; Hatano, T; Higashi, E; Kamata, T; Kondo, D; Nagata, I; Ogura, T; Sakai, S; Sakamoto, H; Suzuki, K; Yamagami, K | 1 |
| Albendín Iglesias, H; Arregui Montoya, F; Bailén Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Lova Navarro, A; Manzano-Fernández, S; Pascual Figal, DA | 1 |
| Hamamura, K; Hirata, S; Irie, T; Ishitsuka, Y; Jono, H; Kadowaki, D; Kakizoe, Y; Kashiyama, M; Kitamura, K; Kondo, Y; Mukoyama, M; Narita, Y; Saito, H; Utsumi, S | 1 |
| Agarwal, M; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Garcia, E; Kairouz, V; Kureti, M; Moon, JY; Nagaraju, D; Rivas Rios, J; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Wali, M; Yaranov, D; Zenni, MM | 1 |
| Gorog, DA | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Batushkin, V; Campo, G; Eckardt, L; Gargiulo, G; Goette, A; Laeis, P; Lewalter, T; Lysak, Z; Milewski, K; Reimitz, PE; Smolnik, R; Tijssen, J; Vakaliuk, I; Valgimigli, M; Vranckx, P; Zierhut, W | 1 |
| Kimura, T; Matsumoto, T; Mukai, Y; Okumura, K; Origasa, H; Takahashi, N; Yamaguchi, K | 1 |
| Fernández-Ruiz, I | 1 |
| Antman, EM; Bergmark, BA; Braunwald, E; Giugliano, RP; Kamphuisen, PW; Kuder, JF; Lanz, HJ; Mercuri, MF; Nordio, F; Ruff, CT; Wiviott, SD | 1 |
| Furukawa, Y; Hashida, T; Ikesue, H; Kinoshita, M; Kitai, T; Muroi, N; Nakagawa, H; Takase, T | 2 |
| Chistolini, A; Foà, R; Santoro, C; Serrao, A | 1 |
| Beauchesne, LM; Bouma, BJ; Khairy, P; Macle, L; Mongeon, FP; Mulder, BJM; Schwerzmann, M | 1 |
| Agnelli, G; Chen, C; Chiu, KM; Choi, WI; Cohen, A; De Caterina, R; Kaburagi, J; Kim, YH; Kirchhof, P; Koretsune, Y; Laeis, P; Nakamura, M; Rauer, H; Reimitz, PE; Thee, U; Unverdorben, M; Wang, CC; Yamashita, T | 1 |
| Bae, HJ; Cho, YK; Choi, SW; Han, S; Hur, SH; Hwang, J; Jun, SW; Kim, H; Kim, IC; Lee, CH; Lee, SH; Nam, CW; Park, HS; Yoon, HJ | 1 |
| Eschler, CM; Exadaktylos, AK; Funk, GC; Lindner, G; Maier, V; Walter, P; Woitok, BK | 1 |
| Antman, EM; Corbalan, R; Duris, T; Giugliano, RP; Juul-Möller, S; Kerschnitzki, M; Nicolau, AM; Nicolau, JC; Nordio, F; Ruff, CT; Trevisan, M; Voitk, J; Zierhut, W | 1 |
| Pastori, D; Pignatelli, P; Violi, F | 1 |
| Büller, HR; Carrier, M; Di Nisio, M; Duggal, A; Gaddh, M; Garcia, D; Grosso, MA; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, G; Royle, G; Segers, A; Shivakumar, S; van Es, N; Verhamme, P; Wang, T; Weitz, JI; Zhang, G | 1 |
| Larsen, TB; Lip, GYH; Nielsen, PB; Skjøth, F; Søgaard, M | 1 |
| Bhat, Y; Dixit, A; Mistri, A; Patel, B; Quoraishi, SH; Uprichard, J | 1 |
| Marti, C; Righini, M; Robert-Ebadi, H; Rossel, A; Stebler-Fontaine, L | 1 |
| Itagaki, H; Katuhiko, S | 1 |
| Bornfleth, P; Bukowska, A; Gardemann, A; Goette, A; Isermann, B; Peter, D; Schild, L; Walles, T; Wiese-Rischke, C | 1 |
| Jimi, S; Kamei, T; Oohata, Y; Takahata, S; Tamura, T | 1 |
| Do Kim, J; Kim, BS; Kim, JM; Yoon, JS | 1 |
| Al-Saady, N; Cohen, A; Goette, A; Goudev, A; Hjortshøj, SP; Huber, K; Jin, J; Kozieł, M; Lip, GYH; Melino, M; Winters, SM | 1 |
| Alpan, L; Devel, P; Dogné, JM; Douxfils, J; Elasaad, K; Laloy, J; Siriez, R | 1 |
| Drabik, L; Potpara, T; Undas, A | 1 |
| Chaiyakunapruk, N; Dilokthornsakul, P; Hollingworth, W; Jahan, NK; Kongpakwattana, K; Lai, NM; Nathisuwan, S; Ng, SS | 1 |
| Aimo, A; De Caterina, R; Petricciuolo, S | 1 |
| Alves, G; Bicker, J; Falcão, A; Fortuna, A; Gouveia, F; Rocha, M; Santos, J | 1 |
| Goto, E; Horinaka, S; Ishimitsu, T; Kato, T | 1 |
| Antman, EM; Braunwald, E; Giugliano, RP; Goudev, A; Grosso, MA; Lanz, HJ; Morais, J; Ostojic, MC; Park, JG; Plitt, A; Ruff, CT | 1 |
| Ali, H; Hanley, DF; Marsh, EB; Nyquist, PA; Shin, SS; Ziai, WC | 1 |
| Attena, E; De Caterina, R; Di Pasquale, G; Diemberger, I; Riva, L; Sangiuolo, R | 1 |
| Bachmann, P; Böhm, M; Custodis, F; Millenaar, D; Schirmer, SH | 1 |
| Castillo, J; Conley, PB; Crowther, M; Curnutte, JT; Karbarz, MJ; Leeds, JM; Levy, GG; Lu, G; Mathur, VS | 1 |
| Zidek, W | 1 |
| De Caterina, R; Goette, A; Huber, K; Jin, J; Kozieł, M; Lip, GYH; Melino, M; Merino, JL | 1 |
| De Caterina, R; Limbruno, U | 1 |
| Gremmel, T; Huber, K | 1 |
| Auer, J; Berent, R; Gurtner, F | 1 |
| Basili, S; Proietti, M; Romiti, GF | 1 |
| Gurbel, PA; Jeong, YH; Kim, YL; Tantry, U | 1 |
| Hirao, K; Hirao, T; Nakamura, RA; Oda, A; Okishige, K; Sasano, T; Shigeta, T; Tachibana, S; Yamauchi, Y; Yoshida, H | 1 |
| Atripaldi, L; D'Onofrio, A; Di Micco, P; Giannetti, L; Golino, P; Laezza, N; Nigro, G; Rago, A; Russo, V | 1 |
| Ivankova, J; Mokan, M; Nehaj, F; Sokol, J; Stasko, J | 1 |
| Barillari, G; Bortoluzzi, C; Dentali, F; Giorgi, M; Orabona, R; Pacetti, E; Sciatti, E; Zaffaroni, M | 1 |
| De Caterina, R; Goette, A; Heidbuchel, H; Huber, K; Jin, J; Lip, GYH; Merino, JL | 1 |
| Arita, T; Kiyosawa, N; Morishima, Y; Otsuka, T; Suzuki, S; Watanabe, K; Yagi, N; Yamashita, T | 1 |
| Ho, KH; Leng, G; van Hove, M | 1 |
| Arya, R; Couchman, L; Kipper, K; Patel, JP; Zhao, Y | 1 |
| Auditeau, C; Blandinières, A; Gendron, N; Smadja, DM; Talbot, A | 1 |
| Acar, RD; Akgün, T; Camm, AJ; Emren, V; Kanat, S; Karacağlar, E; Kepez, A; Kul, Ş; Özel, E; Şimşek, E; Tülüce, K; Türk, UÖ; Yakar Tülüce, S | 1 |
| Liu, X; Xu, ZX; Yu, P; Yuan, P; Zhu, WG | 1 |
| Ajioka, M; Asano, H; Ishii, H; Kambara, T; Murohara, T; Nakashima, Y; Osanai, H; Sakaguchi, T; Tanaka, A; Tobe, A | 1 |
| Ageno, W; Casella, IB; Chee, KH; Desch, M; Donado, E; Goldhaber, SZ; Reilly, PA; Schellong, S; Schulman, S; Singer, DE; Tang, W; Voccia, I | 1 |
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
| Beyer-Westendorf, I; Beyer-Westendorf, J; Bornhäuser, M; Festerling, E; Hänsel, U; Marten, S; Mizera, H; Naue, C; Reitter, A; Schreier, T; Spindler, M; Tittl, L | 1 |
| Jenkins, A; Katada, J; Kohsaka, S; Li, B; Mardekian, J; Saito, K; Terayama, Y | 1 |
| Bauersachs, J; Berliner, D; Flierl, U; Schäfer, A | 1 |
| Akutsu, S; Ariizumi, S; Hoshikawa, K; Kawakami, J; Maekawa, Y; Naito, T; Saotome, M | 1 |
| Kobayashi, H; Nomoto, N; Okoshi, Y; Seki, Y; Sone, H; Uemura, S | 1 |
| Chen, C; Colonna, P; Laeis, P; Santamaria, A; Saxena, M; Unverdorben, M; Vanassche, T; von Heymann, C; Wilkins, R; Wolpert, D | 1 |
| Angheloiu, AA; Angheloiu, GO; Ruse, C; Shaffer, SA; Tan, Y | 1 |
| Alexandre, J; Chrétien, B; Dolladille, C; Fedrizzi, S; Lelong-Boulouard, V; Sassier, M | 1 |
| Birschmann, I; Bombach, P; Ebner, M; Härtig, F; Hörber, S; Kuhn, J; Mengel, A; Peter, A; Poli, S; Sonnleitner, M; Spencer, C; Stefanou, MI; Ziemann, U | 1 |
| Adelmeijer, J; Blokzijl, H; Bos, S; Kamphuisen, PW; Lisman, T; Schreuder, T | 1 |
| Almengló, C; Álvarez, E; González-Juanatey, JR; González-Peteiro, M; Mosquera-Garrote, N | 1 |
| Boriani, G; Corsini, A; Ferri, N; Proietti, M | 1 |
| Ameri, P; De Caterina, R; Di Pasquale, G; Riva, L; Toma, M | 1 |
| Fukushima, K; Hagiwara, N; Haruki, S; Jujo, K; Kikuchi, Y; Minami, Y; Murasaki, K; Ogawa, H; Sekiguchi, H; Tanaka, H; Yoshida, A | 1 |
| Abdelmaseeh, P; Asinger, R; Megaly, M; Sedhom, R | 1 |
| Huang, M; Liu, X; Ma, J; Ye, C; Zeng, C; Zeng, J | 1 |
| Ebner, M; Lankeit, M | 1 |
| Abe, K; Fujita, M; Hayashi, M; Hikichi, T; Imaizumi, H; Nakamura, J; Ohira, H; Sugaya, T; Takagi, T; Takahashi, A | 1 |
| Doyama, H; Fujishiro, M; Fujita, T; Hasatani, K; Hatta, W; Hiasa, Y; Hikichi, T; Igarashi, K; Iguchi, M; Inoue, T; Kawaguchi, K; Kitamura, K; Kuribayashi, S; Mikami, T; Morita, Y; Nishida, T; Nishikawa, J; Oda, I; Sumiyama, K; Sumiyoshi, T; Tomida, H; Tsuji, Y; Uraoka, T; Yada, T; Yamamoto, K; Yanagitani, A; Yoshio, T | 1 |
| Eichinger, S; Grosso, MA; Kyrle, PA; Lin, M; Shi, M | 1 |
| Aballi, S; Bergan, J; Fronas, S; Garabet, L; Ghanima, W; Overstad, S; Tjonnfjord, E | 1 |
| Chen, HB; Li, YH; Xiu, J; Yu, TH | 1 |
| Bakhai, A; de Asmundis, C; De Caterina, R; de Groot, JR; Deharo, JC; Kelly, P; Kirchhof, P; Laeis, P; Levy, P; López-de-Sá, E; Manu, MC; Monteiro, P; Reimitz, PE; Steffel, J; Waltenberger, J; Weiss, TW; Zierhut, W | 1 |
| Lopes, DG; Schipp, B; Siepmann, T; Tamayo, A | 1 |
| Agnelli, G; Ay, C; Bramlage, P; Brüggenjürgen, B; Cohen, AT; Coppens, M; Fronk, EM; Gaine, S; Hainaut, P; Hoffmann, U; Jimenez, D; Laeis, P; Levy, P; Malzer, T; Manu, MC; Reimitz, PE; Schindewolf, M; Zierhut, W | 2 |
| Eckardt, L; Goette, A; Laeis, P; Lewalter, T; Marin, F; Reimitz, PE; Schiele, F; Smolnik, R; Tijssen, J; Unikas, R; Valgimigli, M; Vranckx, P; Zierhut, W | 1 |
| Akao, M; Akashi, S; Akishita, M; Eshima, K; Fukuzawa, M; Hayashi, T; Kawata, M; Lip, GYH; Okazaki, O; Okumura, K; Tanizawa, K; Yamashita, T; Yoshida, T | 1 |
| Carli, G; Farsi, A; Franceschini, L; Landini, G; Matarrese, D | 1 |
| Albertsen, IE; Højen, AA; Larsen, TB; Nielsen, PB; Noble, S; Ording, AG; Overvad, TF; Søgaard, M | 1 |
| Robson, A | 1 |
| Goya, M; Hirao, K; Kawabata, M; Maeda, S; Sasano, T; Takahashi, Y; Yagishita, A | 1 |
| Choe, WS; Choi, EK; Han, KD; Jung, JH; Kwon, S; Lee, E; Lee, SR; Lip, GYH; Oh, S | 1 |
| Dannenberg, L; Hohlfeld, T; Kelm, M; Orban, M; Petzold, T; Polzin, A; Thienel, M; Wolff, G; Zeus, T | 1 |
| Attena, E; Golino, P; Nigro, G; Papa, AA; Parisi, V; Rago, A; Russo, V | 1 |
| Kawano, Y; Tamura, A; Yamamoto, E | 1 |
| Aucella, F; Barcellona, D; Brunori, G; Forneris, G; Genovesi, SC; Grandone, E; Gresele, P; Marietta, M; Poli, D; Testa, S; Tripodi, A | 1 |
| Backman, JT; Havrdová, M; Jalonen, J; Kurkela, M; Olkkola, KT; Peltoniemi, M; Saari, TI; Schramko, A; Tienhaara, A; Vahlberg, T | 1 |
| Camporese, G; Di Micco, P; Fernández-Capitán, C; Font, C; Monreal, M; Prandoni, P; Rivas, A; Sahuquillo, JC; Simioni, P; Villares, P | 1 |
| Bauersachs, R | 1 |
| Avilés Toscano, A; Cristobo Sainz, P; Guerrero-Márquez, FJ; Sainz-Hidalgo, I; Sigler Vilches, I; Soto-Espinosa de Los Monteros, B | 1 |
| Haas, S; Patti, G | 1 |
| Bando, T; Hirai, O; Hori, S; Kuroyama, T; Mikami, K; Shimo, D; Ueno, Y | 1 |
| Ishibashi, S; Nishida, Y; Sugita, Y; Yokota, T | 1 |
| Liuzzo, G; Patrono, C | 1 |
| Hara, N; Motoyama, A; Ouchi, A; Sugiyama, Y; Takamoto, T; Tanaka, R; Tsuchiya, T; Yanagawa, Y | 1 |
| Fanaroff, AC; Lopes, RD | 1 |
| Cho, YS; Jang, BM; Kim, W; Lee, KE; Lee, MK; Lee, OS; Min, KH | 1 |
| Furuta, K; Ishii, K; Kobayashi, M; Morishita, E; Saito, K; Wada, Y | 1 |
| Antman, EM; Braunwald, E; Cohen, DJ; Giugliano, RP; Kwong, WJ; Li, H; Magnuson, EA; Ruff, CT; Vilain, K | 1 |
| Yavelov, IS | 1 |
| Aprile, F; Breccia, M; Chistolini, A; Fiori, L; Gioia, S; Lucani, B; Merli, M; Riggio, O; Serrao, A | 1 |
| Costa, FM; Hemels, MEW | 1 |
| Monteiro, P | 1 |
| Kamata, K; Kitazumi, Y; Osaka, S; Sezai, A; Suzuki, K; Tanaka, M; Taoka, M | 1 |
| Arya, R; Brown, A; Byrne, R; Coles, E; Czuprynska, J; Gee, E; Patel, JP; Patel, R; Rea, C; Roberts, LN; Saul, G; Speed, V; Vadher, B | 1 |
| Bottino, R; Carbone, A; D'Andrea, A; Golino, P; Liccardo, B; Nigro, G; Papa, AA; Rago, A; Russo, V; Spaccarotella, C | 1 |
| Chan, N; Eikelboom, JW; Sobieraj-Teague, M | 1 |
| Camm, AJ; Cappato, R; Diener, HC; Heidbüchel, H; Hohnloser, SH; Kautzner, J; Lanz, HJ; Mont, L; Morillo, CA; Rauer, H; Reimitz, PE; Smolnik, R | 1 |
| Chen, C; Colonna, P; Jin, J; Laeis, P; Santamaria, A; Saxena, M; Unverdorben, M; Vanassche, T; von Heymann, C; Wilkins, R | 1 |
| Arlett, P; Eichler, HG; Kurz, X; Nolte, A; Rasi, G; Straus, S | 1 |
| Clegg, A; Gale, CP; Hall, M; Kunadian, V; Rockwood, K; Searle, SD; Todd, O; Wilkinson, C; Wu, J | 1 |
| Avorn, J; Gagne, JJ; Kesselheim, AS; Rome, BN | 1 |
| Egred, M; Farag, M; Gorog, DA; Gue, YX; Spinthakis, N | 1 |
| Fujitaka, K; Hamai, K; Hongoh, M; Hotta, T; Ishihara, N; Ishikawa, N; Isobe, T; Kobayashi, M; Kubota, T; Nakamura, A; Nishimura, N; Sugisaka, J; Tanino, A; Tsubata, Y; Yamasaki, M | 1 |
| Steinberg, DI | 1 |
| Ahn, JM; Jung, SC; Kang, DY; Kang, JW; Kang, SH; Kao, HL; Kim, DH; Kim, KW; Kim, WJ; Ko, E; Ko, TY; Koo, HJ; Lam, SCC; Lee, JH; Lee, YT; Lin, MS; Park, DW; Park, H; Park, SJ; Wei, J; Wong, AYT; Yang, DH; Yin, WH; Yun, SC | 1 |
| Blankoff, I; Casado Arroyo, R; Catez, E; Cools, F; Crijns, HJGM; de Asmundis, C; De Caterina, R; de Groot, JR; de Pauw, M; de Veer, A; de Vries, TAC; Hemels, MEW; Kirchhof, P; Lancellotti, P; Mairesse, GH; Vanacker, P; Vanassche, T; Yperzeele, L | 1 |
| Antman, EM; Braunwald, E; Giugliano, RP; Lanz, HJ; Nelson, SE; Norden, AD; Park, JG; Rost, NS; Ruff, CT; Silverman, S; Singhal, AB | 1 |
| Holzgreve, H | 1 |
| Colonna, P; Fazio, G; Fischetti, A; Mannarini, A; Mazzetti, M; Squizzato, A | 1 |
| Kawai, H; Shiojiri, T | 1 |
| Honda, Y; Ito, Y; Morishima, Y; Noguchi, K; Shibutani, T | 1 |
| Feng, W; Huang, D; Lu, A; Wang, X | 1 |
| Ando, S; Izumi, T; Kato, T; Matsumoto, Y; Mikkaichi, T; Okudaira, N; Shimizu, T; Yoshigae, Y | 1 |
| Asano, F; Endo, I; Horii, N; Izumisawa, Y; Miura, M; Morioka, D; Nakayama, G; Oyama, N; Sato, Y; Toyoda, J | 1 |
| Liang, X; Lin, Z; Liu, M; Xie, W | 1 |
| Chang, C; Kong, D; Lee, S; Leung, KSK; Liu, T; Tse, G; Wai, AKC; Zhang, Q; Zhou, J | 1 |
| Fukaya, S; Fukuyasu, A; Hayashi, K; Ishikawa, T; Kamata, M; Miyazaki, M; Mukai, K; Nagata, M; Ohnishi, T; Tada, Y; Tanaka, T | 1 |
| Hioki, H; Katayama, T; Kawasugi, K; Kozuma, K; Takahashi, S; Watanabe, Y; Yokoyama, N | 1 |
| Shrikant Kulkarni, N | 1 |
| Steurer, J | 1 |
| Antman, EM; Braunwald, E; Connolly, S; Giugliano, RP; Murphy, SA; Park, JG; Ruff, CT; Steffel, J; Yin, O | 1 |
| Oh, HJ; Park, BJ; Ryu, KH; Yoon, BH | 1 |
| Chao, TF; Chen, C; De Caterina, R; Hong, KS; Kirchhof, P; Lee, BC; Reimitz, PE; Unverdorben, M; Wang, CC | 1 |
| Akashi, YJ; Ako, J; Doi, S; Inomata, T; Ishida, M; Kida, K; Kimura, T; Matsumoto, N; Nabeta, T; Ohta, Y; Shiono, T; Suzuki, N; Takita, A; Tsukahara, M; Yamaguchi, K | 1 |
| Alexandris-Souphis, T; Ali, MA; Barnes, GD; Decamillo, D; Errickson, J; Froehlich, JB; Haymart, B; Kaatz, S; Kline-Rogers, E; Kong, X; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Shankar, SR; Sood, SL | 1 |
| Cuccia, C; Enea, I; Fresco, C; Paciaroni, M; Patti, G; Pecora, D; Rocca, B; Rubboli, A | 1 |
| Daei, M; Heidari, Z; Khalili, H | 1 |
| Bradley, SM; Gosch, KL; Hess, PL; Jani, SM; Maddox, TM; Michael Ho, P; Varosy, PD; Virani, SS | 1 |
| Bourdin, M; Conley, PB; Contant, G; Depasse, F; Herve, T; Lu, G; Mathieu, O; Perrotin, D | 1 |
| Drabik, L; Undas, A | 1 |
| Grove, EL; Larsen, TB; Lip, GYH; Nielsen, PB; Ording, AG; Skjøth, F; Søgaard, M | 1 |
| Jensen, M; Lip, GY; Nielsen, PB; Ording, AG; Søgaard, M | 1 |
| Cappannoli, L; Crea, F; D'Amario, D; De Cristofaro, R; Galli, M | 1 |
| Antman, EM; Braunwald, E; Giugliano, RP; Ruff, CT; Steffel, J | 1 |
| Kimura, T; Mukai, Y; Okumura, K; Origasa, H; Shinohara, T; Takahashi, N; Takita, A; Yamaguchi, K | 1 |
| Giacomuzzi, K; Jani, E; Marschang, P; Mueller, T; Thuile, K | 1 |
| Berger, F; Bhatt, MD; Dave, J; Duggal, A; Goldenberg, NA; Grosso, M; Jacobs, JP; Newburger, J; Pandya, G; Portman, MA | 1 |
| Antman, EM; Berg, DD; Braunwald, E; Giugliano, RP; Im, K; Jarolim, P; Morrow, DA; Ruff, CT; Rutman, H; Tang, M | 1 |
| Ajmal, M; Lassar, T; Pecci, C; Srinivasan, S | 1 |
| Asti, A; Bottino, R; Di Palma, G; Imbalzano, E; Langella, V; Maresca, G; Pomponi, D; Russo, V; Sassone, C | 1 |
| Anderson, R; Baber, U; Boersma, E; Capranzano, P; Chen, C; Dangas, GD; Duggal, A; Hambrecht, R; Hayashida, K; Hengstenberg, C; Jin, J; Kim, HS; Laeis, P; Lang, I; Lanz, H; López-Otero, D; Mehran, R; Meincke, F; Möllmann, H; Moreno, R; Nombela-Franco, L; Nordbeck, P; Ohlmann, P; Pilgrim, T; Rodés-Cabau, J; Saito, S; Shawl, F; Thiele, H; Unverdorben, M; Valgimigli, M; Van Mieghem, NM; Veltkamp, R; Vranckx, P; Watanabe, Y; Yamamoto, M; Zamorano, JL | 1 |
| Bosch, FTM; Büller, HR; Carrier, M; Di Nisio, M; Duggal, A; Garcia, D; Grosso, MA; Huisman, MV; Kamphuisen, PW; Middeldorp, S; Mulder, FI; Raskob, GE; Segers, A; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Zwicker, JI | 1 |
| Aoyama, T; Enomoto, A; Kawano, Y; Mano, Y; Nagata, M; Nishikawa, T; Sasaki, Y; Takahashi, H | 1 |
| Alhamhoom, Y; Islam, N; Izake, EL; Mendhi, J; Muneer, S; Rashid, MA; Sabuj, MZR; Wang, T; Xiao, Y | 1 |
| Bieber, M; Foerster, KI; Haefeli, WE; Kraft, P; Pham, M; Schuhmann, MK | 1 |
| Abrantes, AR; Duarte, R; Lopes, K; Luz, I | 1 |
| Fukuoka, H; Hoshida, S; Inoue, S; Inui, H; Minamisaka, T; Mine, K; Shinoda, Y; Tachibana, K; Ueno, K; Watanabe, T | 1 |
| Chen, C; Colonna, P; Jin, J; Santamaria, A; Saxena, M; Unverdorben, M; Vanassche, T; von Heymann, C; Wilkins, R | 1 |
| Brüggenjürgen, B; Gao, X; Marston, XL; Unverdorben, M; Wang, R; Ye, X; Yeh, YC; Zimmermann, L | 1 |
| Abe, K; Amano, H; Asaoka, Y; Honda, T; Kodashima, S; Komatsuda, S; Kozuma, K; Manabe, D; Tanaka, A; Yamamoto, H; Yamamoto, T; Yanagisawa, D | 1 |
| Duggal, A; Grosso, MA; Kakkar, T; Kotsuma, M; Lanz, H; Shi, M; Yin, O | 1 |
| Bolek, T; Grilusová, K; Mokáň, M; Samoš, M; Škorňová, I; Staško, J | 1 |
| Antman, EM; Bonaca, MP; Braunwald, E; Cunningham, JW; Giugliano, RP; Grosso, MA; Halperin, JL; Lanz, HJ; Murphy, SA; Ruff, CT; Weitz, JI; Wiviott, SD | 1 |
| Chang, C; Hou In Chou, O; Iltaf Satti, D; Ka Chung Wai, A; Lee, S; Liu, T; Liu, X; Roever, L; Tai Loy Lee, T; Tak Wong, W; Tse, G; Zhang, Q; Zhou, J | 1 |
| Antman, EM; Berger, D; Braunwald, E; Chen, C; Eisen, A; Gencer, B; Giugliano, RP; Grip, LT; Lanz, H; Murphy, SA; Nordio, F; Ruff, CT | 1 |
| Benz, AP; Conley, P; Connolly, SJ; Crowther, M; Eikelboom, JW; Lu, G; Middeldorp, S; Milling, TJ; Xu, L; Yue, P | 1 |
| Jaffray, J; Young, G | 1 |
| Bacchiarri, F; Bocchia, M; Calzoni, P; Fineschi, D; Puccetti, L; Sammartano, V; Santoni, A | 1 |
| Haraguchi, Y; Inoue, M; Minami, K; Naito, S; Nakamura, K; Sasaki, T; Yoshimura, S | 1 |
| Colivicchi, F | 1 |
| Akashi, YJ; Ako, J; Doi, S; Inomata, T; Ishida, M; Kida, K; Kimura, T; Matsumoto, N; Morishima, Y; Nabeta, T; Ohta, Y; Shiono, T; Suzuki, N; Takita, A; Tsukahara, M | 1 |
| Cho, MS; Cho, YR; Choi, EK; Hwang, J; Hwang, KW; Jin, ES; Kang, DY; Kim, KH; Kim, PJ; Kim, YR; Kwon, CH; Lee, CH; Lee, JH; Nam, GB; Oh, YS; Park, DW; Park, GM; Park, HW; Park, KH; Park, KM; Yoo, KD | 1 |
| Hudaib, AR | 1 |
| Dangas, GD; Unverdorben, M; Van Mieghem, NM | 1 |
| Akao, M; Amino, M; Fukuzawa, M; Funada, J; Hayashi, T; Nakamura, A; Okumura, K; Shimizu, W; Watanabe, S; Yamashita, T; Yoshida, T | 1 |
| Fang, L; Kawanishi, H; Murohara, T; Ogawa, H; Ohashi, K; Otaka, N; Ouchi, N; Ozaki, Y; Takahara, K; Takefuji, M; Takikawa, T; Tatsumi, M | 1 |
| Ahn, JM; Jung, SC; Kang, DY; Kang, JW; Kang, SH; Kao, HL; Kim, B; Kim, DH; Kim, KW; Kim, WJ; Ko, E; Ko, TY; Koo, HJ; Lam, CCS; Lee, JH; Lee, SA; Lee, YT; Lin, MS; Park, DW; Park, H; Park, SJ; Wei, J; Wong, YTA; Yang, DH; Yin, WH; Yun, SC | 1 |
| Alioğlu, E; De Caterina, R; Diker, E; Mavioğlu, Z; Önsel Türk, U; Özpelit, E | 1 |
| Akao, M; Fukuzawa, M; Hayashi, T; Imamura, Y; Kuroda, M; Lip, GYH; Nose, T; Ogimoto, A; Okumura, K; Tamiya, E; Taura, J; Yamashita, T | 1 |
| Ali, B; Ali, T; Bang, J; Choi, DJ; Choi, S; Hussain, M; Kim, HL; Kim, IC; Kim, IJ; Kim, M; Lee, JH; Lee, S; Park, SJ; Park, SM | 1 |
| Arguello Da Silva, J; Bordignon Primieri, G; Oliveira Rocha, M; Ribeiro Wingert, N; Steppe, M | 1 |
| Bakhai, A; De Caterina, R; Diemberger, I; Fumagalli, S; Gordillo de Souza, JA; Kirchhof, P; Manu, MC; Mazzone, AM; Pecen, L; Reimitz, PE | 1 |
| Beyer-Westendorf, J; Fache, K; Köhler, C; Marten, S; Naue, C; Spindler, M; Stannek, L; Tittl, L | 1 |
| Kato, S; Odajima, S; Okamoto, A; Saito, M; Seki, T; Shoburu, Y; Suzuki, E; Takano, H; Takenaka, M; Tomita, K; Yamada, K | 1 |
| Fukasawa, T; Kawakami, K; Nakashima, M; Seki, T | 1 |
| Ajiki, T; Fukumoto, T; Gon, H; Kido, M; Mizumoto, T; So, S; Toyama, H; Tsugawa, D; Ueshima, E; Yanagimoto, H | 1 |
| Ahn, HJ; Choi, EK; Kwon, S; Lee, SR; Lip, GYH; Oh, S; Rhee, TM | 1 |
| Chen, S; Gong, DW; Li, JL; Ma, YH; Mai, JL; Wang, HB; Xiao, JC; Zhang, M | 1 |
| Akao, M; Akashi, S; Akishita, M; Hayashi, T; Ikeno, E; Manita, M; Oguri, M; Okumura, K; Taura, J; Watanabe, S; Yamashita, T | 1 |
| Fioretti, AM; Giotta, F; Leopizzi, T; Lorusso, V; Luzzi, G; Oliva, S; Puzzovivo, A | 1 |
| Akao, M; Betsuyaku, T; Hayashi, T; Hirabayashi, K; Imamura, Y; Mikami, T; Okawa, K; Okumura, K; Tanizawa, K; Watanabe, S; Yamashita, T | 1 |
| Phizackerley, D | 1 |
| Ge, W; He, H; Jiang, Q; Liu, W; Xu, R | 1 |
| Gwak, HS; Han, JM; Jang, EJ; Kim, DH; Park, J; Song, TJ; Yee, J | 1 |
250 review(s) available for thiazoles and edoxaban
| Article | Year |
|---|---|
New anticoagulants for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K | 2009 |
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2010 |
[Research and development strategy of antithrombotic agents: pharmacology of the oral factor Xa-inhibitor edoxaban].
Topics: Administration, Oral; Animals; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drug Design; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Intracranial Thrombosis; Postoperative Complications; Pyridines; Secondary Prevention; Thiazoles; Thrombosis; Venous Thrombosis | 2010 |
[Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].
Topics: Animals; Anticoagulants; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Humans; Intracranial Thrombosis; Macaca fascicularis; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2010 |
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K | 2011 |
Edoxaban tosylate.
Topics: Animals; Clinical Trials as Topic; Factor Xa; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2011 |
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2011 |
Edoxaban for the prevention of thromboembolic events after surgery.
Topics: Animals; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Postoperative Complications; Pyridines; Thiazoles; Thromboembolism | 2011 |
[Current status and future of anti-Xa inhibitors].
Topics: Anticoagulants; Atrial Fibrillation; Azepines; Benzamides; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2011 |
Long-term benefits of preventing venous thromboembolic events.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Follow-Up Studies; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism | 2012 |
The promise of novel direct oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Warfarin | 2012 |
Oral direct factor Xa inhibitors.
Topics: Animals; Anticoagulants; Drug Design; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Thiazoles; Thrombosis | 2012 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Societies, Medical; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Topics: Absorption; Anticoagulants; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Liver Diseases; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Tissue Distribution; Venous Thromboembolism | 2013 |
[New approaches in the treatment of deep vein thrombosis].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2012 |
New anticoagulants for the treatment of venous thromboembolism.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; Biotin; Dabigatran; Humans; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Thiazoles; Venous Thromboembolism; Vitamin K | 2013 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Use of new oral anticoagulants in antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Animals; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Breast Feeding; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Monitoring; Female; Humans; Infant, Newborn; Maternal Exposure; Morpholines; Pregnancy; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis | 2013 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Bleeding and antidotes in new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Administration Schedule; Hemorrhage; Hemostatics; Humans; Morpholines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2013 |
Advantages and limitations of the new anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
Current state of anticoagulants to treat deep venous thrombosis.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2014 |
The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Venous Thromboembolism | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Data Interpretation, Statistical; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Edoxaban: Review of pharmacology and key phase I to III clinical trials.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Venous Thrombosis; Warfarin | 2014 |
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzamides; Blood Coagulation; Embolism; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia; Thrombosis | 2014 |
[Prevention of venous thromboembolism and anticoagulant therapy].
Topics: Anesthesia, Epidural; Anticoagulants; Biomarkers; Diagnostic Imaging; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Intraoperative Complications; Perioperative Care; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyridines; Risk Factors; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Risk; Thiazoles | 2014 |
Edoxaban: a focused review of its clinical pharmacology.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Drug Interactions; Epidemiologic Methods; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Rabbits; Rats; Thiazoles; Thrombosis | 2014 |
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Outcome Assessment, Health Care; Patient Acuity; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2014 |
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Half-Life; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Translational Research, Biomedical; Treatment Outcome | 2014 |
Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thrombosis | 2015 |
Direct oral anticoagulants: integration into clinical practice.
Topics: Acute Kidney Injury; Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Hemorrhage; Humans; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome | 2014 |
Edoxaban: an update on the new oral direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2014 |
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Atrial fibrillation - new frontiers in anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Pharmacology and laboratory testing of the oral Xa inhibitors.
Topics: Administration, Oral; Benzamides; Blood Coagulation Tests; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.
Topics: Adolescent; Adult; Biological Availability; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Pyridines; Sex Factors; Thiazoles; Young Adult | 2014 |
Oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Morpholines; Patient Preference; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Male; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2015 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Topics: Administration, Oral; Antithrombins; Azepines; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
Strategies for urgent reversal of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Charcoal; Dabigatran; Factor VIIa; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
Target-specific oral anticoagulants and the hospitalist.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Hospitalists; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis; Warfarin | 2015 |
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis; Treatment Outcome; Vitamin K | 2014 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Topics: Drug Monitoring; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2015 |
The role of factor Xa inhibitors in venous thromboembolism treatment.
Topics: Animals; Blood Coagulation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2015 |
Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Warfarin | 2015 |
Cancer-associated thrombosis: investigating the role of new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Recurrence; Thiazoles; Thrombin; Venous Thromboembolism | 2015 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Reversal of anticoagulants: an overview of current developments.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Benzamides; Clinical Trials as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Hemostatics; Heparin; Humans; Infusions, Parenteral; Intracranial Hemorrhages; Polysaccharides; Protamines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombosis; Vitamin K | 2015 |
Using new oral anticoagulants in patients undergoing major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Orthopedic Procedures; Postoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Edoxaban, a Novel Oral Factor Xa Inhibitor.
Topics: Atrial Fibrillation; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy.
Topics: Anticoagulants; Fondaparinux; Heparin; Humans; Japan; Polysaccharides; Pulmonary Embolism; Pyridines; Quality of Life; Risk Factors; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2015 |
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Embolism; Factor Xa Inhibitors; Humans; Mortality; Numbers Needed To Treat; Observational Studies as Topic; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Stroke; Thiazoles; Thrombophilia; Ticlopidine; Vitamin K | 2015 |
Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Dosing of Target-Specific Oral Anticoagulants in Special Populations.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Kidney Diseases; Liver Diseases; Obesity; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Topics: Administration, Oral; Antithrombins; Azetidines; Benzylamines; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thrombosis | 2015 |
Hepatotoxicity of New Oral Anticoagulants (NOACs).
Topics: Administration, Oral; Animals; Anticoagulants; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2015 |
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Odds Ratio; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2015 |
Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation.
Topics: Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Stroke; Thiazoles | 2015 |
Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Warfarin | 2015 |
Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
Topics: Anticoagulants; Atrial Fibrillation; Heart Failure; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Risk Adjustment; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2015 |
[Large studies of NOAC shows good and safe stroke protection].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2015 |
Edoxaban: a review in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Risk Factors; Stroke; Thiazoles; Warfarin | 2015 |
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Treatment of bleeding complications due to oral anticoagulant drugs].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2015 |
Laboratory measurement of the direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
New oral anticoagulants for patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2015 |
Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Topics: Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyridines; Thiazoles; Venous Thrombosis | 2015 |
Treatment of pulmonary embolism.
Topics: Antithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Topics: Atrial Fibrillation; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Embolism; Factor Xa Inhibitors; Humans; Pyridines; Risk; Stroke; Thiazoles; Thromboembolism; Vitamin K; Warfarin | 2015 |
Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2015 |
Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.
Topics: Anti-Bacterial Agents; Creatinine; Critical Illness; Drug Administration Schedule; Humans; Kidney Diseases; Levetiracetam; Piracetam; Pyridines; Renal Elimination; Risk Factors; Thiazoles | 2015 |
Target-specific Oral Anticoagulants in the Emergency Department.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Topics: Anticoagulants; Area Under Curve; Blood Coagulation; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Factor Xa Inhibitors; Half-Life; Humans; Liver Failure; Metabolic Clearance Rate; Protein Binding; Pyridines; Renal Insufficiency; Thiazoles | 2016 |
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2015 |
Monitoring and reversal of direct oral anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Partial Thromboplastin Time; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombin Time | 2015 |
The new oral anticoagulants: Reasonable alternatives to warfarin.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis | 2015 |
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Vitamin K | 2016 |
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; beta-Alanine; Clinical Decision-Making; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Warfarin | 2016 |
Edoxaban in patients with atrial fibrillation.
Topics: Administration, Oral; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles | 2017 |
Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Molecular Structure; Pyridines; Thiazoles; Venous Thromboembolism | 2015 |
Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Defibrillators, Implantable; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Thiazoles; Warfarin | 2016 |
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2015 |
Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Novel oral anticoagulants--issues in clinical practice].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis | 2015 |
Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Medication Errors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[The latest recommendations on the use of new oral anticoagulants in routine practice].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2016 |
Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drugs, Investigational; Evidence-Based Medicine; Humans; Mexico; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2016 |
Management of direct oral anticoagulants-associated bleeding in the trauma patient.
Topics: Administration, Oral; Antifibrinolytic Agents; Antithrombins; Atrial Fibrillation; Clinical Protocols; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; United States; Wounds and Injuries | 2016 |
New drugs 2016, part 1.
Topics: Aminobutyrates; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azabicyclo Compounds; Azepines; Benzazepines; Biphenyl Compounds; Ceftazidime; Drug Approval; Drug Combinations; Humans; Ivabradine; Morphinans; Polyethylene Glycols; Pyridines; Tetrazoles; Thiazoles; Triazoles; United States; United States Food and Drug Administration; Valsartan | 2016 |
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials as Topic; Coronary Artery Disease; Dabigatran; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
Direct oral anticoagulants: a guide for daily practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2016 |
[Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Severity of Illness Index; Surgical Procedures, Operative; Thiazoles | 2016 |
Novel oral anticoagulants in plastic surgery.
Topics: Administration, Oral; Algorithms; Anticoagulants; Dabigatran; Elective Surgical Procedures; Emergencies; Humans; Kidney; Liver; Perioperative Care; Plastic Surgery Procedures; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
Edoxaban in venous thromboembolism and stroke prevention: an appraisal.
Topics: Administration, Oral; Animals; Anticoagulants; Antidotes; Atrial Fibrillation; Blood Coagulation; Coagulants; Hemorrhage; Humans; Pyridines; Recurrence; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Outpatients; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Characteristics; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Treatment of Venous Thromboembolism With New Anticoagulant Agents.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Infusions, Intravenous; Male; Middle Aged; Phlebography; Prognosis; Pulmonary Embolism; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Severity of Illness Index; Survival Analysis; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2016 |
Bleeding management in patients with new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
New anticoagulants for the treatment of venous thromboembolism.
Topics: Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Venous Thromboembolism; Warfarin | 2016 |
Establishing Edoxaban's Role in Anticoagulation.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2016 |
[THE IMPORTANCE OF ANTICOAGULANT THERAPY IN PATIENTS WITH ARTIAL FIBRILLATION IN STROKE PREVENTION--SUMMARY OF INTERNATIONAL DATA AND NOVEL THERAPEUTIC MODALITIES].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Prevalence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2016 |
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism | 2016 |
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.
Topics: Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Anticoagulation for patients with non-valvular atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thrombolytic Therapy; Warfarin | 2016 |
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Arginine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Plasma; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2016 |
Management of bleeding in patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Disease Management; Factor Xa Inhibitors; Hemorrhage; Humans; Incidence; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2016 |
Risk impact of edoxaban in the management of stroke and venous thromboembolism.
Topics: Administration, Oral; Atrial Fibrillation; Blood Coagulation; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban.
Topics: Atrial Fibrillation; Clinical Trials, Phase III as Topic; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Thiazoles | 2017 |
Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials, Phase III as Topic; Coagulants; Dabigatran; Humans; Patient Safety; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Intracranial Hemorrhages; Mortality; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Catheters, Indwelling; Dabigatran; Drug Administration Schedule; Drug Dosage Calculations; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2017 |
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Clinical Protocols; Dabigatran; Emergency Treatment; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative; Thiazoles | 2016 |
Bleeding with direct oral anticoagulants vs warfarin: clinical experience.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Best Clinical Practice: Current Controversies in Pulmonary Embolism Imaging and Treatment of Subsegmental Thromboembolic Disease.
Topics: Anticoagulants; Dabigatran; Decision Making; Humans; Patient Outcome Assessment; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism | 2017 |
Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles | 2017 |
The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
Topics: Administration, Oral; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Humans; Orthopedic Procedures; Patient Safety; Pyridines; Risk Factors; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2017 |
The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Topics: Animals; Atrial Fibrillation; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles | 2017 |
Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Factor Xa Inhibitors; Heart Failure; Humans; Pyridines; Risk Factors; Stroke; Thiazoles; Thromboembolism | 2017 |
Role of agents for reversing the effects of target-specific oral anticoagulants.
Topics: Administration, Oral; Antithrombins; Dabigatran; Drug Evaluation; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; United States; United States Food and Drug Administration | 2017 |
Comparative Efficacy of Clinical Events Prevention of Five Anticoagulants in Patients With Atrial Fibrillation (A Network Meta-Analysis).
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Mortality; Myocardial Infarction; Network Meta-Analysis; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
[Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?]
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Loss, Surgical; Dabigatran; Drug Interactions; Half-Life; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiazoles; Thromboembolism; Vitamin K | 2017 |
Edoxaban: A direct oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Advances in oral anticoagulation therapy - What's in the pipeline?
Topics: Administration, Oral; Animals; Azepines; Benzamides; Blood Coagulation; Drug Discovery; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.
Topics: Age Factors; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Humans; Medication Therapy Management; Practice Guidelines as Topic; Pyridines; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Clinical implications of reversal agents for direct oral anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Forecasting; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2017 |
Anticoagulation Therapy and NOACs in Heart Failure.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
[Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2018 |
The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Thiazoles; Thrombin Time; Warfarin | 2017 |
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Topics: Administration, Oral; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2017 |
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.
Topics: Administration, Oral; Anticoagulants; Clinical Trials as Topic; Factor Xa Inhibitors; Hemorrhage; Hospitalization; Humans; Japan; Neoplasms; Outpatients; Platelet Count; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
[New oral anticoagulants in patients with atrial fibrillation: efficacy and safety data from the real world].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome | 2017 |
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2017 |
Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016).
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Consensus; Dabigatran; Delphi Technique; Europe; Evidence-Based Practice; Female; Humans; Long-Term Care; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Stroke; Thiazoles; Warfarin | 2017 |
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pharmaceutical Research; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2017 |
Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Topics: Acute Disease; Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasms; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2017 |
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamole; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Thiazoles; Ticlopidine; Treatment Outcome; Warfarin | 2017 |
Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Clinical Trials as Topic; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Markov Chains; Middle Aged; Monte Carlo Method; Network Meta-Analysis; Odds Ratio; Pyridines; Randomized Controlled Trials as Topic; Risk; Thiazoles; Warfarin | 2017 |
Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Eye Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Epidemiologic Methods; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
The safety of edoxaban for treating atrial fibrillation.
Topics: Administration, Oral; Animals; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Medication Adherence; Pyridines; Stroke; Thiazoles; Thromboembolism | 2017 |
Reversal agents for oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Electric Countershock; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2018 |
Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Hematoma; Humans; Mortality; Odds Ratio; Phenprocoumon; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Thiazoles; Vitamin K; Warfarin | 2018 |
Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Benzamides; Blood Loss, Surgical; Dabigatran; Deprescriptions; Elective Surgical Procedures; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2017 |
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
An update on the bleeding risks associated with DOACs.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2017 |
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide.
Topics: Androgen Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Benzamides; Dabigatran; Drug Interactions; Embolism; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Progress in the research on venous thromboembolism.
Topics: Anticoagulants; Blood Coagulation Factors; Computed Tomography Angiography; Dabigatran; Genetic Predisposition to Disease; Heparin; Humans; Phlebography; Practice Guidelines as Topic; Pulmonary Embolism; Pyridines; Quality of Life; Recurrence; Risk Factors; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2017 |
Direct oral anticoagulants: An update.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Venous Thromboembolism; Withholding Treatment | 2018 |
Advances in anticoagulation therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thrombosis | 2018 |
[Antidote treatment during use of direct anticoagulants].
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles | 2018 |
Review: An overview and analysis of novel oral anticoagulants and their dental implications.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dental Care; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2018 |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2019 |
Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2018 |
Update on Direct Oral AntiCoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Drug Substitution; Heparin, Low-Molecular-Weight; Humans; Kidney Function Tests; Liver Function Tests; Metabolic Clearance Rate; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
[Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Blood Coagulation Factors; Blood Coagulation Tests; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Premedication; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism | 2018 |
A review of the use of direct oral anticoagulant use in orthotopic heart transplantation recipients.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Heart Transplantation; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2018 |
A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants.
Topics: Administration, Oral; Antithrombins; Bayes Theorem; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Treatment Outcome | 2018 |
Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Enzymes; Humans; Pharmacogenomic Testing; Pharmacogenomic Variants; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2018 |
Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2018 |
The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Dalteparin; Gastrointestinal Neoplasms; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Venous Thromboembolism | 2018 |
Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Warfarin | 2019 |
British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE).
Topics: Ambulatory Care; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Length of Stay; Male; Neoplasms; Patient Discharge; Patient Selection; Pregnancy; Pregnancy Complications, Cardiovascular; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Substance Abuse, Intravenous; Thiazoles | 2018 |
[The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
Topics: Anticoagulants; Arterial Occlusive Diseases; Atrial Fibrillation; Comorbidity; Contraindications; Coronary Disease; Dabigatran; Glomerular Filtration Rate; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2018 |
Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism.
Topics: Heparin, Low-Molecular-Weight; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Safety; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2019 |
The safety of NOACs in atrial fibrillation patient subgroups: A narrative review.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
[Improved stroke prevention in atrial fibrillation: the Stockholm experience of the introduction of NOACs].
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Sweden; Thiazoles; Warfarin | 2018 |
Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Thiazoles; Thromboembolism; Warfarin | 2018 |
Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal.
Topics: Anticoagulants; Dabigatran; Drug Hypersensitivity; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2019 |
Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.
Topics: Humans; Latin America; Practice Guidelines as Topic; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Electric Countershock; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Thromboembolism; Time Factors | 2018 |
Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2019 |
[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2019 |
Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Topics: Anticoagulants; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2019 |
Edoxaban for the prevention of stroke in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Cost-Benefit Analysis; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Thromboembolism; Warfarin | 2019 |
Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
Topics: Administration, Oral; Anticoagulants; Benzamides; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2019 |
Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
Topics: Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2019 |
Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Factor Xa Inhibitors; Humans; Neoplasms; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiazoles; Thrombosis | 2019 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2019 |
Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Dabigatran; Digoxin; Dronedarone; Drug Interactions; Factor Xa Inhibitors; Heart Failure; Hospitalization; Humans; Mortality; Pyridines; Randomized Controlled Trials as Topic; Thiazoles | 2019 |
Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease.
Topics: Administration, Oral; Adult; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Heart Defects, Congenital; Heart Valve Diseases; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Severity of Illness Index; Sex Factors; Stroke; Survival Analysis; Thiazoles; Vitamin K | 2019 |
[Direct oral anticoagulants in the treatment of cancer-associated thrombosis].
Topics: Administration, Oral; Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2019 |
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2020 |
Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Care Bundles; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2020 |
[Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Complications; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Off-Label Use; Prevalence; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Sex Factors; Sleep Apnea, Obstructive; Stroke; Thiazoles; Thromboembolism | 2020 |
Topics: Atrial Fibrillation; Blood Pressure; Humans; Hypertension; Pyridines; Thiazoles; Warfarin | 2020 |
[The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].
Topics: Anticoagulants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasm Proteins; Neoplasms; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Thrombosis; Venous Thromboembolism | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; Medication Therapy Management; Pyridines; Thiazoles; Thromboembolism | 2020 |
Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombi: A Systematic Review.
Topics: Dabigatran; Factor Xa Inhibitors; Heart Diseases; Heart Ventricles; Humans; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Treatment Outcome | 2020 |
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Cost of Illness; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Safety; Stroke; Thiazoles; Warfarin | 2020 |
The risk of bleeding and all-cause mortality with edoxaban versus vitamin K antagonists: A meta-analysis of phase III randomized controlled trials.
Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Vitamin K | 2020 |
Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives.
Topics: Administration, Oral; Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2020 |
Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis.
Topics: Animals; Blood Coagulation; Dabigatran; Factor Xa Inhibitors; Humans; Platelet Activation; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis | 2021 |
Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome | 2020 |
[Direct Oral Anticoagulant Edoxaban in Patients with Non-Valvular Atrial Fibrillation: Results of Direct Comparison with Warfarin].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2020 |
Direct oral anticoagulants: evidence and unresolved issues.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Antithrombins; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Diseases; Heart Ventricles; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Warfarin | 2021 |
Topics: Aged; Atrial Fibrillation; Humans; Patients; Pyridines; Thiazoles | 2021 |
Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2021 |
The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2021 |
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Network Meta-Analysis; Observational Studies as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2021 |
Direct oral anticoagulant safety during breastfeeding: a narrative review.
Topics: Anticoagulants; Breast Feeding; Dabigatran; Factor Xa Inhibitors; Female; Humans; Milk, Human; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2021 |
Edoxaban in cardiovascular disease management: Review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Humans; Pyridines; Stroke; Thiazoles | 2022 |
Cancer-associated thrombosis - treatment and prevention with direct oral factor Xa inhibitors.
Topics: Administration, Oral; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Venous Thromboembolism | 2021 |
Direct oral anticoagulants for use in paediatrics.
Topics: Antithrombins; Child; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pediatrics; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2022 |
Efficacy of edoxaban for the treatment of gynecological cancer-associated venous thromboembolism: analysis of Japanese real-world data.
Topics: Administration, Oral; Anticoagulants; Heparin; Humans; Japan; Neoplasms; Pulmonary Embolism; Pyridines; Thiazoles; Venous Thromboembolism | 2022 |
Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Gastrointestinal Hemorrhage; Humans; Proton Pump Inhibitors; Pyridines; Thiazoles | 2022 |
Short-term efficacy and safety of edoxaban for venous thromboembolism after total hip or knee arthroplasty: a systematic review and meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Hemorrhage; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2022 |
Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review.
Topics: Adult; Anticoagulants; Brachiocephalic Veins; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Male; Pyridines; Seminoma; Testicular Neoplasms; Thiazoles; Thrombosis; Venous Thrombosis | 2022 |
161 trial(s) available for thiazoles and edoxaban
| Article | Year |
|---|---|
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Area Under Curve; Bleeding Time; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Food-Drug Interactions; Half-Life; Humans; International Normalized Ratio; Male; Middle Aged; Partial Thromboplastin Time; Prothrombin Time; Pyridines; Single-Blind Method; Tablets; Thiazoles; Young Adult | 2010 |
Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.
Topics: Administration, Oral; Adult; Anticoagulants; Area Under Curve; Asian People; Blood Coagulation; Body Mass Index; Chromatography, Liquid; Cross-Over Studies; Dietary Fats; Factor Xa Inhibitors; Food-Drug Interactions; Humans; Male; Metabolic Clearance Rate; Models, Biological; Partial Thromboplastin Time; Prothrombin Time; Pyridines; Tandem Mass Spectrometry; Thiazoles; White People; Young Adult | 2011 |
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Canada; Dalteparin; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Europe; Factor Xa; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Subcutaneous; Logistic Models; Male; Middle Aged; Phlebography; Pulmonary Embolism; Pyridines; Risk Assessment; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; United States; Venous Thromboembolism; Venous Thrombosis | 2010 |
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Alanine Transaminase; Anticoagulants; Aspartate Aminotransferases; Atrial Fibrillation; Bilirubin; Biomarkers; Blood Coagulation; Double-Blind Method; Europe, Eastern; Factor Xa; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Time Factors; Treatment Outcome; United States; Warfarin | 2010 |
A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Japan; Middle Aged; Placebos; Pyridines; Thiazoles; Venous Thromboembolism | 2010 |
Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Anticoagulants; Antithrombins; Azetidines; Benzylamines; Blood Coagulation; Dalteparin; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Thiazoles; Thrombosis | 2010 |
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infar
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Pyridines; Retrospective Studies; Stroke; Thiazoles; Thrombolytic Therapy; Treatment Outcome; Warfarin | 2010 |
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Double-Blind Method; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Middle Aged; Pyridines; Thiazoles; Warfarin | 2011 |
A thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitor.
Topics: Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drugs, Investigational; Electrocardiography; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Half-Life; Humans; Male; Pyridines; Thiazoles; Young Adult | 2011 |
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
Topics: Antithrombin III; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Clinical Protocols; Clinical Trials, Phase III as Topic; Drug Dosage Calculations; Factor Xa Inhibitors; Fondaparinux; Humans; Male; Peptide Fragments; Peptide Hydrolases; Platelet Activation; Polysaccharides; Prothrombin; Pyridines; Thiazoles | 2011 |
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Blood Coagulation; Clinical Trials, Phase III as Topic; Computer Simulation; Dose-Response Relationship, Drug; Drug Interactions; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Kidney Diseases; Logistic Models; Male; Models, Biological; Models, Statistical; Pyridines; Research Design; Risk Assessment; Risk Factors; Stroke; Thiazoles; Treatment Outcome | 2012 |
Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Topics: Adult; Blood Coagulation Tests; Chromatography, Liquid; Drug Interactions; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Mass Spectrometry; Pyridines; Thiazoles; Thrombin; Venous Thromboembolism | 2012 |
Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Topics: Administration, Oral; Animals; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Hemostatics; Male; Pyridines; Rats; Rats, Wistar; Thiazoles; Treatment Outcome; Venous Thrombosis; Warfarin | 2012 |
Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; International Normalized Ratio; Japan; Male; Middle Aged; Pyridines; Thiazoles; Warfarin | 2012 |
A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Blood Coagulation Tests; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Thiazoles; Warfarin | 2013 |
Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Bayes Theorem; Factor Xa Inhibitors; Humans; Models, Biological; Postoperative Complications; Postoperative Hemorrhage; Pyridines; Thiazoles; Venous Thromboembolism | 2012 |
Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.
Topics: Adolescent; Adult; Anticoagulants; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiotonic Agents; Cross-Over Studies; Digoxin; Drug Interactions; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Thiazoles; Time Factors; Young Adult | 2012 |
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Predictive Value of Tests; Pyridines; Research Design; Secondary Prevention; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Blood Physiological Phenomena; Cohort Studies; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Naproxen; Platelet Aggregation Inhibitors; Pyridines; Thiazoles; Young Adult | 2013 |
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
Topics: Adolescent; Adult; Anticoagulants; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Agents; Cohort Studies; Cross-Over Studies; Drug Interactions; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Thiazoles; Young Adult | 2013 |
Edoxaban versus warfarin in patients with atrial fibrillation.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Double-Blind Method; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Warfarin | 2013 |
[Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Venous Thromboembolism; Warfarin | 2013 |
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Atrial Function, Left; Double-Blind Method; Echocardiography; Female; Heart Atria; Humans; Male; Prospective Studies; Pyridines; Stroke Volume; Thiazoles; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
Topics: Aged; Blood Loss, Surgical; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Hip Fractures; Humans; Injections, Subcutaneous; Male; Pyridines; Thiazoles; Thromboembolism | 2014 |
Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment.
Topics: Adult; Aged; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Models, Biological; Pyridines; Thiazoles | 2014 |
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2014 |
Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
Topics: Aged; Antithrombins; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Japan; Male; Middle Aged; Pyridines; Taiwan; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2014 |
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Drug Substitution; Factor Xa; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pyridines; Thiazoles; Treatment Outcome; Warfarin | 2014 |
Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Biological Availability; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Models, Biological; Pyridines; Quinidine; Renal Insufficiency; Thiazoles; Young Adult | 2014 |
Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Pyridines; Risk Assessment; Thiazoles; Thromboembolism; Treatment Outcome | 2014 |
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Topics: Administration, Intravenous; Adolescent; Adult; Biopsy, Needle; Blood Coagulation; Blood Coagulation Factors; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prothrombin Time; Pyridines; Thiazoles; Time Factors; Young Adult | 2015 |
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Topics: Administration, Oral; Adult; Area Under Curve; Cross-Over Studies; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Pyridines; Renal Dialysis; Thiazoles; Treatment Outcome | 2015 |
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2015 |
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Topics: Anticoagulants; Atrial Fibrillation; Cytochrome P-450 CYP2C9; Double-Blind Method; Factor Xa Inhibitors; Genetic Variation; Genotype; Hemorrhage; Humans; International Normalized Ratio; Pharmacogenetics; Pyridines; Risk Assessment; Stroke; Thiazoles; Vitamin K Epoxide Reductases; Warfarin | 2015 |
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Topics: Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome | 2015 |
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Topics: Aged; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Europe; Factor Xa Inhibitors; Female; Femoral Artery; Fibrinolytic Agents; Hemorrhage; Humans; Israel; Male; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Popliteal Artery; Pyridines; Research Design; Risk Factors; Stents; Thiazoles; Ticlopidine; Time Factors; Treatment Outcome; United States | 2015 |
Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment.
Topics: Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Factor Xa Inhibitors; Female; Fibrinolysis; Humans; Japan; Male; Middle Aged; Pyridines; Renal Insufficiency, Chronic; Thiazoles | 2015 |
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Electric Countershock; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Pyridines; Research Design; Stroke; Thiazoles; Thromboembolism; Warfarin | 2015 |
Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Pyridines; Renal Insufficiency; Thiazoles | 2015 |
Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule.
Topics: Adolescent; Adult; Aged; Capsules; Colon; Cross-Over Studies; Factor Xa Inhibitors; Fumarates; Gastrointestinal Absorption; Humans; Intestine, Small; Male; Middle Aged; Pyridines; Tablets; Thiazoles; Young Adult | 2015 |
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2015 |
An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Topics: Adolescent; Adult; Aged; Contraindications; Factor Xa Inhibitors; Female; Humans; Liver Diseases; Male; Middle Aged; Partial Thromboplastin Time; Prothrombin Time; Pyridines; Thiazoles; Young Adult | 2015 |
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis.
Topics: Contrast Media; Gadolinium; Humans; Leg; Magnetic Resonance Angiography; Organometallic Compounds; Pelvis; Pyridines; Reproducibility of Results; Thiazoles; Venous Thrombosis | 2015 |
The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.
Topics: Adult; Drug Interactions; Factor Xa Inhibitors; Female; Humans; Male; Prothrombin Time; Pyridines; Rifampin; Thiazoles | 2015 |
Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Asia, Eastern; Asian People; Double-Blind Method; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pulmonary Embolism; Pyridines; Recurrence; Therapeutic Equivalency; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Vitamin K; Warfarin; Young Adult | 2015 |
Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 study.
Topics: Adolescent; Adult; Aged; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Pulmonary Embolism; Pyridines; Thiazoles; Venous Thrombosis | 2015 |
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasms; Prospective Studies; Pulmonary Embolism; Pyridines; Recurrence; Research Design; Sample Size; Thiazoles; Time Factors; Treatment Outcome; Venous Thrombosis | 2015 |
The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.
Topics: Blood Coagulation; Blood Coagulation Factors; Cohort Studies; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Thiazoles | 2015 |
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Embolism; Factor Xa; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Middle Aged; Myocardial Infarction; Pyridines; Retrospective Studies; Thiazoles; Thrombolytic Therapy; Treatment Outcome; Warfarin | 2015 |
Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Monitoring; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Selection; Pyridines; Risk Assessment; Stroke; Survival Analysis; Thiazoles; Treatment Outcome; Warfarin | 2015 |
Effects of a Foot Pump on the Incidence of Deep Vein Thrombosis After Total Knee Arthroplasty in Patients Given Edoxaban: A Randomized Controlled Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Body Mass Index; Female; Humans; Incidence; Japan; Male; Physical Therapy Modalities; Postoperative Complications; Pulmonary Embolism; Pyridines; Sex Factors; Thiazoles; Venous Thrombosis | 2016 |
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardi
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Myocardial Infarction; Pyridines; Stroke; Thiazoles; Thrombolytic Therapy; United States; United States Food and Drug Administration; Warfarin | 2016 |
Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation - An ENGAGE AF-TIMI 48 Subanalysis.
Topics: Aged; Aged, 80 and over; Asia, Eastern; Atrial Fibrillation; Double-Blind Method; Embolism; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Warfarin | 2016 |
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Risk Factors; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2016 |
Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Biological Availability; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Theoretical; Pyridines; Thiazoles | 2016 |
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Thiazoles; Treatment Outcome; United States; Warfarin | 2016 |
The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
Topics: Aged; Antithrombin III; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Male; Osteotomy; Peptide Hydrolases; Postoperative Complications; Prospective Studies; Prothrombin Time; Pyridines; Thiazoles; Tibia; Venous Thromboembolism | 2017 |
Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Topics: Administration, Oral; Anticoagulants; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Risk Factors; Thiazoles; Venous Thromboembolism; Vitamin K; Warfarin | 2016 |
Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Combined Modality Therapy; Double-Blind Method; Electric Countershock; Factor Xa Inhibitors; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Pyridines; Risk Factors; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2016 |
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Topics: Adult; Aged; Anticoagulants; Comparative Effectiveness Research; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pulmonary Embolism; Pyridines; Recurrence; Risk Assessment; Secondary Prevention; Thiazoles; Venous Thromboembolism; Ventricular Dysfunction, Right; Warfarin | 2016 |
Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anticoagulants; Blood Coagulation; Drug Therapy, Combination; Factor Xa Inhibitors; Feasibility Studies; Female; Heparin; Humans; International Normalized Ratio; Magnetic Resonance Angiography; Male; Middle Aged; Phlebography; Predictive Value of Tests; Pyridines; Thiazoles; Time Factors; Treatment Outcome; United States; Venous Thrombosis; Warfarin | 2016 |
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism.
Topics: Aged; Double-Blind Method; Drug Dosage Calculations; Factor Xa Inhibitors; Female; Humans; Male; Pulmonary Embolism; Pyridines; Risk Assessment; Thiazoles; Venous Thrombosis; Warfarin | 2016 |
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Creatinine; Double-Blind Method; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Pyridines; Risk; Thiazoles; Thrombophilia; Warfarin | 2016 |
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyridines; Recurrence; Secondary Prevention; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
Topics: Adult; Aged; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Thiazoles; Venous Thromboembolism; Warfarin | 2016 |
Has the Safety of Edoxaban 60 mg Among East Asian Atrial Fibrillation Patients Been Truly Proven by the ENGAGE AF-TIMI 48 Subanalysis?
Topics: Asian People; Atrial Fibrillation; Female; Humans; Japan; Male; Pyridines; Thiazoles | 2016 |
Has the Safety of Edoxaban 60 mg Among East Asian Atrial Fibrillation Patients Been Truly Proven by the ENGAGE AF-TIMI 48 Subanalysis? - Reply.
Topics: Asian People; Atrial Fibrillation; Female; Humans; Japan; Male; Pyridines; Thiazoles | 2016 |
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Topics: Aged; Double-Blind Method; Equivalence Trials as Topic; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Prognosis; Pyridines; Survival Rate; Thiazoles; Venous Thromboembolism | 2016 |
Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Topics: Administration, Oral; Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cyclosporine; Cytochrome P-450 CYP3A; Drug Administration Schedule; Drug Interactions; Erythromycin; Factor Xa Inhibitors; Healthy Volunteers; Humans; Ketoconazole; Metabolic Clearance Rate; Middle Aged; Pyridines; Substrate Specificity; Thiazoles; Young Adult | 2016 |
Reduced induction of anti-PF4/heparin antibody in RA patients after total knee arthroplasty.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Autoantibodies; Autoantigens; Enzyme-Linked Immunosorbent Assay; Factor Xa Inhibitors; Female; Humans; Immunoblotting; Immunoglobulin G; Male; Middle Aged; Osteoarthritis; Platelet Factor 4; Pyridines; Seroconversion; Thiazoles; Thrombocytopenia; Thromboembolism | 2016 |
A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers.
Topics: Administration, Oral; Adult; Asian People; China; Cross-Over Studies; Factor Xa Inhibitors; Female; Healthy Volunteers; Humans; Male; Pyridines; Thiazoles | 2017 |
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Double-Blind Method; Equivalence Trials as Topic; Europe; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Pulmonary Embolism; Pyridines; Recurrence; Survival Rate; Thiazoles; Venous Thromboembolism; Ventricular Dysfunction, Right; Warfarin; Young Adult | 2016 |
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Middle Aged; Prospective Studies; Pyridines; Stroke; Thiazoles; Thromboembolism; Warfarin | 2016 |
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Risk Factors; Single-Blind Method; Stroke; Thiazoles; Warfarin | 2016 |
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Drug Labeling; Female; Humans; Kidney Function Tests; Male; Prospective Studies; Pyridines; Registries; Thiazoles; United States; United States Food and Drug Administration | 2016 |
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban.
Topics: Administration, Oral; Adult; Arginine; Blood Coagulation; Double-Blind Method; Drug Monitoring; Factor Xa Inhibitors; Humans; Injections, Intravenous; Male; North Carolina; Piperazines; Pyridines; Thiazoles; Whole Blood Coagulation Time | 2017 |
A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Blood Coagulation; China; Drug Administration Schedule; Factor Xa Inhibitors; Female; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Partial Thromboplastin Time; Postprandial Period; Prothrombin Time; Pyridines; Thiazoles | 2017 |
A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Risk Assessment; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyridines; Risk Factors; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2017 |
Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
Topics: Aged; Anticoagulants; Blood Coagulation; Decision Support Techniques; Double-Blind Method; Factor Xa Inhibitors; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Predictive Value of Tests; Pyridines; Risk Assessment; Risk Factors; Thiazoles; Treatment Outcome; Venous Thromboembolism; Vitamin K; Warfarin | 2017 |
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
Topics: Anticoagulants; Atrial Fibrillation; Bioprosthesis; Blood Coagulation; Factor Xa Inhibitors; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Pyridines; Risk Factors; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2017 |
External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
Topics: Aged; Anticoagulants; Disease Progression; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Pyridines; Research Design; Risk; Surveys and Questionnaires; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Heart Valve Diseases; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Warfarin | 2017 |
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Cross-Over Studies; Drug Compounding; Factor Xa Inhibitors; Female; Half-Life; Humans; Intubation, Gastrointestinal; Male; Malus; Middle Aged; Pyridines; Suspensions; Tablets; Therapeutic Equivalency; Thiazoles; Young Adult | 2018 |
Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.
Topics: Adult; Blood Coagulation; Blood Coagulation Tests; Blood Specimen Collection; Chromatography, Liquid; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Tandem Mass Spectrometry; Thiazoles | 2017 |
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Pyridines; Thiazoles; Thrombolytic Therapy; Warfarin | 2017 |
Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Cytochrome P-450 CYP2C9; Double-Blind Method; Drug Monitoring; Factor Xa Inhibitors; Female; Genetic Predisposition to Disease; Hemorrhage; Humans; Male; Middle Aged; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Pyridines; Risk Assessment; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K Epoxide Reductases; Warfarin | 2017 |
Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Double-Blind Method; Europe; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Follow-Up Studies; Heart Rate; Humans; Incidence; Male; Prospective Studies; Pyridines; Risk Factors; Stroke; Survival Rate; Thiazoles; Time Factors; Treatment Outcome; Vitamin K | 2017 |
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Embolism; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Health Status; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyridines; Quality of Life; Risk Factors; Stroke; Surveys and Questionnaires; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2017 |
Monitoring of hemostatic abnormalities in major orthopedic surgery patients treated with edoxaban by APTT waveform.
Topics: Aged; Drug Monitoring; Hemorrhage; Humans; Male; Middle Aged; Orthopedic Procedures; Partial Thromboplastin Time; Pyridines; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Edoxaban Enhances Thromboprophylaxis by Physiotherapy After Total Knee Arthroplasty - The Randomized Controlled ESCORT-TKA Trial.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Combined Modality Therapy; Female; Humans; Incidence; Male; Middle Aged; Physical Therapy Modalities; Postoperative Complications; Pyridines; Thiazoles; Thrombosis; Venous Thromboembolism | 2018 |
Edoxaban is effective in reducing the incidence of asymptomatic phlebographic events following closed-wedge high tibial osteotomy.
Topics: Aged; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Male; Middle Aged; Osteotomy; Partial Thromboplastin Time; Phlebography; Postoperative Complications; Postoperative Period; Prospective Studies; Pyridines; Thiazoles; Tibia; Tomography, X-Ray Computed; Venous Thromboembolism; Venous Thrombosis | 2017 |
The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Creatinine; Dose-Response Relationship, Drug; Electric Countershock; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Pyridines; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2017 |
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Double-Blind Method; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Thiazoles; United States; Venous Thromboembolism; Warfarin | 2017 |
Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Incidence; Japan; Male; Pyridines; Stroke; Survival Rate; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Pyridines; Recurrence; Thiazoles; Venous Thromboembolism | 2018 |
Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
Topics: Age Factors; Aged; Aged, 80 and over; Comorbidity; Double-Blind Method; Female; Humans; Male; Polypharmacy; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients.
Topics: Aged; Anticoagulants; Blood Transfusion; Double-Blind Method; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Odds Ratio; Prospective Studies; Pyridines; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2018 |
Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pyridines; Retrospective Studies; Risk Factors; Stroke; Thiazoles; Thromboembolism; Warfarin; Withholding Treatment | 2018 |
Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
Topics: Administration, Oral; Atrial Fibrillation; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Internationality; Male; Patient Safety; Percutaneous Coronary Intervention; Postoperative Complications; Pyridines; Risk Assessment; Single-Blind Method; Stents; Survival Rate; Thiazoles; Treatment Outcome | 2018 |
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endovascular Procedures; Europe; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Israel; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proof of Concept Study; Prospective Studies; Pyridines; Recurrence; Risk Factors; Thiazoles; Thrombosis; Time Factors; Treatment Outcome; United States; Vascular Patency | 2018 |
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Body Mass Index; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obesity; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2018 |
Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Catheter Ablation; Clinical Protocols; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyridines; Research Design; Risk Factors; Stroke; Thiazoles; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2018 |
Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Cardiac Surgical Procedures; Double-Blind Method; Female; Hemorrhage; Humans; Male; Perioperative Care; Postoperative Complications; Pyridines; Stroke; Thiazoles; Treatment Outcome; United States; Warfarin | 2018 |
Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study.
Topics: Adult; Anticoagulants; Double-Blind Method; Female; Humans; Middle Aged; Pyridines; Thiazoles; Treatment Outcome; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2018 |
Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cost Savings; Cost-Benefit Analysis; Drug Costs; Echocardiography, Transesophageal; Electric Countershock; Emergency Service, Hospital; Europe; Factor Xa Inhibitors; Female; Hemorrhage; Hospital Costs; Humans; Male; Middle Aged; Patient Readmission; Patient Satisfaction; Pyridines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; United States; Warfarin | 2018 |
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Topics: Aged; Dose-Response Relationship, Drug; Embolism; Factor Xa; Factor Xa Inhibitors; Female; Half-Life; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Pyridines; Risk Factors; Stroke; Thiazoles; Treatment Outcome | 2018 |
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Pyridines; Thiazoles; Thrombolytic Therapy; Treatment Outcome; Warfarin | 2019 |
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Topics: Aged; Anticoagulants; Clinical Decision-Making; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Patient Selection; Pyridines; Recurrence; Risk Assessment; Risk Factors; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2018 |
Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Dose-Response Relationship, Drug; Europe; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pyridines; Secondary Prevention; Stroke; Thiazoles | 2018 |
Multicenter, Open-Label, Randomized Controlled Trial of Warfarin and Edoxaban Tosilate Hydrate for the Treatment of Deep Vein Thrombosis in Persons with Severe Motor Intellectual Disabilities.
Topics: Anticoagulants; Factor Xa Inhibitors; Hemorrhage; Humans; Intellectual Disability; Intelligence; Japan; Motor Activity; Motor Disorders; Multicenter Studies as Topic; Persons with Mental Disabilities; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Time Factors; Treatment Outcome; Venous Thrombosis; Warfarin | 2018 |
Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
Topics: Aortic Valve; Aortic Valve Stenosis; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridines; Standard of Care; Thiazoles; Thromboembolism; Thrombolytic Therapy; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2018 |
Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Hospitalization; Humans; Intracranial Hemorrhages; Latin America; Male; Myocardial Infarction; Pyridines; Stroke; Thiazoles; Warfarin | 2018 |
Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy.
Topics: Adult; Aged; Aged, 80 and over; Asymptomatic Diseases; Atrial Fibrillation; Catheter Ablation; Factor Xa Inhibitors; Female; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Peptide Fragments; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Prospective Studies; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2019 |
A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthritis; Arthroplasty, Replacement, Knee; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Prospective Studies; Pyridines; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiac Resynchronization Therapy Devices; Defibrillators, Implantable; Device Removal; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pacemaker, Artificial; Prosthesis Implantation; Pyridines; Risk Assessment; Risk Factors; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2019 |
Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.
Topics: Aged; American Indian or Alaska Native; Anticoagulants; Asian People; Atrial Fibrillation; Black People; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Proportional Hazards Models; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin; White People | 2019 |
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Comorbidity; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Obesity; Overweight; Proportional Hazards Models; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2019 |
Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial.
Topics: Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Electric Countershock; Factor Xa Inhibitors; Female; Follow-Up Studies; Heart Rate; Humans; Male; Middle Aged; Pyridines; Remission, Spontaneous; Retrospective Studies; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Topics: Administration, Oral; Adolescent; Adult; Atrial Fibrillation; Case-Control Studies; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles; Young Adult | 2019 |
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
Topics: Aged; Atrial Fibrillation; Catheter Ablation; Cerebral Hemorrhage; Factor Xa Inhibitors; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Postoperative Hemorrhage; Pyridines; Stroke; Thiazoles; Vitamin K | 2019 |
Safety and Effectiveness of Edoxaban in Japanese Patients With Venous Thromboembolism - An Interim Analysis of Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan).
Topics: Aged; Aged, 80 and over; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Pyridines; Thiazoles; Venous Thromboembolism | 2019 |
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Topics: Aged; Blood Coagulation; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Neoplasms; Prospective Studies; Pulmonary Embolism; Pyridines; Recurrence; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2019 |
Design and rationale of the STroke secondary prevention with catheter ABLation and EDoxaban clinical trial in patients with non-valvular atrial fibrillation: The STABLED study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Embolism; Female; Humans; Japan; Male; Prospective Studies; Pyridines; Recurrence; Secondary Prevention; Stroke; Thiazoles | 2019 |
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Comorbidity; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Logistic Models; Male; Patient Safety; Prognosis; Proportional Hazards Models; Pyridines; Risk Assessment; Severity of Illness Index; Stroke; Survival Analysis; Thiazoles; Treatment Outcome; Warfarin | 2019 |
Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography, Transesophageal; Electric Countershock; Factor Xa Inhibitors; Female; Heart Atria; Heart Diseases; Humans; Male; Prospective Studies; Pyridines; Thiazoles; Thrombosis; Treatment Outcome; Warfarin | 2019 |
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Topics: Aged; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Coronary Artery Disease; Cyclooxygenase 1; Drug Interactions; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Pyridines; Receptors, Purinergic P2Y12; Survival Analysis; Thiazoles | 2020 |
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Topics: Acute Coronary Syndrome; Aged; Atrial Fibrillation; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Stents; Stroke; Thiazoles; Vitamin K | 2019 |
Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation - The Prospective KYU-RABLE Study.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Blood Coagulation; Catheter Ablation; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Prospective Studies; Pyridines; Risk Factors; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome | 2019 |
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
Topics: Aged; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Middle Aged; Pyridines; Risk Factors; Thiazoles; Warfarin | 2019 |
Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes.
Topics: Action Potentials; Aged; Antithrombins; Atrial Fibrillation; Blood Coagulation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Female; Heart Rate; Humans; Japan; Male; Middle Aged; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Whole Blood Coagulation Time | 2019 |
Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Pyridines; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2020 |
Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method.
Topics: Chromatography, High Pressure Liquid; Factor Xa Inhibitors; Humans; Pyridines; Tandem Mass Spectrometry; Thiazoles | 2020 |
Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial.
Topics: Anticoagulants; Atrial Fibrillation; Diabetes Mellitus; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome | 2020 |
[ETNA-AF study: Italian baseline data and comparison with the European population in atrial fibrillation patients treated with edoxaban].
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Europe; Factor Xa Inhibitors; Female; Humans; Italy; Male; Middle Aged; Pyridines; Registries; Thiazoles; Thromboembolism | 2020 |
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
Topics: Anticoagulants; Factor Xa; Factor Xa Inhibitors; Healthy Volunteers; Humans; Pyridines; Recombinant Proteins; Rivaroxaban; Thiazoles; United States | 2020 |
Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial.
Topics: Aged; Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2020 |
Point-of-care testing of coagulation in patients treated with edoxaban.
Topics: Aged; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Point-of-Care Testing; Prospective Studies; Pyridines; Stroke; Thiazoles | 2020 |
[One-year follow-up of Italian patients with atrial fibrillation treated with edoxaban in ETNA-AF Europe].
Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Italy; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyridines; Stroke; Thiazoles; Thromboembolism | 2020 |
Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyridines; Stroke; Thiazoles; Treatment Outcome | 2020 |
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Topics: Aged, 80 and over; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Patient Dropouts; Pyridines; Stroke; Thiazoles | 2020 |
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Pyridines; Risk Assessment; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2020 |
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Heparin; Humans; Pyridines; Thiazoles; Treatment Outcome; Vitamin K | 2021 |
Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Follow-Up Studies; Frailty; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyridines; Thiazoles; Treatment Outcome; Warfarin | 2020 |
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement.
Topics: Aortic Valve; Aortic Valve Stenosis; Humans; Platelet Aggregation Inhibitors; Pyridines; Republic of Korea; Risk Factors; Thiazoles; Thrombosis; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2021 |
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyridines; Thiazoles; Warfarin | 2021 |
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Topics: Aged; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Thiazoles | 2021 |
ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolism.
Topics: Adult; Anticoagulants; Child; Heart Diseases; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2021 |
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Topics: 4-Hydroxycoumarins; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Mortality; Phenindione; Postoperative Complications; Pyridines; Thiazoles; Thromboembolism; Transcatheter Aortic Valve Replacement; Vitamin K | 2021 |
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban.
Topics: Anticoagulants; Case-Control Studies; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Pyridines; Retrospective Studies; Risk Factors; Thiazoles; Venous Thromboembolism | 2021 |
Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min.
Topics: Anticoagulants; Atrial Fibrillation; Creatinine; Double-Blind Method; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2022 |
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
Topics: Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Peripheral Arterial Disease; Pyridines; Stroke; Thiazoles; Warfarin | 2022 |
Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Body Weight; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2022 |
Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial.
Topics: Aged, 80 and over; Atrial Fibrillation; Female; Humans; Kidney Function Tests; Male; Pyridines; Thiazoles | 2022 |
Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial.
Topics: Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Humans; Platelet Aggregation Inhibitors; Pyridines; Risk Factors; Thiazoles; Thromboembolism; Thrombosis; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2022 |
Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Warfarin | 2022 |
Rationale design and efficacy of a smartphone application for improving self-awareness of adherence to edoxaban treatment: study protocol for a randomised controlled trial (adhere app).
Topics: Atrial Fibrillation; Humans; Mobile Applications; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Smartphone; Stroke; Thiazoles | 2022 |
Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Embolism; Factor Xa Inhibitors; Female; Frail Elderly; Frailty; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles | 2022 |
Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Creatinine; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Warfarin | 2022 |
399 other study(ies) available for thiazoles and edoxaban
| Article | Year |
|---|---|
DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
Topics: Administration, Oral; Animals; Area Under Curve; Blood Coagulation; Factor Xa Inhibitors; Female; Macaca fascicularis; Male; Platelet Aggregation; Pyridines; Rats; Rats, Wistar; Serine Proteinase Inhibitors; Thiazoles | 2008 |
Factor Xa and thrombin as targets for new oral anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
[New anticoagulants in the prevention and treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Costs; Drugs, Investigational; Factor Xa Inhibitors; Humans; Hungary; Morpholines; Oligosaccharides; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2011 |
In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Topics: Anticoagulants; Blood Coagulation; Blood Platelets; Cells, Cultured; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fondaparinux; Humans; In Vitro Techniques; Polysaccharides; Pyridines; Thiazoles; Thrombin | 2012 |
Edoxaban: a new oral direct factor xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Rabbits; Rats; Stroke; Thiazoles; Venous Thrombosis | 2011 |
Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Topics: Animals; Anticoagulants; Antithrombins; Blood Flow Velocity; Carotid Arteries; Disease Models, Animal; Factor Xa Inhibitors; Fondaparinux; Humans; Male; Polysaccharides; Pyridines; Rats; Rats, Wistar; Thiazoles; Thrombosis; Vena Cava, Inferior | 2011 |
Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
Topics: Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Enzyme Activation; Factor Xa; Feedback, Physiological; Heparin; Humans; Protein C; Pyridines; Thiazoles; Thrombin; Thrombomodulin | 2011 |
The new oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2011 |
Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation Factors; Factor VIIa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Male; Prothrombin Time; Pyridines; Rats; Rats, Inbred Strains; Thiazoles | 2012 |
Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats.
Topics: Animals; Antithrombins; Azetidines; Benzylamines; Blood Coagulation Disorders; Factor Xa Inhibitors; Heparin; Male; Pyridines; Rats; Rats, Wistar; Thiazoles; Thromboplastin | 2012 |
Edoxaban in Japanese patients with nonvalvular atrial fibrillation: not the same dose for everybody.
Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Pyridines; Thiazoles; Warfarin | 2012 |
Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pyridines; Thiazoles; Thrombosis; Treatment Outcome | 2012 |
Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.
Topics: Administration, Oral; Adult; Area Under Curve; Biotransformation; Carbon Radioisotopes; Factor Xa; Factor Xa Inhibitors; Feces; Humans; Male; Middle Aged; Pyridines; Thiazoles | 2012 |
The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Carboxylic Acids; Enzyme-Linked Immunosorbent Assay; Factor Xa; Factor Xa Inhibitors; Male; Osteocalcin; Osteoporosis; Protein Processing, Post-Translational; Prothrombin Time; Pyridines; Rats; Rats, Wistar; Risk Factors; Thiazoles; Time Factors; Vitamin K; Warfarin | 2013 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
Topics: Animals; Anticoagulants; Antithrombin III; Blood Coagulation Tests; Enoxaparin; Factor Xa Inhibitors; Female; Fondaparinux; Gene Deletion; Hemostasis; Male; Mice; Mice, Inbred C57BL; Polysaccharides; Pyridines; Thiazoles; Venous Thrombosis | 2013 |
Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Topics: Animals; Anticoagulants; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Heparin; Hirudins; Male; Pyridines; Rats; Rats, Wistar; Recombinant Proteins; Thiazoles; Thromboembolism; Warfarin | 2013 |
Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Topics: Animals; Anticoagulants; Antithrombins; Azetidines; Benzylamines; Cerebral Hemorrhage; Collagenases; Disease Models, Animal; Factor Xa Inhibitors; Heparin; Male; Pyridines; Rats; Rats, Wistar; Thiazoles | 2014 |
Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Enoxaparin; Female; Fondaparinux; Humans; Incidence; Knee Joint; Male; Osteoarthritis, Knee; Polysaccharides; Pyridines; Retrospective Studies; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2014 |
Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Orthopedic Procedures; Pyridines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2013 |
[Edoxaban is safer than vitamin K antagonists].
Topics: Administration, Oral; Anticoagulants; Hemorrhage; Humans; Pulmonary Embolism; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Thiazoles; Venous Thrombosis; Vitamin K; Warfarin | 2013 |
New oral anticoagulants for acute venous thromboembolism.
Topics: Acute Disease; Anticoagulants; Benzimidazoles; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Another novel oral anticoagulant matches warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Embolism; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Risk; Stroke; Thiazoles; Warfarin | 2014 |
Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Factor Xa Inhibitors; HEK293 Cells; Hepatocytes; Humans; Kidney; Liver; Male; Mice; Mice, Knockout; Oocytes; Organic Anion Transporters; Organic Cation Transport Proteins; Pyridines; Substrate Specificity; Thiazoles; Tissue Distribution; Xenopus laevis | 2014 |
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Are direct oral anticoagulants such as edoxaban safer than heparin or vitamin K-antagonists when intracranial hemorrhage occurs?
Topics: Administration, Oral; Animals; Anticoagulants; Heparin; Humans; Intracranial Hemorrhages; Pyridines; Rats; Thiazoles; Vitamin K | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chromatography, Liquid; Dabigatran; Humans; Mass Spectrometry; Molecular Structure; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Warfarin | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
Severe upper gastrointestinal bleeding in extraluminal diverticula in the third part of the duodenum.
Topics: Aged; Anticoagulants; Colonoscopes; Diverticulum; Duodenal Diseases; Duodenoscopy; Gastrointestinal Hemorrhage; Humans; Male; Pyridines; Severity of Illness Index; Thiazoles; Venous Thrombosis | 2014 |
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Half-Life; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Factor X; Factor Xa Inhibitors; HEK293 Cells; Humans; Mutation; Pyridines; Thiazoles | 2015 |
Critique of Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation trial.
Topics: Adult; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Intracranial Hemorrhages; Italy; Markov Chains; Pyridines; Quality-Adjusted Life Years; Stroke; Thiazoles; Warfarin | 2015 |
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Monte Carlo Method; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
New oral anticoagulants in the management of venous thromboembolism: a major advance?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Ex vivo reversal of the anticoagulant effects of edoxaban.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Factor VIIa; Hemostatics; Humans; Partial Thromboplastin Time; Prothrombin Time; Pyridines; Recombinant Proteins; Thiazoles | 2014 |
Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombin III; Disease Models, Animal; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Fondaparinux; Male; Peptide Hydrolases; Polysaccharides; Pyridines; Rats; Rats, Wistar; Thiazoles; Venous Thrombosis | 2014 |
Once-daily edoxaban: a safer option than well-managed warfarin for patients with atrial fibrillation?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Drug Administration Schedule; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Warfarin | 2014 |
Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban.
Topics: Aged; Biomarkers; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Orthopedic Procedures; Platelet Membrane Glycoproteins; Postoperative Complications; Pyridines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Venous Thrombosis | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin | 2014 |
Use of PER977 to reverse the anticoagulant effect of edoxaban.
Topics: Arginine; Blood Coagulation; Factor Xa Inhibitors; Heparin Antagonists; Humans; Piperazines; Pyridines; Thiazoles | 2014 |
Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.
Topics: Acute Disease; Animals; Blood Coagulation Factors; Blood Coagulation Tests; Chinchilla; Endpoint Determination; Female; Hemorrhage; Hemorrhagic Disorders; Hemostatics; In Vitro Techniques; Pyridines; Rabbits; Thiazoles; Thrombin | 2015 |
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Costs and Cost Analysis; Dabigatran; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Myocardial Infarction; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; United States; Venous Thromboembolism; Warfarin | 2015 |
Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
Topics: Blood Coagulation; Blood Coagulation Tests; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Platelet-Rich Plasma; Prothrombin Time; Pyridines; Thiazoles; Thrombin | 2015 |
Edoxaban approved for embolism prevention.
Topics: Atrial Fibrillation; Drug Approval; Embolism; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; United States; United States Food and Drug Administration | 2015 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Are new oral anticoagulant dosing recommendations optimal for all patients?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.
Topics: Adenosine; Adenosine Diphosphate; Blood Coagulation; Blood Coagulation Tests; Factor Xa Inhibitors; Humans; Platelet-Rich Plasma; Purinergic P2Y Receptor Antagonists; Pyridines; Thiazoles; Thrombin; Thromboplastin; Ticagrelor | 2015 |
Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.
Topics: Anticoagulants; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2015 |
Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Germany; Humans; Pyrazoles; Pyridines; Pyridones; Quality of Life; Quality-Adjusted Life Years; Rivaroxaban; Thiazoles; Warfarin | 2015 |
Edoxaban (Savaysa)--the fourth new oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Embolism; Humans; Pyridines; Stroke; Thiazoles; United States; United States Food and Drug Administration; Venous Thromboembolism | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia | 2015 |
Use of Oral Anticoagulants According to the Degree of Renal Impairment in Japanese Patients With Atrial Fibrillation--Which Non-Vitamin K Antagonist Oral Anticoagulant to Select?
Topics: Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Renal Insufficiency, Chronic; Thiazoles | 2015 |
[Simplified therapy regimen receives recommendation for approval].
Topics: Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Embolism; Humans; Pyridines; Recurrence; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2015 |
Edoxaban and amiodarone: interactions on multiple levels.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Pyridines; Thiazoles; Warfarin | 2015 |
Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
Topics: Anticoagulants; Antithrombins; Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Drug Synergism; Factor Xa Inhibitors; Heparin; Humans; Pyridines; Thiazoles; Thrombin; Thromboplastin | 2015 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Direct oral anticoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Drug Costs; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2015 |
[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Topics: Aged; Factor Xa Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Pyridines; Thalidomide; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism | 2015 |
Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
Topics: Atrial Fibrillation; Dose-Response Relationship, Drug; Europe; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Models, Theoretical; Population Surveillance; Pyridines; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Survival Rate; Thiazoles; Treatment Outcome | 2015 |
[The ENGAGE AF-TIMI 48 study].
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Warfarin | 2015 |
Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Stroke; Thiazoles | 2015 |
Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities.
Topics: Adult; Age Factors; Anticoagulants; Child; Child, Preschool; Clinical Trials as Topic; Dabigatran; Disease Management; Evidence-Based Medicine; Heparin, Low-Molecular-Weight; Humans; Infant; Multicenter Studies as Topic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
Topics: Antithrombins; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Calibration; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Fibrinogen; Hemostasis; Humans; Lupus Coagulation Inhibitor; Partial Thromboplastin Time; Plasma; Protein C; Protein S; Prothrombin Time; Pyridines; Sensitivity and Specificity; Thermogravimetry; Thiazoles; Thrombin; Thrombophilia | 2016 |
Drug updates and approvals: 2015 in review.
Topics: Amlodipine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atazanavir Sulfate; Azabicyclo Compounds; Benzazepines; Ceftazidime; Cobicistat; Drug Approval; Drug Combinations; Humans; Injections, Subcutaneous; Ivabradine; Liraglutide; Nurse Practitioners; Perindopril; Pyridines; Thiazoles; United States; United States Food and Drug Administration | 2015 |
Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
Topics: Adult; Anticoagulants; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2015 |
Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Topics: Administration, Oral; Adult; Anticoagulants; Area Under Curve; Cross-Over Studies; Dabigatran; Drug Substitution; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Rivaroxaban; Thiazoles; Young Adult | 2016 |
Edoxaban: Efficacy, Laboratory Monitoring, and Approach to Reversal.
Topics: Blood Coagulation Factors; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Thiazoles | 2015 |
[Your patient needs an antithrombotic drug. Venous thrombosis of the leg: how and how long anticoagulation?].
Topics: Administration, Oral; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Fibrinolytic Agents; General Practice; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thrombosis | 2015 |
Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Japan; Male; Middle Aged; Pyridines; Thiazoles | 2016 |
Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase.
Topics: Aged; Blood Platelets; Collagen; Factor Xa Inhibitors; Female; Healthy Volunteers; HSP27 Heat-Shock Proteins; Humans; Male; MAP Kinase Signaling System; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Platelet Activation; Platelet Aggregation; Pyridines; Rivaroxaban; Thiazoles; Venous Thrombosis | 2016 |
A study of usefulness for portal vein thrombus with edoxaban.
Topics: Aged; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Portal Vein; Pyridines; Thiazoles; Thrombosis | 2016 |
[IQWiG confirms significant additional applications for edoxaban ].
Topics: Adult; Anticoagulants; Atrial Fibrillation; Drug Approval; Germany; Humans; National Health Programs; Pulmonary Embolism; Pyridines; Stroke; Thiazoles; Thromboembolism; Venous Thrombosis | 2015 |
Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Topics: Antithrombins; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Factor Xa; Factor Xa Inhibitors; Female; Fondaparinux; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polysaccharides; Pyridines; Thiazoles; Thromboplastin | 2016 |
Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect.
Topics: Blood Coagulation Factors; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Humans; Prothrombin Time; Pyridines; Thiazoles | 2016 |
Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Drug Monitoring; Humans; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2017 |
Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Male; Markov Chains; Pyridines; Quality-Adjusted Life Years; Stroke; Thiazoles; Warfarin | 2016 |
Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Loss, Surgical; Cerebral Hemorrhage; Clinical Trials as Topic; Dabigatran; Drug Approval; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; United States; United States Food and Drug Administration | 2016 |
Clinical Assessment of Postoperative Anemia Associated with Edoxaban in Patients Undergoing Total Knee Arthroplasty Compared to Fondaparinux.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Female; Fondaparinux; Humans; Injections, Subcutaneous; International Normalized Ratio; Male; Partial Thromboplastin Time; Polysaccharides; Postoperative Complications; Prothrombin Time; Pyridines; Thiazoles; Thrombosis | 2016 |
Efficacy of non-vitamin K antagonist oral anticoagulants for Lemierre syndrome.
Topics: Administration, Oral; Ampicillin; Anti-Bacterial Agents; Anticoagulants; Bacteremia; Factor Xa Inhibitors; Female; Heparin; Humans; Lemierre Syndrome; Middle Aged; Pyridines; Streptococcal Infections; Streptococcus pyogenes; Sulbactam; Thiazoles | 2016 |
To measure or not to measure direct oral anticoagulants before surgery or invasive procedures.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation Tests; Factor Xa Inhibitors; Hemorrhage; Humans; Mass Spectrometry; Patient Safety; Preoperative Period; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin; Thrombin Time | 2016 |
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cost-Benefit Analysis; Dabigatran; Humans; Insurance, Health; Middle Aged; Models, Theoretical; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin | 2016 |
Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.
Topics: Animals; Chromatography, High Pressure Liquid; Factor Xa Inhibitors; Pyrazoles; Pyridines; Pyridones; Rats; Reference Standards; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles | 2016 |
Edoxaban in the secondary prevention of VTE.
Topics: Anticoagulants; Humans; Pyridines; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2016 |
Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain; Brain Ischemia; Cryosurgery; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Anticoagulants: What is new and what is the standard?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Topics: Administration, Oral; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
Topics: Animals; Anti-Inflammatory Agents; Blood Coagulation; Cell Line; Cytokines; Diabetic Nephropathies; Disease Models, Animal; Endothelial Cells; Factor Xa; Factor Xa Inhibitors; Genotype; Humans; Inflammation Mediators; Insulin; Kidney Glomerulus; Macrophages; Male; Mice, Knockout; Nitric Oxide Synthase Type III; Phenotype; Podocytes; Pyridines; Receptor, PAR-2; Signal Transduction; Thiazoles; Up-Regulation | 2016 |
Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Topics: Administration, Oral; Animals; Antithrombins; Arteries; Biomarkers; Bleeding Time; Drug Interactions; Factor Xa Inhibitors; Male; Platelet Aggregation Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Thiazoles; Thrombin; Thrombosis | 2016 |
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Hemorrhage; Humans; Models, Statistical; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles; Thromboembolism; Warfarin | 2016 |
[Venous Thromboembolism during the Cisplatin-based Adjuvant Chemotherapy;Report of a Case].
Topics: Anticoagulants; Chemotherapy, Adjuvant; Cisplatin; Drug Substitution; Drug Therapy, Combination; Echocardiography; Female; Fibrinolytic Agents; Fondaparinux; Humans; Lung Neoplasms; Middle Aged; Polysaccharides; Pyridines; Thiazoles; Thrombolytic Therapy; Tomography, X-Ray Computed; Treatment Outcome; Urokinase-Type Plasminogen Activator; Venous Thromboembolism | 2016 |
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Cardiotonic Agents; Death, Sudden, Cardiac; Digitalis Glycosides; Factor Xa Inhibitors; Female; Heart Failure; Heart Rate; Humans; Hypertrophy, Left Ventricular; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Out-of-Hospital Cardiac Arrest; Proportional Hazards Models; Protective Factors; Pyridines; Risk Factors; Stroke Volume; Thiazoles | 2016 |
Remote intracerebral hemorrhage followed by re-bleeding after intravenous thrombolysis in a patient taking a non-vitamin K antagonist oral anticoagulant: A case report.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Brain; Cerebral Hemorrhage; Drug Therapy, Combination; Female; Humans; Pyridines; Recurrence; Stroke; Thiazoles; Thrombolytic Therapy | 2016 |
Direct oral anticoagulants and cancer: no swansong yet for the low-molecular-weight heparins.
Topics: Anticoagulants; Double-Blind Method; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2016 |
Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney Function Tests; Male; Metabolic Clearance Rate; Nutrition Surveys; Outcome Assessment, Health Care; Pyridines; Renal Elimination; Rivaroxaban; Thiazoles; United States | 2016 |
Resolving Thrombus in the Left Atrial Appendage by Edoxaban Treatment after Acute Ischemic Stroke: Report of 2 Cases.
Topics: Aged, 80 and over; Angiography, Digital Subtraction; Atrial Appendage; Atrial Fibrillation; Brain Ischemia; Cerebral Angiography; Echocardiography, Transesophageal; Factor Xa Inhibitors; Female; Humans; Magnetic Resonance Angiography; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Thrombectomy; Thrombosis; Time Factors; Treatment Outcome | 2016 |
Edoxaban for pulmonary embolism with right ventricular dysfunction.
Topics: Humans; Pulmonary Embolism; Pyridines; Thiazoles; Venous Thromboembolism; Ventricular Dysfunction, Right | 2016 |
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles | 2016 |
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hormone Replacement Therapy; Humans; Menorrhagia; Middle Aged; Progesterone; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Uterine Hemorrhage; Venous Thromboembolism | 2016 |
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pulmonary Veins; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Edoxaban had similar efficacy to and better safety than warfarin in AF, regardless of previous stroke or TIA.
Topics: Humans; Pyridines; Stroke; Thiazoles; Warfarin | 2016 |
Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.
Topics: Administration, Oral; Atrial Fibrillation; Cost Savings; Cost-Benefit Analysis; Drug Costs; Europe; Factor Xa Inhibitors; Forecasting; Humans; Models, Economic; Practice Patterns, Physicians'; Pyridines; Stroke; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2016 |
An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Female; Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Pyridines; Thiazoles | 2018 |
Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale.
Topics: Administration, Oral; Adult; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Emergency Treatment; Female; Humans; Male; Medication Therapy Management; Outcome and Process Assessment, Health Care; Pyrazoles; Pyridines; Pyridones; Quality Improvement; Registries; Rivaroxaban; Stroke; Thiazoles; United States; Warfarin | 2016 |
Increasing the methodological quality and relevance of cost effectiveness analysis.
Topics: Administration, Oral; Anticoagulants; Cost-Benefit Analysis; Decision Making; Humans; Probability; Pyridines; Thiazoles; Warfarin | 2017 |
Population Pharmacokinetics of Edoxaban in Japanese Atrial Fibrillation Patients With Severe Renal Impairment.
Topics: Administration, Oral; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Japan; Male; Metabolic Clearance Rate; Pyridines; Renal Insufficiency; Thiazoles | 2017 |
Edoxaban Versus Warfarin: Bone Fractures Due to Falling.
Topics: Accidental Falls; Atrial Fibrillation; Fractures, Bone; Humans; Pyridines; Thiazoles; Warfarin | 2017 |
[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Electric Countershock; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Intensive Care Units; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin; Thromboembolism; Vitamin K | 2017 |
Italian intersociety consensus on DOAC use in internal medicine.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Competence; Consensus; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Food-Drug Interactions; Humans; Internal Medicine; Italy; Liver Diseases; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Time Factors; Venous Thromboembolism | 2017 |
Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles | 2017 |
Thrombosis in an Internal Jugular Vein and an Upper Limb Deep Vein Treated with Edoxaban.
Topics: Brachiocephalic Veins; Factor Xa Inhibitors; Humans; Jugular Veins; Male; Middle Aged; Pyridines; Subclavian Vein; Thiazoles; Thrombosis; Tomography, X-Ray Computed; Treatment Outcome; Upper Extremity | 2017 |
Antithrombotic Therapy for Venous Thromboembolic Disease.
Topics: Antithrombins; Dabigatran; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Review Literature as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Vitamin K | 2017 |
Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
Topics: Ablation Techniques; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Belgium; Cryosurgery; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Intraoperative Period; Italy; Male; Middle Aged; Postoperative Complications; Prognosis; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Survival Rate; Thiazoles; Time Factors; Vitamin K | 2017 |
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Quality-Adjusted Life Years; Taiwan; Thiazoles; Warfarin | 2017 |
Is it reasonable to use a lower DOAC dose in some patients with VTE? NO.
Topics: Administration, Oral; Anticoagulants; Evidence-Based Medicine; Humans; Pyridines; Thiazoles; Venous Thromboembolism; Vitamin K | 2017 |
Choice of oral anticoagulants in older patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Craniocerebral Trauma; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Stroke; Thiazoles; Warfarin | 2017 |
Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
A comparison between vitamin K antagonists and new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2017 |
[Usefulness of Edoxaban for Deep Cerebral Venous Sinus Thrombosis with Hemorrhagic Infarction:A Case Report].
Topics: Cerebral Angiography; Cranial Sinuses; Factor Xa Inhibitors; Humans; Infarction; Intracranial Hemorrhages; Magnetic Resonance Imaging; Male; Middle Aged; Pyridines; Sinus Thrombosis, Intracranial; Thiazoles; Tomography, X-Ray Computed | 2017 |
Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
Topics: Adolescent; Anticoagulants; Factor Xa Inhibitors; Humans; Livedo Reticularis; Lower Extremity; Male; Pyridines; Skin; Skin Ulcer; Thiazoles; Thrombosis; Vascular Diseases | 2017 |
Prothrombin time-international normalized ratio is a useful marker for edoxaban efficacy in preventing venous thromboembolism after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Biomarkers; Early Ambulation; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Postoperative Complications; Postoperative Period; Pre-Exposure Prophylaxis; Prospective Studies; Prothrombin Time; Pyridines; ROC Curve; Thiazoles; Ultrasonography, Doppler, Color; Venous Thromboembolism; Venous Thrombosis | 2018 |
Edoxaban was Effective for Treating Renal Vein Thrombosis in a Patient with Nephrotic Syndrome.
Topics: Adult; Factor Xa Inhibitors; Heparin; Humans; Male; Nephrotic Syndrome; Pulmonary Embolism; Pyridines; Renal Veins; Thiazoles; Treatment Outcome; Venous Thrombosis; Warfarin | 2017 |
Edoxaban Use in Nonvalvular Atrial Fibrillation With Valvular Heart Disease-Insights from ENGAGE AF-TIMI 48.
Topics: Atrial Fibrillation; Heart Valve Diseases; Humans; Pyridines; Thiazoles | 2017 |
Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
Topics: Administration, Oral; Aged; Anticoagulants; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2018 |
Measuring Direct Oral Anticoagulants.
Topics: Administration, Oral; Antithrombins; Blood Coagulation; Dabigatran; Drug Monitoring; Endopeptidases; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin Time; Venous Thromboembolism | 2017 |
New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Diet; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Cholesterol Crystal Embolism Induced by Direct Factor Xa Inhibitor: A First Case Report.
Topics: Aged, 80 and over; Anticoagulants; Embolism, Cholesterol; Factor Xa Inhibitors; Humans; Male; Middle Aged; Pyridines; Renal Insufficiency; Thiazoles; Toes; Tretoquinol; Venous Thrombosis | 2018 |
Edoxaban improves venous thrombosis via increasing hydrogen sulfide and homocysteine in rat model.
Topics: Animals; Anticoagulants; Chlorides; Cystathionine beta-Synthase; Cystathionine gamma-Lyase; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelial Cells; Ferric Compounds; Gene Expression Regulation; Homocysteine; Hydrogen Sulfide; Male; Matrix Metalloproteinase 9; Phosphatidylinositol 3-Kinases; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Pyridines; Rats; Rats, Sprague-Dawley; Signal Transduction; Thiazoles; Venous Thrombosis | 2017 |
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Japan; Magnetic Resonance Imaging; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Retrospective Studies; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2018 |
Cardiovascular drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzazepines; Cardiovascular Agents; Humans; Ivabradine; Pyridines; Thiazoles | 2017 |
[Antiembolic Stockings - Great Effects in Edoxaban Approval Studies].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Combined Modality Therapy; Drug Approval; Evidence-Based Medicine; Germany; Guideline Adherence; Postoperative Complications; Pyridines; Stockings, Compression; Thiazoles; Thromboembolism; Venous Thrombosis | 2017 |
Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
Topics: Acute Disease; Aged; Anticoagulants; Antithrombin III; Female; Humans; Male; Middle Aged; Protein C; Protein S; Pulmonary Embolism; Pyridines; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2018 |
Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban.
Topics: Animals; Antifibrinolytic Agents; Factor Xa Inhibitors; Hemorrhage; Male; Pyridines; Rats, Sprague-Dawley; Thiazoles; Tranexamic Acid | 2018 |
Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug Utilization; Female; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Stroke; Thiazoles | 2018 |
Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
Topics: Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Venous Thrombosis; Warfarin | 2018 |
Comparison of Direct Oral Anticoagulants and Warfarin in the Treatment of Deep Venous Thrombosis in the Chronic Phase.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Chronic Disease; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Thiazoles; Treatment Outcome; Ultrasonography; Venous Thrombosis; Warfarin | 2018 |
Safety of Uninterrupted Periprocedural Edoxaban Versus Phenprocoumon for Patients Who Underwent Left Atrial Catheter Ablation Procedures.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Electrocardiography; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Phenprocoumon; Pulmonary Veins; Pyridines; Radiofrequency Ablation; Thiazoles; Treatment Outcome | 2018 |
Prothrombin times in the presence of edoxaban - in-vivo experience from King's College hospital.
Topics: Anticoagulants; Female; Humans; Male; Prothrombin Time; Pyridines; Stroke; Thiazoles; United Kingdom; Venous Thromboembolism | 2019 |
Reversible Parkinsonism and Multiple Cerebral Infarctions after Pulmonary Endarterectomy in a Patient with Antiphospholipid Syndrome.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Cerebral Infarction; Chronic Disease; Endarterectomy; Heparin; Humans; Hypertension, Pulmonary; Male; Parkinsonian Disorders; Postoperative Complications; Pyridines; Thiazoles; Treatment Outcome; Warfarin | 2018 |
Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants: Comparison with Warfarin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Circadian Rhythm; Female; Humans; Male; Middle Aged; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2018 |
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Chromatography; Clinical Laboratory Techniques; Dabigatran; Hematology; Humans; International Cooperation; Mass Spectrometry; Partial Thromboplastin Time; Point-of-Care Testing; Prothrombin; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Quality Assurance, Health Care; Rivaroxaban; Thiazoles | 2018 |
Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
Topics: Aged; Anticoagulants; Carcinoma, Non-Small-Cell Lung; Heparin; Humans; Lung Neoplasms; Male; Pyridines; Thiazoles; Tumor Burden; Venous Thromboembolism; Warfarin | 2018 |
Edoxaban for the Treatment of Venous Thromboembolism in Patients with Cancer.
Topics: Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Humans; Neoplasms; Pyridines; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2018 |
A quantitative LC/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Chromatography, Liquid; Factor Xa Inhibitors; Female; Humans; Linear Models; Male; Postoperative Complications; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles; Thromboembolism | 2018 |
Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Catheter Ablation; Factor Xa Inhibitors; Female; Heparin; Humans; Male; Middle Aged; Perioperative Period; Predictive Value of Tests; Pyridines; Thiazoles; Time Factors; Treatment Outcome; Warfarin; Whole Blood Coagulation Time | 2018 |
[The efficacy and safety of edoxaban in non-valvular atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Thrombolytic Therapy; Warfarin | 2018 |
Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
Topics: Antithrombins; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles | 2018 |
Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Topics: Animals; Anticoagulants; Antidotes; Blood Coagulation; Disease Models, Animal; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Male; Pyridines; Rabbits; Recombinant Proteins; Thiazoles | 2018 |
Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants.
Topics: Administration, Oral; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.
Topics: Adult; Aged; Anticoagulants; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2018 |
Double venous compression due to duplicated inferior vena cava-induced right common iliac vein thrombosis.
Topics: Chest Pain; Constriction, Pathologic; Factor Xa Inhibitors; Female; Humans; Iliac Vein; Middle Aged; Pyridines; Thiazoles; Thrombolytic Therapy; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2018 |
Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
Topics: Aged; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Neoplasms; Pulmonary Embolism; Pyridines; Recurrence; Retrospective Studies; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban (Savaysa) for the Prevention of Thromboembolic Events.
Topics: Atrial Fibrillation; Cost-Benefit Analysis; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyridines; Stroke; Thiazoles; Treatment Outcome; Venous Thrombosis | 2018 |
A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Carotid Artery Injuries; Factor Xa; Factor Xa Inhibitors; Hyperplasia; Mice; Neointima; Pyridines; Thiazoles; Thrombosis; Vascular System Injuries | 2018 |
The clinical impact of edoxaban for the patients with postoperative anemia after total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Anemia; Anticoagulants; Arthroplasty, Replacement, Hip; Blood Coagulation Tests; Chemoprevention; Factor Xa Inhibitors; Female; Fondaparinux; Humans; Male; Middle Aged; Predictive Value of Tests; Pyridines; Retrospective Studies; Thiazoles; Venous Thromboembolism | 2018 |
Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk Adjustment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2018 |
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2018 |
[Stroke prevention in the elderly: effectiveness and safety of edoxaban in elderly patients according to the results of the ENGAGE AF study].
Topics: Aged; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Hungary; Male; Patient Safety; Pyridines; Stroke; Thiazoles; Thromboembolism; Treatment Outcome | 2018 |
Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Caregivers; Dabigatran; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Self Report; Thiazoles | 2018 |
Abnormal vaginal bleeding in the 'DOAC' era.
Topics: Female; Humans; Pyridines; Thiazoles; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2018 |
Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin.
Topics: Anticoagulants; Heparin; Heparin, Low-Molecular-Weight; Humans; Pyridines; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Predisposition to multi-drug hypersensitivity after administration of mogamulizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Diuretics; Drug Eruptions; Esomeprazole; Factor Xa Inhibitors; Fatal Outcome; Female; Furosemide; Humans; Immunologic Factors; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Middle Aged; Proton Pump Inhibitors; Pyridines; Thiazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Use of NOACs in the Peri-Operative Management of Patients with Atrial Fibrillation: To Stop, Bridge or Continue?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Humans; Pyridines; Thiazoles; Warfarin | 2018 |
Edoxaban for Cancer-Associated Venous Thromboembolism.
Topics: Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban for Cancer-Associated Venous Thromboembolism.
Topics: Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban for Cancer-Associated Venous Thromboembolism.
Topics: Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban for Cancer-Associated Venous Thromboembolism.
Topics: Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban for Cancer-Associated Venous Thromboembolism.
Topics: Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node.
Topics: Action Potentials; Animals; Atrial Fibrillation; Factor Xa Inhibitors; Guanidines; Male; Microelectrodes; Models, Animal; Myocytes, Cardiac; Oligopeptides; Patch-Clamp Techniques; Pulmonary Veins; Pyridines; Rabbits; Ranolazine; Receptor, PAR-1; Rivaroxaban; Sinoatrial Node; Sodium-Calcium Exchanger; Stroke; Thiazoles | 2018 |
Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis.
Topics: Animals; Cells, Cultured; Databases, Factual; Factor Xa Inhibitors; Humans; Inflammation; Kidney Diseases; Macrophages; Male; Mice; Mice, Inbred C57BL; Nephritis, Interstitial; Pyridines; Thiazoles; Ureteral Obstruction | 2018 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; Hemorrhage; Humans; Multicenter Studies as Topic; Neoplasms; Observational Studies as Topic; Patient Acceptance of Health Care; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Outcome of Direct Oral Anticoagulant Treatment for Acute Lower Limb Deep Venous Thrombosis After Total Knee Arthroplasty Or Total Hip Arthroplasty.
Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Female; Humans; Lower Extremity; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Thiazoles; Venous Thrombosis | 2019 |
Role of Hypertension and Other Clinical Variables in Prognostication of Patients Presenting to the Emergency Department With Major Bleeding Events.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Blood Glucose; Blood Transfusion; Cardiovascular Diseases; Creatinine; Dabigatran; Emergency Service, Hospital; Epistaxis; Female; Gastrointestinal Hemorrhage; Hematuria; Hemoptysis; Hemorrhage; Humans; Hypertension; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prognosis; Propensity Score; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Sex Factors; Thiazoles; Warfarin | 2018 |
Delayed hypersensitivity to new oral anticoagulants. Demonstration of cross reactivity for the drug category and definition of non-irritant concentrations for patch tests.
Topics: Aged; Anticoagulants; Cross Reactions; Drug Hypersensitivity; Factor Xa Inhibitors; Female; Humans; Hypersensitivity, Delayed; Patch Tests; Pyridines; Thiazoles | 2019 |
All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thromboembolism; Warfarin | 2018 |
Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays.
Topics: Anticoagulants; Automation; Calibration; Chromatography, High Pressure Liquid; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Solid Phase Extraction; Tandem Mass Spectrometry; Thiazoles | 2018 |
Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety.
Topics: Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Cohort Studies; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Mortality; National Health Programs; Pyridines; Republic of Korea; Stroke; Thiazoles; Treatment Outcome | 2018 |
Edoxaban's Journey: From East Asia to the Globe, Back to East Asia.
Topics: Asia; Atrial Fibrillation; Humans; Pyridines; Thiazoles | 2018 |
The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Databases, Factual; Drug Dosage Calculations; Female; Hemorrhage; Humans; Inappropriate Prescribing; Incidence; Japan; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Prevalence; Pyrazoles; Pyridines; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome | 2018 |
Pacemaker-associated thrombosis in ongoing therapy with edoxaban tosylate.
Topics: Echocardiography; Factor Xa Inhibitors; Humans; Pacemaker, Artificial; Pyridines; Thiazoles; Thrombosis | 2018 |
Safety of Edoxaban 30 mg in Elderly Patients with Severe Renal Impairment.
Topics: Aged; Aged, 80 and over; Factor Xa Inhibitors; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Pyridines; Registries; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Stroke; Thiazoles | 2018 |
Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2019 |
Edoxaban in Latin America.
Topics: Atrial Fibrillation; Humans; Latin America; Pyridines; Thiazoles; Warfarin | 2018 |
[Evaluation of adverse drug reactions associated with direct oral anticoagulants recorded in the Italian Pharmacovigilance Network database using a specifically developed risk index].
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Italy; Pharmacovigilance; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles | 2018 |
[Treatment of cancer-associated venous thromboembolism].
Topics: Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2018 |
[Edoxaban in patients with atrial fibrillation and cancer].
Topics: Anticoagulants; Atrial Fibrillation; Cancer Survivors; Cardiovascular Diseases; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Neoplasms; Pyridines; Stroke; Thiazoles; Warfarin | 2018 |
Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Japan; Lower Extremity; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2019 |
Prevention of Stent Thrombosis in Rats by a Direct Oral Factor Xa Inhibitor Edoxaban.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Male; Platelet Aggregation Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Stents; Thiazoles; Thrombosis | 2019 |
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Warfarin | 2018 |
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Embolism; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Prostatic Neoplasms; Pyridines; Stroke; Thiazoles; Warfarin | 2018 |
Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Angiography; Dabigatran; Diffusion Magnetic Resonance Imaging; Female; Humans; Infarction, Middle Cerebral Artery; International Normalized Ratio; Logistic Models; Magnetic Resonance Angiography; Male; Multivariate Analysis; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin | 2018 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hepatic Insufficiency; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2018 |
Gastrointestinal bleeding in a patient on multiple medications including edoxaban.
Topics: Aged; Arterial Occlusive Diseases; Arthritis, Rheumatoid; Atrial Fibrillation; Drug Interactions; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Hypertension; Male; Polypharmacy; Pulmonary Disease, Chronic Obstructive; Pyridines; Thiazoles | 2018 |
Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Hemorrhage; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles | 2018 |
[NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease].
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Cardiovascular Diseases; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Sweden; Thiazoles | 2018 |
Topics: Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasms; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Topics: Anticoagulants; Antithrombins; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Point-of-Care Testing; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin Time | 2018 |
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Topics: Administration, Oral; Atrial Fibrillation; Europe; Factor Xa Inhibitors; Hemorrhage; Humans; Prospective Studies; Pyridines; Registries; Research Design; Stroke; Thiazoles; Time Factors; Treatment Outcome | 2019 |
Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Humans; Incidence; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Disease Progression; Health Care Costs; Humans; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Hemorrhagic risk and intracranial complications in patients with minor head injury (MHI) taking different oral anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Craniocerebral Trauma; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2019 |
Stroke prevention in AF: Of Asians and non-Asians.
Topics: Asian People; Atrial Fibrillation; Humans; Pyridines; Stroke; Thiazoles | 2019 |
Resolution of left ventricular thrombus by edoxaban after failed treatment with warfarin overdose: A case report.
Topics: Adult; Anticoagulants; Brain Ischemia; Heart Failure; Heart Ventricles; Humans; Male; Pyridines; Retreatment; Stroke; Thiazoles; Thrombosis; Warfarin | 2019 |
Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Spain; Stroke; Thiazoles; Treatment Outcome | 2019 |
Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles | 2019 |
Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles | 2019 |
Direct oral anticoagulant successfully used to treat an adult nephrotic patient complicated with portal vein thrombosis.
Topics: Administration, Oral; Adult; Anticoagulants; Chemical and Drug Induced Liver Injury; Factor Xa Inhibitors; Humans; Male; Nephrotic Syndrome; Portal Vein; Pyridines; Thiazoles; Treatment Outcome; Venous Thrombosis | 2019 |
Edoxaban (Lixiana°).
Topics: Anticoagulants; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Pulmonary Embolism; Pyridines; Stroke; Thiazoles; Venous Thrombosis; Warfarin | 2017 |
Stroke prevention in atrial fibrillation: Closing the gap.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misuse; Hemorrhage; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Warfarin | 2019 |
Deep Venous Thrombosis with Decreased Cerebral Blood Flow to the Thalamus was Completely Restored by Factor Xa Inhibitor.
Topics: Blood Coagulation; Cerebral Angiography; Cerebrovascular Circulation; Computed Tomography Angiography; Diffusion Magnetic Resonance Imaging; Factor Xa Inhibitors; Female; Humans; Intracranial Thrombosis; Male; Middle Aged; Phlebography; Pyridines; Thalamus; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Venous Thrombosis | 2019 |
Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement.
Topics: Administration, Oral; Anticoagulants; Austria; Brain Injuries, Traumatic; Consensus; Dabigatran; Deamino Arginine Vasopressin; Humans; Interdisciplinary Communication; Partial Thromboplastin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Tomography, X-Ray Computed; Tranexamic Acid; Treatment Outcome; Vitamin K | 2019 |
Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Drug Labeling; Female; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Republic of Korea; Risk Factors; Rivaroxaban; Thiazoles; Vitamin K | 2019 |
Elucidating the tight-binding mechanism of two oral anticoagulants to factor Xa by using induced-fit docking and molecular dynamics simulation.
Topics: Administration, Oral; Anticoagulants; Benzamides; Factor Xa; Hydrogen Bonding; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Pyridines; Thermodynamics; Thiazoles | 2020 |
[Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiazoles; Venous Thromboembolism | 2019 |
Management of severe congenital protein C deficiency with a direct oral anticoagulant, edoxaban: A case report.
Topics: Child, Preschool; Disease Management; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Prognosis; Protein C Deficiency; Purpura Fulminans; Pyridines; Thiazoles | 2019 |
Recurrent Acute Ischemic Stroke Associated with Dolichoectatic Aneurysm of the Internal Carotid Artery.
Topics: Aged, 80 and over; Aneurysm; Anticoagulants; Brain Ischemia; Carotid Artery Diseases; Carotid Artery, Internal; Clopidogrel; Humans; Male; Platelet Aggregation Inhibitors; Pyridines; Recurrence; Stroke; Thiazoles; Vertebrobasilar Insufficiency | 2019 |
Edoxaban suppresses the progression of atrial fibrosis and atrial fibrillation in a canine congestive heart failure model.
Topics: Animals; Atrial Fibrillation; Atrial Remodeling; Cardiac Pacing, Artificial; Dogs; Echocardiography; Electrophysiological Phenomena; Factor Xa Inhibitors; Fibrosis; Heart Atria; Heart Failure; Pyridines; Thiazoles | 2019 |
Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Disease Progression; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Heparin; Humans; Intracranial Embolism; Lung Neoplasms; Middle Aged; Pyridines; Thiazoles; Venous Thromboembolism | 2019 |
Letter by Martin et al Regarding Article, "Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial".
Topics: Factor Xa; Pyridines; Thiazoles | 2019 |
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Critical Care Nursing; Dabigatran; Female; Humans; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Topics: alpha-2-Antiplasmin; Anticoagulants; Blood Coagulation; Carboxypeptidase B2; Dose-Response Relationship, Drug; Fibrin Clot Lysis Time; Fibrinolysin; Fibrinolysis; Humans; Pyridines; Thiazoles; Tissue Plasminogen Activator; Venous Thromboembolism | 2019 |
In vitro assessment of edoxaban anticoagulant effect in pediatric plasma.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Factor Xa Inhibitors; Female; Humans; Infant; Male; Plasma; Pyridines; Thiazoles | 2019 |
Paradoxical Brain Embolism Caused by Isolated Pulmonary Arteriovenous Fistula Successfully Treated with Recombinant Tissue Plasminogen Activator.
Topics: Aged, 80 and over; Arteriovenous Fistula; Cerebral Angiography; Computed Tomography Angiography; Diffusion Magnetic Resonance Imaging; Embolism, Paradoxical; Embolization, Therapeutic; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Intracranial Embolism; Magnetic Resonance Angiography; Pulmonary Artery; Pulmonary Veins; Pyridines; Recombinant Proteins; Thiazoles; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome; Venous Thrombosis | 2019 |
Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain?
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Cost-Benefit Analysis; Drug Costs; Embolism; Facilities and Services Utilization; Factor Xa Inhibitors; Health Resources; Humans; Male; Middle Aged; Pyridines; Quality of Life; Quality-Adjusted Life Years; Spain; Stroke; Thiazoles | 2019 |
The evolving obesity paradigm story: from heart failure to atrial fibrillation.
Topics: Atrial Fibrillation; Body Mass Index; Heart Failure; Humans; Obesity; Pyridines; Thiazoles; Warfarin | 2019 |
Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Cause of Death; Disease Susceptibility; Drug Administration Schedule; Factor Xa Inhibitors; Female; Flow Cytometry; Follow-Up Studies; Hemorrhage; Humans; Incidence; Infant; Male; Middle Aged; Patient Outcome Assessment; Population Surveillance; Pyridines; Rivaroxaban; Thiazoles | 2019 |
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy.
Topics: Anticonvulsants; Atrial Fibrillation; Carbamazepine; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Ischemic Attack, Transient; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Thiazoles | 2019 |
Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency.
Topics: Administration, Oral; Aged; Anticoagulants; Humans; Male; Protein S Deficiency; Pyrazoles; Pyridines; Pyridones; Recurrence; Thiazoles; Venous Thromboembolism | 2019 |
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Taiwan; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).
Topics: Administration, Oral; Aged; Atrial Fibrillation; Biomarkers; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Partial Thromboplastin Time; Predictive Value of Tests; Prospective Studies; Prothrombin Time; Pyridines; ROC Curve; Stroke; Thiazoles; Treatment Outcome | 2019 |
Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Prognosis; Pyridines; Retrospective Studies; Thiazoles; Thromboembolism | 2019 |
Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Score-Matched Cohort Study.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Propensity Score; Pyridines; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2019 |
Continuous anticoagulation with catheter ablation: answers and questions.
Topics: Anticoagulants; Atrial Fibrillation; Catheter Ablation; Humans; Pyridines; Thiazoles; Vitamin K | 2019 |
[Dissolution and maintenance of portal vein thrombosis with antithrombin III and edoxaban in liver cirrhosis:a case report].
Topics: Aged; Anticoagulants; Antithrombin III; Humans; Liver Cirrhosis; Male; Portal Vein; Pyridines; Solubility; Thiazoles; Thrombosis | 2019 |
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy.
Topics: Aged; Factor Xa Inhibitors; Gastroscopy; Gastrostomy; Humans; Male; Pyridines; Thiazoles; Treatment Outcome | 2019 |
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Gastrointestinal Neoplasms; Humans; Markov Chains; Models, Theoretical; Neoplasms; Pyridines; Quality-Adjusted Life Years; Thiazoles; Thrombosis; United States | 2019 |
[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cilostazol; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Combinations; Epirubicin; Factor Xa Inhibitors; Fatal Outcome; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Male; Oxonic Acid; Pyridines; Radiotherapy, Intensity-Modulated; Skin Neoplasms; Syndrome; Tegafur; Thiazoles; Thrombophilia | 2019 |
Factors related to inappropriate edoxaban use.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyridines; Renal Insufficiency; Republic of Korea; Retrospective Studies; Stroke; Thiazoles | 2019 |
DOACs in Patients With Atrial Fibrillation and Liver Disease: Time to Expand the Safety Zone?
Topics: Atrial Fibrillation; Humans; Liver Diseases; Pyridines; Thiazoles; Warfarin | 2019 |
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
Topics: Administration, Oral; Aged; Aged, 80 and over; Atrial Fibrillation; Drug Labeling; Drug Utilization; Europe; Factor Xa Inhibitors; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Pyridines; Registries; Risk Assessment; Risk Factors; Stroke; Thiazoles; Time Factors; Treatment Outcome | 2019 |
VTE and anti-coagulation therapy in cancer patients.
Topics: Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dalteparin; Factor Xa Inhibitors; Humans; Neoplasms; Pyridines; Recurrence; Risk Factors; Secondary Prevention; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2019 |
Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis.
Topics: alpha-2-Antiplasmin; Factor Xa Inhibitors; Fibrinolysin; Fibrinolysis; Humans; Pyridines; Thiazoles; Thrombin | 2020 |
Thrombosis of Large Aneurysm Induced by Flow-Diverter Stent and Dissolved by Direct Factor Xa Inhibitor.
Topics: Abducens Nerve Diseases; Carotid Artery Diseases; Carotid Artery, Internal; Factor Xa Inhibitors; Female; Humans; Intracranial Aneurysm; Intracranial Thrombosis; Leg; Middle Aged; Postoperative Complications; Pyridines; Stents; Thiazoles; Venous Thrombosis | 2019 |
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles | 2019 |
Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity.
Topics: Anticoagulants; Cell Line; Electron Spin Resonance Spectroscopy; Factor Xa Inhibitors; Free Radical Scavengers; Humans; Hydroxyl Radical; Oxidative Stress; Pyridines; Reactive Oxygen Species; Thiazoles | 2019 |
Understanding the Effects of NOAC Combined with Antiplatelet Therapy on Clot Kinetics.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Dimaprit; Humans; Kinetics; Platelet Aggregation Inhibitors; Pyridines; Thiazoles | 2020 |
Dual antithrombotic therapy for atrial fibrillation and PCI.
Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K | 2019 |
Edoxaban noninferior to VKA in AF after PCI.
Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K | 2019 |
Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7).
Topics: Aged; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Chromatography, Liquid; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Japan; Male; Middle Aged; Predictive Value of Tests; Pyridines; Registries; Reproducibility of Results; Tandem Mass Spectrometry; Thiazoles; Treatment Outcome | 2020 |
Effect of the number of dose adjustment factors on bleeding risk in patients receiving 30 mg/day edoxaban.
Topics: Aged; Aged, 80 and over; Creatinine; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Pyridines; Retrospective Studies; Risk; Thiazoles | 2020 |
Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Pyridines; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2020 |
The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
Topics: Atrial Fibrillation; Databases, Factual; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2019 |
NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surveys and Questionnaires; Thiazoles | 2020 |
Oral Anticoagulation in Patients in the Emergency Department: High Rates of Off-Label Doses, No Difference in Bleeding Rates.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2020 |
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comorbidity; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2020 |
Anticoagulants in Atrial Fibrillation and Liver Disease.
Topics: Anticoagulants; Atrial Fibrillation; Humans; Liver Diseases; Pyridines; Thiazoles; Warfarin | 2019 |
Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.
Topics: Anticoagulants; Humans; Neoplasm Recurrence, Local; Pyridines; Thiazoles; Venous Thromboembolism | 2020 |
Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort.
Topics: Aged; Atrial Fibrillation; Cohort Studies; Denmark; Female; Humans; Male; Pyridines; Thiazoles | 2021 |
A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Humans; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; United Kingdom | 2019 |
Risk Factors for Major Bleeding and Clinically Relevant Non-major Bleeding in Japanese Patients Treated with Edoxaban.
Topics: Aged; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Pyridines; Retrospective Studies; Risk Factors; Thiazoles | 2020 |
Gallbladder hemorrhage during orally administered edoxaban therapy: a case report.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Cholecystectomy, Laparoscopic; Endoscopy; Female; Gallbladder Diseases; Hemorrhage; Humans; Melena; Pyridines; Thiazoles; Tomography, X-Ray Computed | 2019 |
Activated clotting factor X mediates mitochondrial alterations and inflammatory responses via protease-activated receptor signaling in alveolar epithelial cells.
Topics: Apoptosis; Cell Line, Tumor; Dipeptides; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Factor Xa; Factor Xa Inhibitors; Humans; Inflammation; Isoxazoles; Mitochondria; Pyridines; Receptors, Proteinase-Activated; Signal Transduction; Thiazoles | 2020 |
[Successful Management of Deep Vein Thromboembolism and Pulmonary Embolism by Edoxaban for Long-Term 5-FU-Based Chemotherapy for Colon Cancer-A Case Report].
Topics: Aged; Anticoagulants; Colonic Neoplasms; Fluorouracil; Humans; Pulmonary Embolism; Pyridines; Thiazoles; Thromboembolism; Venous Thromboembolism | 2019 |
Spontaneous muscular hematoma as a rare complication of edoxaban.
Topics: Aged; Anticoagulants; Female; Hematoma; Humans; Muscular Diseases; Pyridines; Quadriceps Muscle; Thiazoles | 2020 |
Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma.
Topics: Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Humans; Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Solid Phase Extraction; Spectrophotometry; Thiazoles | 2020 |
Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation Tests; Chromatography, Liquid; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles; Venous Thromboembolism | 2020 |
Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Blood Coagulation Factors; Coagulants; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Glasgow Outcome Scale; Humans; Intracranial Hemorrhage, Traumatic; Length of Stay; Male; Middle Aged; Mortality; Neurosurgical Procedures; Plasma; Platelet Transfusion; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2020 |
Effects of edoxaban and warfarin on vascular remodeling: Atherosclerotic plaque progression and collateral artery growth.
Topics: Animals; Anticoagulants; Atherosclerosis; Collateral Circulation; Disease Models, Animal; Factor Xa Inhibitors; Fibrosis; Hindlimb; Ischemia; Mice, Inbred C57BL; Mice, Knockout, ApoE; Muscle, Skeletal; Neovascularization, Physiologic; Plaque, Atherosclerotic; Pyridines; Thiazoles; Vascular Remodeling; Warfarin | 2020 |
Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial.
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clinical Decision-Making; Duration of Therapy; Echocardiography, Transesophageal; Electric Countershock; Enoxaparin; Female; Heart Diseases; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Thrombosis; Warfarin | 2020 |
Antithrombotic treatment strategies after PCI.
Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K | 2020 |
Antithrombotic treatment strategies after PCI.
Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K | 2020 |
Antithrombotic treatment strategies after PCI.
Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K | 2020 |
Antithrombotic treatment strategies after PCI.
Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K | 2020 |
Antithrombotic treatment strategies after PCI.
Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K | 2020 |
Blood Coagulation Status during Cryofreezing Ablation and Effects of the Direct Anticoagulants Dabigatran and Edoxaban.
Topics: Aged; Antithrombins; Cryosurgery; Dabigatran; Female; Humans; Male; Middle Aged; Pyridines; Thiazoles; Thromboembolism | 2020 |
Edoxaban in elderly patient with morbid obesity and atrial fibrillation: the role of plasma levels evaluation for selecting the appropriate dose.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Drug Therapy, Combination; Humans; Male; Obesity, Morbid; Pyridines; Thiazoles | 2020 |
Edoxaban affects TRAP-dependent platelet aggregation.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Platelet Aggregation; Prospective Studies; Pyridines; Stroke; Thiazoles | 2020 |
Management of antithrombotic therapy in gray areas of venous thromboembolism: a Delphi consensus panel.
Topics: Administration, Oral; Delphi Technique; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Humans; Male; Pyridines; Thiazoles; Venous Thromboembolism; Warfarin | 2020 |
Exploratory Analysis of Circulating miRNA Signatures in Atrial Fibrillation Patients Determining Potential Biomarkers to Support Decision-Making in Anticoagulation and Catheter Ablation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Biomarkers; Catheter Ablation; Circulating MicroRNA; Decision Making; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Regulatory Networks; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles | 2020 |
Trends in anticoagulant prescribing: a review of local policies in English primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; England; Female; Humans; Male; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; State Medicine; Stroke; Thiazoles; Warfarin | 2020 |
A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies.
Topics: Administration, Oral; Anticoagulants; Breast Feeding; Chromatography, High Pressure Liquid; Female; Humans; Lactation; Limit of Detection; Milk, Human; Molecular Structure; Pyrazoles; Pyridines; Pyridones; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles | 2020 |
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiologists; Clinical Trials, Phase III as Topic; Consensus; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2020 |
Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Thiazoles | 2020 |
Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Anticoagulants; Asia; Comorbidity; Cross-Sectional Studies; Dabigatran; Diabetes Mellitus; Europe; Factor Xa Inhibitors; Female; Fondaparinux; Heparin; Humans; Hypertension; Latin America; Male; Middle Aged; Middle East; Neoplasms; Postoperative Complications; Practice Patterns, Physicians'; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Wounds and Injuries | 2020 |
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |
Rates, management and outcome of bleeding complications during edoxaban therapy in daily care - results from the DRESDEN NOAC REGISTRY.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridines; Registries; Stroke; Thiazoles; Treatment Outcome | 2020 |
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electronic Health Records; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Simple LC-MS/MS method using core-shell ODS microparticles for the simultaneous quantitation of edoxaban and its major metabolites in human plasma.
Topics: Biosensing Techniques; Blood Specimen Collection; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Metabolomics; Microspheres; Pyridines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Silicon Dioxide; Tandem Mass Spectrometry; Thiazoles | 2020 |
Successful Treatment with Edoxaban for Disseminated Intravascular Coagulation in a Case of Aortic Dissection Complicated with Immune Thrombocytopenic Purpura.
Topics: Aged; Anticoagulants; Aortic Dissection; Atrial Fibrillation; Disseminated Intravascular Coagulation; Female; Humans; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Thiazoles | 2020 |
Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Period; Prospective Studies; Pyridines; Thiazoles; Thromboembolism; Treatment Outcome | 2020 |
In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution.
Topics: Adsorption; Albumins; Chromatography, Liquid; Factor Xa Inhibitors; Humans; Pyridines; Styrenes; Thiazoles | 2020 |
Direct acting oral anticoagulants and alopecia: to go further with data mining in pharmacovigilance databases.
Topics: Administration, Oral; Alopecia; Anticoagulants; Dabigatran; Data Mining; Databases, Factual; Humans; Minoxidil; Pharmacovigilance; Platelet-Rich Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2020 |
Anticoagulant activity of edoxaban in patients with cirrhosis.
Topics: Adult; Aged; Blood Coagulation; Factor Xa Inhibitors; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Pyridines; Thiazoles; Thrombosis | 2020 |
Edoxaban's contribution to key endothelial cell functions.
Topics: Cell Adhesion; Cells, Cultured; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes, Mononuclear; Pyridines; Pyrroles; Quinazolines; Thiazoles; Wound Healing | 2020 |
Quantitative Volumetric Comparison of Direct Oral Anticoagulant and Vitamin K Antagonist Treatment for Pulmonary Thrombus Reduction During the Acute Phase in Symptomatic Patients.
Topics: Aged; alpha-2-Antiplasmin; Anticoagulants; Antithrombin III; Contrast Media; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysin; Heparin; Humans; International Normalized Ratio; Length of Stay; Male; Middle Aged; Peptide Hydrolases; Prothrombin Time; Pulmonary Artery; Pulmonary Embolism; Pyridines; Retrospective Studies; Thiazoles; Tomography, X-Ray Computed; Treatment Outcome; Warfarin | 2020 |
[Antithrombotic Treatment of Pulmonary Embolism].
Topics: Acute Disease; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrinolytic Agents; Fondaparinux; Guideline Adherence; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasms; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles | 2020 |
Sigmoid Colon Varices due to Massive Thrombosis of a Noncirrhotic Extrahepatic Portosystemic Shunt.
Topics: Adult; Anticoagulants; Chondroitin Sulfates; Colon, Sigmoid; Dermatan Sulfate; Factor Xa Inhibitors; Heparitin Sulfate; Hepatic Encephalopathy; Humans; Male; Portal Vein; Portasystemic Shunt, Transjugular Intrahepatic; Pyridines; Thiazoles; Thrombosis; Treatment Outcome; Varicose Veins | 2020 |
Influence of anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection: a multicenter retrospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Endoscopic Mucosal Resection; Female; Humans; Japan; Male; Middle Aged; Postoperative Complications; Postoperative Hemorrhage; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stomach; Stomach Neoplasms; Thiazoles; Thromboembolism; Warfarin | 2021 |
Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial.
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Male; Pyridines; Thiazoles; Venous Thromboembolism; Warfarin | 2020 |
Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - A report of 4 cases.
Topics: Adult; Ambulatory Care; Bed Rest; COVID-19; Factor Xa Inhibitors; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Factors; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2020 |
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Europe; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Pyridines; Stroke; Thiazoles | 2021 |
Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil.
Topics: Anticoagulants; Brazil; Cost-Benefit Analysis; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Quality-Adjusted Life Years; Thiazoles; Thrombosis; Warfarin | 2020 |
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries.
Topics: Anticoagulants; Europe; Factor Xa Inhibitors; Female; Humans; Prospective Studies; Pyridines; Thiazoles; Venous Thromboembolism | 2020 |
Delayed hypersensitivity reactions to edoxaban.
Topics: Aged; Drug Hypersensitivity; Factor Xa Inhibitors; Female; Humans; Hypersensitivity, Delayed; Male; Pyridines; Thiazoles | 2021 |
Low-dose edoxaban in elderly patients with AF.
Topics: Aged; Atrial Fibrillation; Humans; Pyridines; Thiazoles | 2020 |
A Survey of Direct Oral Anticoagulant Cessation in General Surgery and Outcomes in Patients with Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Loss, Surgical; Carotid Artery Diseases; Cerebral Infarction; Dabigatran; Digestive System Surgical Procedures; Elective Surgical Procedures; Embolism; Endoscopy; Factor Xa Inhibitors; Female; Humans; Male; Myocardial Infarction; Orthopedic Procedures; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thromboembolism; Urologic Surgical Procedures; Vascular Surgical Procedures | 2020 |
Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study.
Topics: Aged, 80 and over; Atrial Fibrillation; Brain Ischemia; Databases, Factual; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Republic of Korea; Stroke; Thiazoles; Vitamin K; Warfarin | 2020 |
Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Electric Countershock; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Medication Adherence; Middle Aged; Propensity Score; Pyridines; Stroke; Thiazoles; Vitamin K | 2021 |
Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Peptide Fragments; Prospective Studies; Prothrombin; Pyridines; Stroke; Thiazoles; Warfarin | 2020 |
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
Topics: Aged; Anticoagulants; Europe; Female; Humans; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyridines; Risk Assessment; Thiazoles; Venous Thromboembolism | 2020 |
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.
Topics: Administration, Oral; Antidotes; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Interactions; Drug Monitoring; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Metabolic Clearance Rate; Observational Studies as Topic; Polypharmacy; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2020 |
Relationship of Edoxaban Plasma Concentration and Blood Coagulation in Healthy Volunteers Using Standard Laboratory Tests and Viscoelastic Analysis.
Topics: Adolescent; Adult; Blood Coagulation; Blood Coagulation Tests; Blood Viscosity; Healthy Volunteers; Humans; Longitudinal Studies; Male; Pyridines; Thiazoles; Young Adult | 2021 |
Edoxaban for the Long-Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?
Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug Tapering; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyridines; Recurrence; Registries; Thiazoles; Time Factors; Venous Thromboembolism | 2021 |
Utilize the full potential of real world evidence.
Topics: Europe; Humans; Pyridines; Thiazoles | 2020 |
[Effectiveness of the EQ-5D and CRES-4 questionnaire for assessing the impact on the quality of life of patients and the level of satisfaction after exchanging dicumarinics for edoxabán: Real-life experience based on a multicentre study].
Topics: Humans; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Pyridines; Quality of Life; Surveys and Questionnaires; Thiazoles | 2021 |
Clinical Trial Based Rationale for the Successful Use of DOAC in the Treatment of Cerebral Venous Sinus Thrombosis (CVST): A Case Report.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Clinical Trials as Topic; Drug Substitution; Factor Xa Inhibitors; Female; Heparin; Humans; Infusions, Intravenous; Intracranial Thrombosis; Pyridines; Sinus Thrombosis, Intracranial; Thiazoles; Treatment Outcome | 2020 |
Convexity Subarachnoid Hemorrhage Soon after Starting a Direct Oral Anticoagulant in 2 Patients with Acute Infarction.
Topics: Administration, Oral; Aged; Brain Infarction; Drug Substitution; Factor Xa Inhibitors; Female; Humans; Pyrazoles; Pyridines; Pyridones; Subarachnoid Hemorrhage; Thiazoles; Time Factors | 2020 |
Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial.
Topics: Aged; Atrial Fibrillation; Humans; Pyridines; Stroke; Thiazoles | 2020 |
Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Intracranial Thrombosis; Magnetic Resonance Imaging; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyridines; SARS-CoV-2; Thiazoles; Tomography, X-Ray Computed; Venous Thrombosis | 2020 |
Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy.
Topics: Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles | 2020 |
Association of risk factors and bleeding complications in Asian patients taking edoxaban.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Risk Factors; Thiazoles; Treatment Outcome | 2021 |
Recurrent Cerebral Venous Thrombosis Treated with Direct Oral Anticoagulants in a Japanese Man with Hereditary Protein C Deficiency.
Topics: Administration, Oral; Adult; Drug Substitution; Factor Xa Inhibitors; Heterozygote; Humans; Intracranial Thrombosis; Male; Mutation; Protein C; Protein C Deficiency; Pyridines; Recurrence; Thiazoles; Treatment Outcome; Venous Thrombosis | 2021 |
Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis.
Topics: Acenocoumarol; Adult; Anticoagulants; Budd-Chiari Syndrome; Duration of Therapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mesenteric Ischemia; Middle Aged; Portal Vein; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thrombosis; Warfarin | 2021 |
Atrial fibrillation management: Time for new goals.
Topics: Atrial Fibrillation; Goals; Humans; Pyridines; Thiazoles; Time | 2020 |
Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Male; Pyridines; Stroke; Thiazoles | 2020 |
A Comparative Prospective Observational Study on the Use of Direct Oral Anticoagulants after Cardiac Surgery for the Management of Atrial Fibrillation.
Topics: Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Time Factors; Treatment Outcome | 2021 |
Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic.
Topics: Administration, Oral; Anticoagulants; Counseling; COVID-19; Drug Monitoring; Drug Substitution; Hospitals, University; Humans; Informed Consent; London; Pandemics; Patient Acceptance of Health Care; Patient Education as Topic; Pyridines; Quarantine; Rivaroxaban; SARS-CoV-2; Telemedicine; Tertiary Care Centers; Thiazoles; Thrombophilia; Warfarin | 2021 |
Edoxaban (LIXIANA
Topics: Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2021 |
Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, ob
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Asia; Atrial Fibrillation; Cerebrovascular Disorders; Drug Administration Schedule; Europe; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Perioperative Care; Postoperative Hemorrhage; Prospective Studies; Pyridines; Registries; Risk Assessment; Risk Factors; Thiazoles; Thromboembolism; Treatment Outcome | 2020 |
Increasing the impact of Post Authorisation Safety Studies: transparency is key.
Topics: Europe; Humans; Pyridines; Thiazoles | 2021 |
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Deductibles and Coinsurance; Drug Costs; Factor Xa Inhibitors; Female; Humans; Male; Medicare Part C; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sample Size; Stroke; Thiazoles; United States; Warfarin | 2021 |
Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Factor Xa Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridines; Thiazoles; Venous Thromboembolism | 2021 |
In older patients with AF, low-dose edoxaban reduced stroke or systemic embolism without increasing major bleeding.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Embolism; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome | 2021 |
Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Belgium; Europe; Factor Xa Inhibitors; Humans; Netherlands; Prospective Studies; Pyridines; Thiazoles; Treatment Outcome | 2021 |
[Periprocedural edoxaban interruption is associated with low bleeding and thromboembolic risk: the Italian data of the EMIT-AF/VTE study].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Italy; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2021 |
Internal jugular vein thrombosis associated with
Topics: Abscess; Anti-Bacterial Agents; Blood Culture; Buttocks; Carnobacteriaceae; Drainage; Duration of Therapy; Factor Xa Inhibitors; Gram-Positive Bacterial Infections; Humans; Jugular Veins; Male; Middle Aged; Pulmonary Embolism; Pyridines; Thiazoles; Thrombophlebitis; Tomography, X-Ray Computed | 2021 |
Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats.
Topics: Animals; Blood Coagulation Disorders; Cytokines; Factor Xa Inhibitors; Lipopolysaccharides; Liver; Pyridines; Rats; Thiazoles; Thrombosis | 2021 |
Quantitative analysis of an impact of P-glycoprotein on edoxaban's disposition using a human physiologically based pharmacokinetic (PBPK) model.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Humans; Models, Biological; Pyridines; Thiazoles | 2021 |
Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by paradoxical enhancement of thrombin generation: comparison with a direct factor Xa inhibitor edoxaban.
Topics: Antithrombins; Azetidines; Benzylamines; Factor Xa Inhibitors; Fibrin Clot Lysis Time; Fibrinolysis; Humans; Pyridines; Thiazoles; Thrombin | 2021 |
Treatment of acute exacerbation of liver-cirrhosis-associated portal vein thrombosis with direct-acting oral anticoagulant, edoxaban, used as an initial treatment in the early postoperative period after abdominal surgery: a case report.
Topics: Aged; Factor Xa Inhibitors; Humans; Liver Cirrhosis; Male; Portal Vein; Postoperative Period; Pyridines; Thiazoles | 2021 |
Low rates of liver injury in edoxaban users: Evidence from a territory-wide observational cohort study.
Topics: Cohort Studies; Humans; Liver; Pyridines; Thiazoles | 2021 |
Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fever; Fibrin Fibrinogen Degradation Products; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyridones; Skin Neoplasms; Sulfonamides; Thiazoles | 2021 |
Blood Coagulation Changes With or Without Direct Oral Anticoagulant Therapy Following Transcatheter Aortic Valve Implantation.
Topics: Aged, 80 and over; Antithrombin III; Aortic Valve Stenosis; Blood Coagulation; Cohort Studies; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Peptide Fragments; Peptide Hydrolases; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Transcatheter Aortic Valve Replacement | 2021 |
Low-Dose Edoxaban Effective for Stroke Prevention in Older Patients with Atrial Fibrillation.
Topics: Aged; Atrial Fibrillation; Humans; Pyridines; Stroke; Thiazoles | 2021 |
Topics: Atrial Fibrillation; Humans; Pyridines; Thiazoles | 2021 |
Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Databases, Factual; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Republic of Korea; Stroke; Taiwan; Thiazoles | 2021 |
Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Heart Failure; Humans; Pyridines; Thiazoles | 2021 |
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2021 |
How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Italy; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Surveys and Questionnaires; Thiazoles; Thrombosis; Treatment Outcome | 2021 |
Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa.
Topics: Blood Coagulation; Blood Coagulation Tests; Factor Xa; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2021 |
Unsolved issues of The Efficacy and Safety of Edoxaban.
Topics: Atrial Fibrillation; Humans; Pyridines; Thiazoles; Warfarin | 2021 |
Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Confidence Intervals; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyridines; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2022 |
Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?
Topics: Humans; Pyridines; Thiazoles | 2021 |
Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?
Topics: Humans; Pyridines; Thiazoles | 2021 |
Catheter Ablation Energy Sources and Myocardial Injury and Coagulation Biomarkers During Uninterrupted Periprocedural Edoxaban Use - A Subanalysis of KYU-RABLE.
Topics: Anticoagulants; Atrial Fibrillation; Biomarkers; Catheter Ablation; Heart Injuries; Hemorrhage; Humans; Pyridines; Thiazoles; Treatment Outcome | 2022 |
Evaluation of the in vitro stability of direct oral anticoagulants in blood samples under different storage conditions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Specimen Collection; Dabigatran; Humans; Middle Aged; Preservation, Biological; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2021 |
A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48.
Topics: Atrial Fibrillation; Biomarkers; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Proteomics; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thiazoles; Thromboembolism | 2021 |
Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients.
Topics: Adult; Aged; COVID-19; Factor Xa Inhibitors; Female; Fondaparinux; Humans; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pulmonary Embolism; Pyridines; Respiratory Distress Syndrome; Retrospective Studies; SARS-CoV-2; Thiazoles | 2021 |
Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Japan; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles | 2021 |
Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection.
Topics: Administration, Inhalation; Aerosols; Blood Coagulation Disorders; COVID-19; Dry Powder Inhalers; Humans; Particle Size; Powders; Pyridines; Thiazoles | 2021 |
Treatment with Edoxaban Attenuates Acute Stroke Severity in Mice by Reducing Blood-Brain Barrier Damage and Inflammation.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Disease Models, Animal; Humans; Infarction, Middle Cerebral Artery; Inflammation; Mice; Pyridines; Severity of Illness Index; Stroke; Thiazoles | 2021 |
Anticoagulant-related nephropathy to edoxaban.
Topics: Anticoagulants; Humans; Pyridines; Thiazoles | 2021 |
Difference in left atrial D-dimer level in patients with atrial fibrillation treated with direct oral anticoagulant.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Biomarkers; Dabigatran; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Thiazoles; Treatment Outcome | 2021 |
Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures: Outcomes of the Global EMIT program.
Topics: Aged; Anticoagulants; Cardiac Resynchronization Therapy Devices; Europe; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemia; Male; Pacemaker, Artificial; Prospective Studies; Pyridines; Republic of Korea; Risk Factors; Taiwan; Thiazoles; Thromboembolism | 2022 |
Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2022 |
Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thrombosis | 2021 |
Hip fractures risks in edoxaban versus warfarin users: A propensity score-matched population-based cohort study with competing risk analyses.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Female; Hip Fractures; Humans; Male; Middle Aged; Propensity Score; Pyridines; Retrospective Studies; Risk Assessment; Stroke; Thiazoles; Warfarin | 2022 |
Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.
Topics: Aged, 80 and over; Anticoagulation Reversal; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyridines; Recombinant Proteins; Thiazoles; Thrombosis | 2022 |
Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy.
Topics: Adult; COVID-19; Factor Xa Inhibitors; Female; Humans; Italy; Lupus Coagulation Inhibitor; Male; Middle Aged; Pandemics; Pulmonary Embolism; Pyridines; Quarantine; Thiazoles; Venous Thromboembolism | 2022 |
Antiphospholipid Syndrome Diagnosed as a Result of the Occurrence of an Ischemic Stroke After a Successful Catheter Ablation of Atrial Fibrillation and Continuous Direct Oral Anticoagulants.
Topics: Aged; Antiphospholipid Syndrome; Atrial Fibrillation; Catheter Ablation; Factor Xa Inhibitors; Female; Humans; Ischemic Stroke; Pyridines; Thiazoles | 2022 |
In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding.
Topics: Anticoagulants; Atrial Fibrillation; Hemorrhage; Humans; Pyridines; Thiazoles; Transcatheter Aortic Valve Replacement | 2022 |
D-dimer levels in patients with nonvalvular atrial fibrillation and acute heart failure treated with edoxaban.
Topics: Anticoagulants; Atrial Fibrillation; Fibrin Fibrinogen Degradation Products; Heart Failure; Humans; Ischemic Stroke; Pyridines; Stroke; Thiazoles | 2022 |
Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: Rationale and design of the randomized EPIC-CAD trial.
Topics: Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Pyridines; Stroke; Thiazoles; Treatment Outcome | 2022 |
Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Topics: Anticoagulants; Atrial Fibrillation; Humans; Pyridines; Thiazoles; Transcatheter Aortic Valve Replacement; Vitamin K | 2022 |
Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR. Reply.
Topics: Anticoagulants; Atrial Fibrillation; Humans; Pyridines; Thiazoles; Transcatheter Aortic Valve Replacement; Vitamin K | 2022 |
Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial-mesenchymal transition and inflammatory response.
Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Epithelial-Mesenchymal Transition; Factor Xa Inhibitors; Fibrosis; Inflammation Mediators; Kidney; Mice; Nephrectomy; Pyridines; Renal Insufficiency, Chronic; Thiazoles | 2022 |
Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey Study: Design and Rationale.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridines; Stroke; Thiazoles; Treatment Outcome; Turkey | 2022 |
Development and validation of capillary zone electrophoresis and high-performance liquid chromatography methods for the determination of oral anticoagulant edoxaban in pharmaceutical tablets.
Topics: Anticoagulants; Chromatography, High Pressure Liquid; COVID-19; Electrophoresis, Capillary; Humans; Pyridines; Reproducibility of Results; SARS-CoV-2; Tablets; Thiazoles; Venous Thromboembolism | 2022 |
Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Europe; Female; Frailty; Humans; Prospective Studies; Pyridines; Stroke; Thiazoles | 2022 |
Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY.
Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Attack, Transient; Prospective Studies; Pyridines; Registries; Stroke; Thiazoles; Treatment Outcome | 2022 |
Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: A cohort study.
Topics: Anticoagulants; Cohort Studies; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2022 |
Successful recanalization of completely obstructed portal vein thrombosis after right hepatectomy for perihilar cholangiocarcinoma by aspiration thrombectomy via the ileocolic mesenteric vein and subsequent systemic anticoagulation with edoxaban.
Topics: Aged, 80 and over; Anticoagulants; Bile Duct Neoplasms; Bilirubin; Female; Hepatectomy; Humans; Klatskin Tumor; Liver Diseases; Mesenteric Veins; Portal Vein; Pyridines; Thiazoles; Thrombectomy; Thrombosis; Urokinase-Type Plasminogen Activator; Venous Thrombosis | 2022 |
Swapping patients to edoxaban but at what cost?
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles | 2023 |
Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution.
Topics: Adult; Anticoagulants; Computer Simulation; Drug Interactions; Humans; Models, Biological; Pyridines; Renal Insufficiency; Thiazoles | 2023 |
Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban.
Topics: Alleles; Humans; Liver-Specific Organic Anion Transporter 1; Polymorphism, Single Nucleotide; Pyridines; Thiazoles | 2023 |